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Abstract 
 
Inflammation has incompletely characterized effects on cardiopulmonary vascular 
reactivity. Sepsis is a major inflammatory disease characterized by two main vasomotor 
complications, generalized vasodilation with hyporesponsiveness to vasoconstrictors and 
pulmonary hypertension. The main aim of this study is to examine the molecular 
mechanisms involved in cardiopulmonary vascular reactivity changes induced by the 
powerful inflammatory stimulus lipopolysaccharide (LPS). Pulmonary and aortic rings from 
male Wistar rats (250-300g) were isolated and incubated for 20 h in culture medium 
(DMEM+10% FBS) with or without LPS (E. coli O55:B5, 10 µg.ml-1). The effect of organ 
culture and LPS type, concentration and incubation time in addition to tissue contraction to 
endothelin-1 (ET-1), phenylephrine, 80 mM KCl, and U46619; and relaxation responses to 
ACh, sodium nitroprusside (SNP), 8-pCPT-cGMP, BAY 41-2272, T-0156, nifedipine, 
SKF-96365, Ro-31-8425, and Y-27632 were measured by standard organ bath techniques. 
Nitric oxide (NO) production was measured by the Griess method and SNP-induced cGMP 
production was measured by ELISA.  mRNAs expression levels of eNOS, iNOS, ET-1, ETA 
and ETB were measured by qRT-PCR and the expression levels of PKC, sGCα1, sGCβ1 and 
PDE5 and phosphorylation of MLC20, ROKα, CPI-17 and MYPT1 were measured by 
immunoblotting. The effect of endothelium removal, indomethacin, trolox, external Ca2+ 
removal, 1400W, ODQ, glibenclamide, iberiotoxin and cycloheximide in addition to changes 
in intracellular Ca2+ ([Ca2+]i) in aortic vascular smooth muscle cells (VSMCs) induced by 
ET-1 were also measured. LPS selectively induced vascular hyporeactivity to different 
vasoconstrictors in rat aorta but not in the pulmonary artery, which is not due to organ 
culturing and is not affected by changing the LPS type, but is enhanced by increasing LPS 
concentration or the incubation time. This aortic hypocontractility to ET-1 is largely 
mediated by NO-independent activation of sGC and depends on external Ca2+ influx through 
non-VOCCs, but not on ET-1 receptor expression or Ca2+ sensitization. In addition, this 
aortic hyporeactivity to ET-1 is dependent on protein synthesis. The pulmonary artery is not 
affected because LPS induces a desensitization of the sGC/cGMP dependent pathway by 
decreasing protein expression levels of sGCβ1, and hence sGC activity, and increasing PDE5 
activity. Neither the endothelium, cyclooxygenase, reactive oxygen species nor K+ channels 
are involved in these LPS effects.  Therefore, it is likely that both Ca2+ homeostasis and the 
sGC/cGMP pathway play important roles in vasomotor complications in sepsis. sGC and/or 
PDE5-selective inhibitors, together with manipulating VSMC [Ca2+]i, could be important in 
controlling systemic and pulmonary vasomotor complications in sepsis. 
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Chapter 1 
 
1.1 Inflammation, Lipopolysaccharide and vascular reactivity 
 
Inflammation is a series of local vascular and lymphatic changes occurring in 
living organisms. The main features of the inflammatory response include 
vasodilation, increased vascular permeability, cellular infiltration and activation of 
cells of the immune system (Ryan & Majno, 1977). Inflammation normally leads to 
recovery from infections, limits tissue injury and initiates healing and repair. 
However, if inflammation is not properly controlled, it can lead to persistent tissue 
damage (Webster & Galley, 2003).  The role of vascular cells is critically important 
in inflammatory diseases, including atherosclerosis, hypertension, ischemia-
reperfusion and septic shock (Tedgui & Mallat, 2001).  
 
1.1.1 Inflammation and vascular reactivity 
 
Cardiovascular homeostasis is, in part, governed by blood pressure, expressed 
as the product of total peripheral resistance and cardiac output (Reddi & Carpenter, 
2005). The contraction of vascular smooth muscle cells (VSMCs) controls vascular 
tone, and thus regulates total peripheral resistance, blood pressure and tissue 
perfusion. The vascular tone depends on a complex interplay between endothelial 
cells (ECs) and VSMCs through the release of different vasoconstrictors 
[endothelin-1 (ET-1), thromboxane A2 (TxA2), prostaglandin H2, angiotensin-II 
(AngII) and superoxide anion (O2.–)] and vasodilators [nitric oxide (NO), 
endothelium-dependent hyperpolarizing factor (EDHF), prostacyclin (PGI2) and 
prostaglandin E2] (Davis et al., 2003; Vila & Salaices, 2005).  
 
Inflammatory stimuli, such as inflammatory cytokines and bacterial endotoxins, 
have multiple and diverse effects on both ECs ands VSMCs, leading to altered 
vascular reactivity and selective permeability, leukocyte adhesion, platelet activation 
and conversion to procoagulant state, VSMC proliferation and extracellular matrix 
deposition (Tan et al., 1999; Aird, 2003).  
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One of the major examples of inflammatory diseases affecting the vascular 
system is sepsis, which is a complex dysregulation of inflammation arising when the 
host is unable to successfully contain an infection (Buras et al., 2005). Sepsis has two 
stages: an early hyperdynamic stage characterized by increased heart rate, cardiac 
output, vascular resistance and proinflammatory cytokines; and a later hypodynamic 
stage characterized by decreased heart rate, cardiac output and vascular resistance 
and increased levels of anti-inflammatory cytokines (Hoesel & Ward, 2004). 
Complications arising from sepsis include disseminated intravascular coagulation, 
systemic vascular collapse, multi-organ failure, and development of vascular leak 
syndromes, including acute respiratory distress syndrome (Bannerman & Goldblum, 
2003). The two main vasomotor complications are septic shock and pulmonary 
hypertension (Parsons et al., 1989; Manthous et al., 1993; Lorente et al., 1993). The 
mechanism of this difference in vascular reactivity between the systemic and the 
pulmonary vascular beds in sepsis is unclear. 
 
1.1.2 Lipopolysaccharide  
 
Lipopolysaccharide (LPS) or endotoxin is a major component of the 
Gram-negative bacterial cell wall released, as example, by cell lysis. LPS is a 
di-phosphorylated polar macromolecule composed of an O-specific hydrophilic 
polysaccharides chain, a core oligosaccharide region and a hydrophobic lipid A 
component which is responsible for the proinflammatory properties of LPS 
(Alexander & Rietschel, 2001). LPS forms microaggregates in biologic fluids and 
then rapidly interacts with a variety of serum or membrane-bound lipophilic proteins 
(Opal, 2007). LPS is the key molecule involved in the initiation of sepsis. The 
administration of LPS, both in humans (Suffredini et al., 1989) and in animals 
(Ruetten et al., 1996; Peters & Lewis, 1996; Gardiner et al., 1996b), has been used as 
a model to study sepsis and septic shock. 
 
1.1.2.1 LPS recognition and signalling 
 
LPS binds to a 60-kDa LPS-binding protein (LBP) which is an acute phase 
protein primarily synthesized by hepatocytes (Schumann et al., 1990). The LPS-LBP 
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complex is recognized by CD14, which is either expressed by 
monocytes/macrophages (mCD14) or released as a soluble form by monocytes 
(sCD14) (Hiki et al., 1998). sCD14-LPS complexes have been shown to stimulate 
mCD14-negative cells, such as epithelial cells, ECs, fibroblasts and SMCs (Pugin et 
al., 1993; Heine et al., 2001). The CD14-LPS complexes induce cell signalling 
through toll-like receptors (TLRs) (Akira et al., 2006). Ten TLRs subtypes have been 
identified in human: TLR-4 mediates the responses to LPS, while TLR2 mediates 
responses to toxins from Gram-positive bacteria, yeast and mycobacteria (Akira et 
al., 2006). Endothelial cells express two of the known TLRs, predominantly TLR4 
and very low levels of TLR2 and the expression of both is regulated by the 
transcription factor nuclear factor-κB (NF- κB) and interferon-γ (Faure et al., 2000). 
Activation of TLR4 leads to stimulation of both MyD88-dependent and MyD88-
independent pathways (Figure 1.1). These pathways involve signalling through 
NF-κB, mitogen-activated protein kinases (MAPKs) and phosphatidylinositol-3-
kinase (Dauphinee & Karsan, 2006).  
 
Further LPS recognition molecules may involve CD11/CD18 (β2-integrin), 
selectins, scavenger receptors, membrane-organizing extension spike protein 
(moesin) and heptose-specific lipopolysaccharide receptors (Van Amersfoort et al., 
2003). Generally, LPS recognition and signalling involve various membrane 
molecules as well as intracellular receptors (Heine et al., 2001). Different recognition 
systems such as scavenger receptors contribute to the clearance of LPS in the 
circulation mainly by Kupffer cells and hepatocytes in the liver (Hampton et al., 
1991; Satoh et al., 2008). 
 
1.1.2.2 LPS and inflammation 
 
LPS is a powerful stimulator of inflammatory pathways with the generation of 
pro- and anti-inflammatory mediators, including cytokines, coagulation factors, cell 
adhesion molecules, myocardial depressants and heat shock proteins (Heine et al., 
2001; Peters et al., 2003). The degree of cytokine expression in response to 
inflammatory stimuli such as LPS is principally regulated by NF-κB which is also 
responsible for the regulation of cell adhesion molecules, immunoreceptors, 
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procoagulants, acute phase proteins, NO production, and VSMCs migration and 
proliferation (Collins & Cybulsky, 2001). 
 
 
Figure 1.1 LPS recognition and signalling. The main LPS signalling 
pathway through TLR is boxed, comprising both MyD88-dependent and 
-independent pathways, while alternative pathways are shown by shaded lines. 
AP-1, activator protein-1;  CXCR4, chemokines receptor 4; DAP-12,  DNAX-
activating protein; ERK, extracellular signal-regulated kinase; GDF5, growth 
differentiation factor 5; hsp70/90, heat shock protein 70/90; IRAK, IL-1 receptor-
associated kinase; IRF3, interferon (INF) regulatory factor 3; JNK, c-jun NH2-
terminal kinase; K+, potassium channels; LBP, LPS-binding protein; MAPK, 
mitogen-activated protein kinase; MyD-88, myeloid differentiation factor 88; NF-
κB, nuclear factor-κB; Nod2, nucleotide-binding oligomerization domain protein-
2; RIP2, receptor interacting protein 2; TLR, Toll-like receptors;TRAF6, tumor 
necrosis factor (TNF) receptor-associated factor 6; TREM-1, Triggering receptor 
expressed on myeloid cells-1; TIR, TLR-IL-1 receptor domain (adapted from 
(Heine et al., 2001; Mitchell et al., 2007). 
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1.1.2.3 LPS and vascular reactivity 
 
Different models have been developed to study LPS-induced changes in 
vascular reactivity. Examples include in vitro models (McKenna, 1990; Hall et al., 
1996; O'Brien et al., 2001; Piepot et al., 2002; Boer et al., 2005), in vivo models 
(Curzen et al., 1995; Gardiner et al., 1995; Ruetten et al., 1996; Griffiths et al., 1997; 
Mitaka et al., 1999; Hirata & Ishimaru, 2002) and ex vivo models using vessels 
harvested from endotoxic animals (Schneider et al., 1992; Gunnett et al., 1998; Wu 
et al., 2004). Although vascular hyporeactivity was induced by LPS in most models, 
some models using smaller rodent vessels were unable to demonstrate diminished 
responses to vasoconstrictors (Mitchell et al., 1993; Glembot et al., 1995; Wu et al., 
2004). Table 1.1 represents the variability of vascular reactivity responses to LPS. 
This variability may be attributed to the difference in experimental models. However, 
different vascular beds respond variably to different vasoconstrictors in the same 
model (Piepot et al., 2002; Farmer et al., 2003), suggesting that complex 
mechanisms are present depending on the type of vascular bed and the 
vasoconstrictor. Exploring these mechanisms using a suitable model is important in 
understanding vascular reactivity changes induced by LPS. 
 
Of the several mediators suspected to be involved in LPS-induced vascular 
reactivity changes, NO and ET-1 play major roles in systemic hypotension, vascular 
hyporesponsiveness and pulmonary hypertension induced by LPS (Pittet et al., 1991; 
Lorente et al., 1993; Szabo et al., 1995; Curzen et al., 1997; Liu et al., 1997; Fujii et 
al., 2000; Piechota et al., 2007).  
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Table 1.1 Variability of LPS effects on vascular reactivity 
 
Reference 
Study 
type 
Animal/ 
human tissue 
Main LPS-induced effects 
(Biguad et 
al., 1990) 
ex vivo Rat aorta 
- Hyporeactivity to phenylephrine, KCl, Bay K 
8644 and calimycin 
(Farmer et 
al., 2003) 
ex vivo 
Rat aorta, 
mesenteric and 
renal arteries 
- Hyporeactivity to methoxamine in aorta and 
mesenteric, but not in renal arteries 
- KCl, caffeine and U46619 not affected 
(Umans et 
al., 1993) 
ex vivo 
Rat and rabbit 
aortas 
- Hypocontractility to phenylephrine, AngII, 
KCl and serotonin 
- Impaired relaxation to ACh and A23187  
(Gardiner et 
al., 1996b) 
in vivo Rat 
- Depressor and dilator effects of LPS infusion 
was opposed by AngII in first 1-2 h, ET-1 
between 2-8h and vasopressin after 24 h 
(Guc et al., 
1990) 
in vivo Rat 
- Hypocontractility to phenylephrine, 
vasopressin, cirazoline and serotonin, but not 
to ET-1 
(Wakabayash
i et al., 1987) 
ex vivo Rat aorta 
- Hypocontractility to norepinephrine, KCl and 
serotonin 
(Piepot et al., 
2002) 
in vitro 
Rat coronary, 
mesenteric, 
hepatic and 
renal arteries 
-Hyporeactivity to KCl in all vessels tested, to 
noradrenaline in mesenteric and hepatic and to 
U46619 in coronary 
(Buyukafsar 
et al., 2004) 
ex vivo 
Rat mesenteric 
arteries 
- Hyporeactivity to phenylephrine, AngII, but 
enhanced responses to ET-1 
(Mitchell et 
al., 1993) 
ex vivo 
Rat perfused 
mesenteric 
vascular bed 
- Responses to ET-1, phenylephrine, U46619 
and serotonin were not affected 
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1.2 Nitric oxide 
 
NO is one of the most ubiquitous substances in mammalian species, involved in 
the control of many cellular functions in different parts of the body. NO, being one of 
the most important endogenous vasodilators, plays an important role in inflammatory 
diseases. For example, it has been shown to contribute to the development of delayed 
hypotension, vasoplegia and acute lung injury in patients with septic shock 
(Manthous et al., 1993; Lorente et al., 1993; Feihl et al., 2001; Lopez et al., 2004) as 
well as in animals injected with LPS (Szabo et al., 1995; Griffiths et al., 1995; 
Bishop-Bailey et al., 1997).  
 
The recognition that exogenous NO gas as well as NO generated from various 
nitrocompounds has biological activity through activating soluble guanylyl cyclase 
(sGC) and inducing smooth muscle relaxation (Arnold et al., 1977), was followed by 
the discovery of an endothelium-derived relaxing factor (EDRF) (Furchgott & 
Zawadzki, 1980). Ten years later, it was confirmed that NO represents EDRF in the 
vasculature (Ignarro et al., 1987).  
 
1.2.1 Synthesis of NO 
  
NO  is  synthesized  from  the  amino  acid  L-arginine  by  a family of  heme 
containing enzymes named  the NO  synthases (NOS) (Nathan & Hibbs, Jr., 1991). 
The substrate L-arginine is metabolized by NOS to produce NO in addition to 
L-citrulline (Ignarro et al., 1987; Michel & Feron, 1997). The  synthesis of  NO  by  
NOS  involves  the  transfer  of  electrons  between  various  co-factors  including 
molecular oxygen, flavin adenine dinucleotide (FAD) and mononucleotide, 
tetrahydrobiopterin (BH4), reduced nicotinamide adenine dinucleotide phosphate 
(NADPH) and a heme moiety, with one atom of oxygen finally binding with  the  
terminal guanidine nitrogen  from arginine to form NO (Stuehr, 1999).  In addition, a 
small amount of NO is non-enzymatically produced from the chemical reduction of 
nitrite (Weitzberg & Lundberg, 1998). 
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1.2.2 NO synthases 
 
At least 3 NOS isoforms have been identified, namely neuronal NOS (nNOS, 
or NOS I), inducible NOS (iNOS, or NOSII) and endothelial NOS (eNOS, or NOS 
III) (Alderton et al., 2001).  Both nNOS and eNOS isoforms are constitutively 
expressed and are activated by calcium (Ca2+)-calmodulin.  iNOS is regulated 
primarily at the transcriptional level, independent of agonist stimulation and 
intracellular Ca2+ ([Ca2+]i). Constitutive nNOS and eNOS require an increase in 
resting [Ca2+]i for their binding of calmodulin and subsequent full activation (Michel 
& Feron, 1997). However, iNOS is able to bind calmodulin with extremely high 
affinity even at the low [Ca2+]i characteristic of resting cells and therefore its 
activation is not regulated by alterations in [Ca2+]i (Xie & Nathan, 1994).  
 
eNOS, expressed in ECs, is the predominant NOS isoform in the vessel wall 
(Alderton et al., 2001).  ET-1 and Ang II (Li et al., 1999; Alderton et al., 2001) have 
been shown to upregulate eNOS expression. Cytokines and LPS, potent upregulators 
of iNOS expression, appear to have the opposite effect on eNOS (Li et al., 2002). At 
high concentrations, NO itself works in a negative feedback manner to inhibit both 
activity and expression of eNOS (Abu-Soud et al., 2000).  
 
The [Ca2+]i required to activate constitutive NOS also inhibits GC (Coleman, 
2001). Therefore cells in which constitutive NOS is activated cannot respond to the 
NO produced. Cells expressing iNOS probably utilise glutathione as their defence 
against NO (Coleman, 2001). 
 
1.2.3 Metabolism of NO    
 
NO is an extremely unstable molecule, remaining effective for only few  
seconds (Griffith et al., 1984), due to rapid oxidation of NO by O2 and free oxygen 
radicals forming  inactive nitrogen  dioxide,  which  is converted to nitrite then 
nitrate. Both nitrite and nitrate are eliminated in urine within 5 hours, with basal 
nitrates concentration in blood 100 fold higher (30 mmol L-1) than nitrites (Moncada 
& Higgs, 1993).   
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In the blood, NO is rapidly inactivated by binding to hemoglobin, forming 
methaemoglobin, therefore keeping the concentration of NO in the nanomolar range 
(Beckman & Koppenol, 1996). However, hemoglobin is rapidly regenerated by red 
blood cell methaemoglobin reductase with nitrate as a by-product. The high  affinity  
of  NO  for  hemoglobin  and  its  inactivation  by  binding  to hemoglobin means  
that  its  physiological  actions  remain  localized  to  the site  of  its  generation  and 
are  rapidly  terminated (Anggard, 1994).  
 
1.2.4 Mechanism of Action of NO 
 
NO is a gas at physiological temperature and pressure, with a complete lack of 
reactivity with water making it lipophilic, and thus rapidly  diffuses  to  interact with 
molecular  targets  in  cells  in  the  vascular wall  and  lumen (Grisham et al., 1999; 
Hughes, 2008). NO  interacts with  metal  centres and thiol groups within  diverse 
protein  targets,  including membrane  receptors,  ion channels, cytosolic enzymes, 
and transcription factors such as AP-1 and NF-κB  (Stamler, 1994).  S-Nitrosylation  
of  thiol  groups  in plasma  proteins  such as  albumin  generates  a  circulating  pool  
of  NO-donating  groups  (Keaney, Jr. et al., 1993), whereas  S-nitrosylation  of 
hemoglobin  in  the  lung  provides  nitrosothiol groups  to  the  peripheral 
vasculature and regulates oxygen delivery (Gow et al., 1999). 
   
The most important receptor molecule for NO is NO-sensitive sGC, which 
catalyzes the formation of 3',5'-cyclic guanosine monophosphate (cGMP). The 
biological effects of cGMP are mediated by protein kinase G (PKG), cGMP-gated 
ion channels and cGMP-regulated phosphodiesterases (PDEs) (Beavo, 1995; 
Hofmann et al., 2006).The amplitude and duration of a cGMP signal are determined 
by the activity of sGC, a heterodimeric cGMP-forming enzyme, and PDEs which 
degrade cGMP (Juilfs et al., 1999). Only two sGC isoforms, α1/ β1 and α2/ β1 exist 
with the α1/ β1 sGC heterodimer being the predominant isoform in most tissues 
including lung (Friebe & Koesling, 2003). The major cGMP-degrading PDE isoform 
in vascular smooth muscle is the cGMP-binding PDE5 (Beavo, 1995; Maurice et al., 
2003).  
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1.2.5 Dysfunction of NO pathway 
 
Dysfunction of NO can occur as a result of decreased production, enhanced 
degradation and decreased sensitivity. In vascular diseases such as hypertension and 
atherosclerosis, the NO substrate L-arginine may be depleted secondary to an 
increase in arginase activity (Loscalzo, 2000). In addition, asymmetric 
dimethylarginine can act as an endogenous competitive NOS inhibitor (Cooke, 
2000). At suboptimal concentrations of the cofactor BH4 or the substrate L-arginine, 
NOS becomes 'uncoupled', leading to the production of O2.– and hydrogen peroxide 
thus decreasing NO production and increasing its inactivation (Xia et al., 1998; Cai 
& Harrison, 2000). Furthermore, dysfunction of the NO pathway can occur by a 
decrease in the expression of eNOS (Alderton et al., 2001). 
  
The interaction between NO and O2.– or lipid peroxides deplete NO levels by 
directly forming peroxynitrites or indirectly by attenuating NO release (Hogg & 
Kalyanaraman, 1999; Cai & Harrison, 2000). Oxidized LDL, hypertension, ageing 
and hyperglycaemia have all been shown to decrease the expression of sGC (Friebe 
& Koesling, 2003). Altering the redox state of sGC itself makes it unresponsive to 
both endogenous and exogenous NO (Stasch et al., 2006).  
 
1.2.6 Physiological effects of NO 
 
Direct NO effects occur at low (nanomolar) concentrations of NO resulting 
from the constitutive NOS isoforms. These include relaxation of vascular and 
non-vascular smooth muscle, inhibition of platelet aggregation, and inhibition of 
leukocyte adhesion to the endothelium (Nathan & Xie, 1994). NO, at high 
concentrations produced from iNOS, competes with O2 leading to inhibition of 
constitutive isoforms of NOS (Griscavage et al., 1995), and downregulates the 
activity of key enzymes in oxidative metabolism, thus negatively influencing cellular 
energetics in conditions such as sepsis (Gardner et al., 1997). In contrast with this 
potentially deleterious action, NO may be highly protective against oxidative stress 
by scavenging several free radicals such as O2.–, hydroxyl radical and hydrogen 
peroxide (Grisham et al., 1999).  
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Indirect effects of NO occur at high (micromolar) concentrations of NO 
resulting from iNOS through the formation of other mediators. These involve the 
carcinogenic compounds N-nitrosamines (Hecht, 1997), and S-nitrosothiols that play 
significant roles in a large number of biological processes (Broillet, 1999). In 
addition, the highly reactive and cytotoxic oxidant species peroxynitrite depletes 
glutathione, nitrates tyrosine residues in proteins and causes DNA damage and 
activation of the nuclear enzyme poly(ADP-ribose) polymerase, a pathway 
increasingly recognized as a major mechanism of NO/peroxynitrite-mediated 
cytotoxicity (Szabo & Dawson, 1998).  
 
1.2.7 Role of NO in inflammation and sepsis 
 
NO may exert either anti- or pro-inflammatory effects. NO is proinflammatory 
at low concentrations by inducing vasodilation and the recruitment of neutrophils, 
whereas at high concentrations it downregulates cell adhesion molecules, suppresses 
activation and induces apoptosis of inflammatory cells (Coleman, 2001). NO can 
interact with the pathways of gene expression controlled by the transcription factor 
NF-kB. When activated by various extracellular inflammatory triggers (e.g., 
stimulation of CD14 by LPS), NF-kB translocates to the nucleus, where it induces 
the transcription of numerous genes coding for proteins involved in inflammation, 
such as cytokines, cell adhesion molecules, and iNOS (Janssen-Heininger et al., 
2000). Both activation (Kalra et al., 2000) and inhibition (DelaTorre et al., 1997) of 
NF-kB activity by NO have been described.  
 
Excessive NO production, derived mainly from iNOS, has been shown to 
contribute to the development of delayed hypotension, vasoplegia and acute lung 
injury in patients with septic shock (Feihl et al., 2001; Lopez et al., 2004) as well as 
in animals injected with LPS (Szabo et al., 1995; Bishop-Bailey et al., 1997). 
Different strategies have been used to control excessive NO production in sepsis, 
such as inhibiting NO production with various NOS inhibitors or by inhibiting 
NO-dependent pathways such as sGC, however results have been conflicting. Table 
1.2 represents variable results relating to the involvement of NO in LPS-induced 
vascular dysfunction. 
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Table 1.2 Variability of the role of NO in LPS-induced changes in vascular 
reactivity 
 
Reference 
Study 
type 
Animal/ 
human tissue 
Main findings 
(Peters & 
Lewis, 1996) 
in vivo 
Rat hindquarter 
bed 
- Relaxation responses to ACh and sodium 
nitroprusside (SNP) impaired by LPS 
(Parker et al., 
1994) 
ex vivo 
Guinea pig 
aorta 
- Relaxation responses to ACh, but not to 
SNP, impaired by LPS 
(Mitolo-
Chieppa et 
al., 1996) 
ex vivo 
Rat perfused 
mesenteric 
vascular bed 
- L-NAME failed to restore reactivity to 
norepinephrine after LPS 
(Yen et al., 
1995) 
ex vivo Rat aorta 
- L-NAME and aminoguanidine partially 
restored reactivity to norepinephrine after LPS 
(Hernanz et 
al., 2004) 
in vitro 
Rat superior 
mesenteric 
artery 
- 1400W restored reactivity to noradrenaline 
after LPS 
(Boyle, III et 
al., 2000) 
ex vivo 
Mouse 
mesenteric 
resistance 
arteries 
- iNOS knockout protected against 
LPS-induced hyporeactivity to norepinephrine 
(Virdis et al., 
2005) 
ex vivo 
Rat mesenteric 
resistance 
arteries 
- LPS increases iNOS mRNA, but eNOS not 
affected 
(Tsai et al., 
2006) 
ex vivo 
Rat pulmonary 
artery and aorta 
- LPS increases iNOS mRNA in the 
pulmonary artery, but not the aorta 
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1.3 Endothelins 
 
ET-1, being the most powerful endogenous vasoconstrictor identified to date, 
has been suggested to play an important role in vascular changes in diseases 
involving inflammation, such as sepsis and associated syndromes and pulmonary 
hypertension (Wanecek et al., 2000; Luscher & Barton, 2000; Dhaun et al., 2007). 
ET-1 was isolated, characterized and cloned from the culture medium of porcine ECs 
(Yanagisawa et al., 1988). ET-1 was subsequently demonstrated to be one of a 
family of potent vasoactive peptides, designated ET-1, ET-2 and ET-3, which have 
been shown to be encoded by three distinct genes (Inoue et al., 1989). A similar 
peptide has been discovered following genomic cloning in mice (Saida et al., 1989) 
and termed vasoactive intestinal contractor or β-endothelin. This has subsequently 
been found to be a murine and rat homolog of human ET-2 (Bloch et al., 1991). 
Apart from this example, data suggest that there are little interspecies differences in 
the sequences of the ET subtypes.  
 
1.3.1 ET structure 
 
ETs are 21 amino acid peptides containing four cysteine residues forming two 
disulphide bonds between Cys1-Cys15 and Cys3-Cys11, which hold the peptide chains 
in a hairpin loop configuration (Inoue et al., 1989). ET-2 differs from ET-1, the 
major isoform, by 2 amino acids, while ET-3 differs from ET-1 by 6 amino acids 
(Figure 1.2). 
 
The three ETs isopeptides show a remarkable resemblance, both in structure (~ 
67% sequence homology) and biological activity, to sarafotoxins, a family of 
peptides isolated from the venom of Atractaspis engaddenis (Landan et al., 1991). 
 
1.3.2 ET biosynthesis and secretion 
 
ET isopeptides arise from post-translational, proteolytic processing of large 
precursor peptides termed preproendothelins -1, -2 and -3, which consists of 
approximately 200 amino acids (Yanagisawa et al., 1988; Itoh et al., 1988). The 
preproETs undergo cleavage to produce a 38 (human) or 39 (porcine) amino acid 
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peptides known as bigETs (proETs) (Figure 1.2). The bigETs are then cleaved at 
Trp21-Val22 by ET convering enzymes (ECEs) to produce the active peptides 
(Schmidt et al., 1994; Emoto & Yanagisawa, 1995).  
 
ET-1 is the main isoform released from the endothelium, and is also produced 
by airway epithelial cells, VSMCs, macrophages, fibroblasts, cardiomyocytes and 
neurons (Nakamura et al., 1990; Luscher & Barton, 2000). ET-2 is expressed by 
intestinal epithelial cells, while ET-3 is produced by brain neurons, intestinal 
epithelial cells and renal tubular epithelial cells (Matsumoto et al., 1989; Kedzierski 
& Yanagisawa, 2001). 
 
Regulation of the ET system takes place mainly at the synthesis level, 
particularly during transcription, because cells do not store endothelins (Matsumoto 
et al., 1989; Teder & Noble, 2000; Hynynen & Khalil, 2006; Dhaun et al., 2007). 
ET-1 mRNA can be upregulated or downregulated by several factors (Figure 1.2).  
 
1.3.3 ET metabolism/clearance 
 
ET-1 concentration in vascular tissue is approximately 100 times higher than 
that in plasma and its half life in blood is 4 to 7 minutes because of quick binding to 
tissues and rapid metabolism by neutral endopeptidase present in the lung, kidney 
and central nervous system (Abassi et al., 1992; Mateo & De Artinano, 1997). Other 
forms of ET metabolism may involve its uptake and lysosomal targeting by 
endothelial ETB receptors that could function as “clearance receptors” (Bremnes et 
al., 2000; Kedzierski & Yanagisawa, 2001).  
 
Prolonged exposure of  cells to ET can lead to a reduction in the responsiveness 
to a second exposure to ET i.e. desensitization can occur (Le Monnier de Gouville  & 
Cavero, 1991). It has been shown also that ETs can indirectly decrease the stability 
of ETB receptor mRNA (Sakurai et al., 1992) and alter receptor expression, leading 
to receptor internalization/downregulation (Marsault et al., 1991). 
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Figure 1.2 Schematic diagram of endothelins synthesis pathways. Amino 
acids in dark circles are different compared to ET-1. ANP, atrial natriuretic 
peptide; ECE, endothelin-converting enzyme; ET, endothelin; MP, 
metalloprotease; oxLDL, oxidised LDL (adapted from (Luscher & Barton, 2000; 
Hynynen & Khalil, 2006; Dhaun et al., 2007).  
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1.3.4 ET receptors 
 
There are two main known ET receptors, ETA and ETB, in addition to another 
two proposed ones, ETC and ETAX. ETA and ETB receptors are widely expressed in 
vascular tissues, airway smooth muscle, cardiomyocytes, hepatocytes, neurons, 
osteoblasts, reproductive system and some regions of the kidney (Kedzierski & 
Yanagisawa, 2001). ETA and ETB share 63% amino acid identity and are encoded by 
distinct genes located on chromosomes 4 and 13, respectively (Hynynen & Khalil, 
2006). In VSMCs, the ETA/ETB ratio is often considered to increase with vessel size 
(Kirkby et al., 2008). ETA receptors mediate vasoconstriction and cell proliferation 
and show a great affinity for ET-1 and ET-2 over ET-3 (Luscher & Barton, 2000). 
The prolonged persisting contractile response mediated through ETA receptors may 
be due its extremely slow dissociation from ET-1, which acts essentially as an 
irreversible ligand (Bremnes et al., 2000). ETB receptors show equal affinity for ET 
isoforms and are important for ET clearance, EC survival, release of NO and PGI2, 
inhibition of ECE-1 and promotion of natriuresis and diuresis (Nakamura et al., 
1991; Dhaun et al., 2007). The ETC receptor has been cloned from Xenopus leavis 
dermal melanophores and shows selectivity for ET-3 over ET-1 (Karne et al., 1993), 
and an ETAX receptor has been cloned from Xenopus heart (Kumar et al., 1994). ETC 
and ETAX receptors have no mammalian equivalent (Kirkby et al., 2008). 
 
Based on their in vivo pharmacology, ETB receptors have been subdivided into 
ETB1, located on the ECs and mediating vasorelaxation through release of NO and 
PGI2, and ETB2, located directly on the VSM and mediating vasoconstriction 
(Sudjarwo et al., 1993). 
 
1.3.5 ET receptor-mediated signalling pathways 
 
ET peptides evoke complex, tightly regulated pathways of signal transduction 
that result in both short-term (e.g. contraction, secretion) and long-term (e.g. 
mitogenesis) biological effects. ET receptors belong to the superfamily of seven 
transmembrane receptors linked to G proteins (Davenport et al., 1995). ETA 
receptors are functionally coupled to Gq/11 protein to activate phospholipase Cβ 
(PLCβ), and to Gi protein to inhibit adenylyl cyclase (Figure 1.3) (Robin et al., 
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2002). ETA receptor-mediated activation of Gq/11 and PLCβ result in the breakdown 
of phosphatidylinositol 4,5-bisphosphate, and the generation of inositol 1,4,5- 
trisphosphate  (IP3) and diacylglycerol (DAG). IP3 acts on specific receptors on the 
[Ca2+]i stores and stimulates Ca2+ release, while DAG stimulates protein kinase C 
(PKC) activity (Neylon, 1999; McNair et al., 2004). 
 
ET also activates plasma membrane Ca2+ channels, including voltage-operated 
Ca2+ channels (VOCCs), receptor-operated Ca2+ channels (ROCCs) and 
store-operated Ca2+ channels (SOCCs), and thus stimulates Ca2+ influx from the 
extracellular space (Miwa et al., 2005). ETA receptor stimulation can also activate 
phospholipase D (PLD) with generation of DAG, phospholipase A2 (PLA2) resulting 
in release of arachidonic acid, the Na+/H+ exchanger, as well as tyrosine kinases, 
MAPKs and phosphatidylinositol 3-kinase (Hynynen & Khalil, 2006) that are 
involved both in vasoconstriction and mitogenesis (Figure 1.3). ET-1 has also been 
shown also to inhibit ATP-sensitive K+ (KATP) channels (Satoh, 1995).  
 
Stimulation of endothelial ETB receptors activates signalling pathways that 
promote the release of relaxing factors such as NO, PGI2 and EDHFs (Figure 1.3). 
The ETB receptor-mediated release of NO from ECs may account for the transient 
vasodilator action of ET-1.  
 
1.3.6 ET physiological and pathophysiological actions 
 
ETs are postulated to be involved in the maintenance of basal vascular tone, 
regulation of water balance, local and systemic role in haemorrhage, and paracrine-, 
autocrine-, and endocrine signalling, embryonic development, gastrointestinal and 
endocrine function and prostate growth (Rubanyi & Polokoff, 1994; Luscher & 
Barton, 2000). Pathological conditions thought to involve ETs include coronary and 
cerebral vasospasm, myocardial ischemia, congestive heart failure, sepsis and 
associated syndromes, gastric ulceration, bronchial asthma and pulmonary 
hypertension (Wanecek et al., 2000; Luscher & Barton, 2000; Dhaun et al., 2007; 
Kirkby et al., 2008).  
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Figure 1.3 Schematic diagram of signalling pathways of (a) ETA and (b) 
ETB receptors. AC, adenylyl cyclase; CaD, caldesmon; CaM, calmodulin; CaP, 
calponin; COX, cyclooxygenase; DAG, diacylglycerol; ER, endoplasmic 
reticulum; ET, endothelin; GC, guanylyl cyclase; GEF, guanine nucleotide 
exchange factor; IP3, inositol 1,4,5- trisphosphatase; MAPK, mitogen-activated 
protein kinase; MEK, MAPK kinase; MLCK, myosin light chain kinase; MLCP, 
MLC phosphatase; NO, nitric oxide; PGI2, prostacyclin; PKC, protein kinase C; 
PLCβ, phospholipase Cβ; ROCKII, Rho-Kinase II; SR, sarcoplasmic reticulum 
(adapted from (Luscher & Barton, 2000; Hynynen & Khalil, 2006; Dhaun et al., 
2007).  
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1.3.7 ET interactions with NO 
 
There are close interactions between NO and ET-1 in the vascular wall. NO 
inhibits the production of ET-1 in ECs (Boulanger & Luscher, 1990) and ET-1 is 
known to stimulate the release of NO via activation of the ETB receptors located on 
ECs (Clozel et al., 1992). However, ET-1 may reduce the bioavailability of NO in 
the vessel wall, through increasing O2.– production (Maczewski & Beresewicz, 
2000). ET-1 may also reduce iNOS activity (Ikeda et al., 1997), an effect that can be 
restored in dogs by dual ETA/ETB receptor blockade (Shaw et al., 2001).  
 
1.3.8 ET role in inflammation and sepsis 
 
ET-1 is suggested to act as a proinflammatory cytokine because it stimulates 
macrophages and monocytes to release ROS and cytokines (McMillen & Sumpio, 
1995; Fujii et al., 2000; Luscher & Barton, 2000). ET-1 also induces neutrophil 
adhesion, platelet aggregation, chemotaxis of macrophages, and mast cell activation 
(McMillen & Sumpio, 1995; Fujii et al., 2000; Luscher & Barton, 2000). In addition, 
ET-1 has been shown to have mitogenic activity for SMCs, myocytes and fibroblasts 
(Battistini et al., 1993). 
 
ET-1 is suggested to play an important role in the inflammatory response to 
sepsis since plasma ET-1 levels are elevated in animal models of sepsis (Takahashi et 
al., 1990; Weitzberg et al., 1996; Mitaka et al., 1999; Fujii et al., 2000; Hirata & 
Ishimaru, 2002) and in septic patients, where its level correlates with the severity of 
illness (Pittet et al., 1991). Also, vascular ET-1 mRNA expression and arterial ET-1 
concentration are elevated after LPS treatment in rats (Curzen et al., 1997). 
 
Interestingly, the use of different ET receptors antagonists to counteract the 
increased ET-1 levels in sepsis has resulted in conflicting results (Gardiner et al., 
1995; Weitzberg et al., 1996; Curzen et al., 1997; Fujii et al., 2000; Hirata & 
Ishimaru, 2002; Konrad et al., 2004). Table 1.3 represents variable results relating to 
the involvement of ET in in LPS-induced vascular dysfunction. 
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Table 1.3 Variability of the role of ET-1 in LPS-induced changes in vascular 
reactivity 
 
Reference 
Study 
type 
Animal/ 
human tissue 
Main findings 
(Ros et al., 
1997) 
in vitro 
Human 
vascular ECs 
- LPS increases ET-1 release in culture 
medium 
(Schuetz et 
al., 2007) 
in vivo Human 
- Plasma ET-1 increases in sepsis and its levels 
correlate with severity of sepsis 
(Forni et al., 
2005) 
ix vivo Pig - LPS treatment increases plasma ET-1 levels 
(Curzen et 
al., 1997) 
ex vivo 
Rat pulmonary 
artery and aorta 
- LPS increases ET-1 mRNA and protein 
levels 
(Gardiner et 
al., 1996a) 
in vivo Rat 
- Non-selective ETA/ETB blocker increases 
hypotension induced by LPS 
(Wanecek et 
al., 1997) 
in vivo Pig 
- Non-selective ETA/ETB blocker abolishes 
pulmonary hypertension induced by LPS, but 
plasma ET-1 levels remains elevated 
(Ruetten et 
al., 1996) 
in vivo Rat 
- Selective ETA blocker do not attenuate 
hypotension and vascular hyporeactivity 
induced by LPS 
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1.4 Regulation of VSM contraction  
 
Since vascular reactivity is changed in inflammation, the identification of 
mechanisms that control VSM contraction are important to understand how 
inflammatory stimuli, either directly or through the release of vasoactive mediators, 
affect vascular tone. The contraction of VSM is primarily regulated by the reversible 
phosphorylation of the 20 kDa regulatory myosin light chain (MLC20) (Ikebe et al., 
1987). MLC20 is specifically phosphorylated by Ca2+/calmodulin-dependent myosin 
light chain kinase (MLCK), which in turn is activated by the release of Ca2+ from 
internal stores (Adelstein & Hathaway, 1979; Sommerville & Hartshorne, 1986) or 
the influx of Ca2+ across the plasmalemma through different Ca2+ channels (Hughes, 
1995). The degree of MLC20 phosphorylation is further regulated by myosin light 
chain phosphatase (MLCP) (Bialojan et al., 1985; Haeberle et al., 1985).  
 
When a greater contraction is produced for a given elevation of [Ca2+]i, this 
phenomenon is referred to as “Ca2+ sensitization of the contractile apparatus”, which 
occurs with several receptor-mediated contractile stimulations (Somlyo & Somlyo, 
1994). Therefore, vascular tone depends on the regulation of [Ca2+]i and Ca2+ 
sensitization of the contractile apparatus (Figure 1.4). This section will describe the 
principal mechanisms regulating VSM contraction.  
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Figure 1.4 Schematic diagram of signal transduction pathways involved 
in contraction of VSMCs. A, agonist; AA, arachidonic acid; CaM, calmodulin; 
CaMKII, Ca2+/CaM-dependent protein kinase II; CPI-17, PKC-potentiated 
phosphatase inhibitor protein-17 kDa; DAG, diacylglycerol; GEF, guanine 
nucleotide exchange factor; GPCR, G protein-coupled receptor; IP3, inositol 
1,4,5- trisphosphate; MAPK, mitogen-activated protein kinase; MEK, MAPK 
kinase R, receptor; MLCK, myosin light chain kinase; MYPT1, myosin 
phosphatase targeting subunit 1; PKC, protein kinase C; PLA2, phospholipase A2; 
PLCβ, phospholipase Cβ; PP1Cδ, δ-isoform of type 1 protein phosphatase 
catalytic subunit; ROCK, Rho-activated kinase (adapted from (Salamanca & 
Khalil, 2005; Woodsome et al., 2006). 
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1.4.1 Intracellular Ca2+ regulation  
 
At rest, [Ca2+]i is much lower within VSMCs  than in the extracellular fluid 
(Orallo, 1996). In response to vasoconstrictor stimuli, Ca2+ is mobilized from either 
intracellular stores such as the sarcoplasmic reticulum (SR) or the extracellular space 
to increase [Ca2+]i in VSMCs. The majority of contractile agonists such as 
norepinephrine, AngII, ATP and ET-1 evoke contraction via binding to G-protein-
coupled receptors to activate PLC-β resulting in the breakdown of 
phosphatidylinositol 4,5-bisphosphate and the generation of IP3 and DAG (Sanders, 
2001). IP3 diffuses from the cell membrane into the cytosol and stimulates 
IP3-sensitive receptors (IP3R) on SR to release Ca2+ (Neylon, 1999; McNair et al., 
2004). The IP3-mediated increase in [Ca2+]i, in turn, may induce further Ca2+  release 
from SR via a Ca2+-induced Ca2+-release mechanism (McPherson & Campbell, 
1993). DAG, which can also be generated by the PLD-mediated hydrolysis of 
phosphatidylcholine, remains in the cell membrane and stimulates PKC activity 
(Galizzi et al., 1987). Thus, the initial rapid phasic component observed in 
contractile response to these agonists reflects the IP3-mediated Ca2+ release from the 
SR, followed by a tonic increase in [Ca2+]i, which is dependent on extracellular Ca2+ 
(Hashimoto et al., 1986; Karaki et al., 1997). 
 
1.4.1.1 Ca2+ release from SR  
 
In VSMCs, Ca2+ is stored intracellularly in the SR, which contains at least two 
types of voltage-independent Ca2+-release channels, those sensitive to IP3 (IP3R) and 
those sensitive to the plant alkaloid ryanodine (ryanodine receptor, RyR) (Iino, 1990; 
Laporte & Laher, 1997). The IP3R function can be modulated by [Ca2+]i, cytosolic 
ATP and phosphorylation by various protein kinases, including cyclic adenosine 
3′,5′-monophosphate (cAMP)-dependent protein kinase (protein kinase A, PKA) and 
PKC (Marin et al., 1999). The RyR is regulated mainly by Ca2+ in addition to cyclic 
adenosine diphosphoribose (McPherson & Campbell, 1993; Jaggar et al., 1998; Lesh 
et al., 1998).  
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1.4.1.2 Ca2+ influx across the plasmalemma  
 
VOCCs, ROCCs and SOCCs are responsible for Ca2+ influx across the 
plasmalemma. L-type channels are the most important VOCCs and the most 
important route of Ca2+ influx in VSMC (Hofmann et al., 1994). Contractile agonists 
may directly activate non-selective cation channels (NSCCs), and thereby cause 
membrane depolarization (Guibert et al., 2008). On the other hand, Ca2+ released 
from the SR and/or entering through NSCCs may activate Ca2+-dependent cation 
channels and/or Cl− channels, eliciting membrane depolarization. However, the rise 
in [Ca2+]i could also activate Ca2+-dependent K+ channels, thus opposing the 
depolarizing effects of the activation of Ca2+-dependent Cl− channels (Nilsson, 
1998).  
 
ROCCs may be subdivided into ligand-gated Ca2+ channels and second 
messenger-operated Ca2+ channels (Somlyo & Somlyo, 1968; Bolton, 1979; Felder et 
al., 1994). The ligand-gated Ca2+ channels are probably NSCCs with some degree of 
selectivity for divalent cations, coupled to specific receptors and are directly 
activated by receptor agonists, including ATP, norepinephrine, vasopressin, ET, 
AngII, and serotonin (Orallo, 1996; Nilsson, 1998). Second messenger-operated Ca2+ 
channels are indirectly activated by diffusible second messengers such as IP3, or Ca2+ 
following receptor activation, but there is limited evidence for their existence in 
VSMCs (Felder et al., 1994; Hughes, 1995).  
 
Depletion of the intracellular SR Ca2+ stores by diverse mechanisms (receptor 
agonists, Ca2+-induced Ca2+-release activators, SR-Ca2+ ATPase inhibitors, Ca2+ 
ionophores) has been reported to cause capacitive Ca2+  entry through SOCCs in a 
wide range of cell types, including VSMCs (Gibson et al., 1998; Putney, Jr., 1999). 
Unlike receptor-operated NSCCs, SOCCs are highly selective for Ca2+ over other 
cations (Hoth & Penner, 1992). Transient receptor potential (TRP) channels have 
been suggested as excellent candidates for SOCCs and also ROCCs in mammalian 
cells (Walker et al., 2001; Clapham et al., 2001). Current research suggests that 
TRP1, TRP3, TRP6, and TRP7 encode NSCCs, that TRP2, TRP4, and TRP5 are 
SOCCs, and that TRP3, TRP4, TRP6, and TRP7 can be expressed in VSMCs 
(Walker et al., 2001; Clapham et al., 2001).  
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1.4.1.3 Mechanisms that reduce [Ca2+]i  
 
Several mechanisms exist that reduce cytosolic free Ca2+  level, including the 
plasma membrane Ca2+-ATPase (PMCA) pump, the SR Ca2+-ATPase (SERCA) 
pump, the Na+/Ca2+  exchanger (NCX), and cytosolic Ca2+-binding proteins 
(Juhaszova et al., 1996; Laporte & Laher, 1997). 
 
PMCA utilizes energy from ATP hydrolysis to produce Ca2+ efflux. The 
PMCA activity can be increased by binding to CaM and phosphorylation by several 
protein kinases such as PKA, PKC, cGMP-dependent protein kinase (protein kinase 
G; PKG) and Ca2+/CaM-dependent protein kinase (CaMK), while autoinhibition 
occurs when CaM is absent (Gonzalez et al., 1996).  
 
Like the PMCA, the SERCA pump also utilizes the energy supplied by the 
hydrolysis of ATP to accumulate Ca2+ inside the SR. Once Ca2+ is taken up into the 
SR lumen, it is bound by several small hydrophilic proteins, such as calreticulin or 
calsequestrin that are capable of binding large amounts of Ca2+ (Marin et al., 1999). 
The SERCA pump is regulated by the transmembrane protein phospholamban and 
sarcolipin, instead of CaM (Traaseth et al., 2008). The phosphorylation of 
phospholamban by PKA, PKG and CaMK increases SERCA Ca2+ affinity and the 
rate of its Ca2+ transport (Raeymaekers et al., 1990; Traaseth et al., 2008).  
 
The NCX may contribute to either Ca2+ extrusion or even Ca2+ influx, 
depending on the conditions, and its physiological significance in VSMCs has been 
questioned (Juhaszova et al., 1996).  
 
The myoplasma of the smooth muscle contains many Ca2+-binding proteins that 
may provide a mechanism for the rapid removal of Ca2+ and limiting its diffusion 
(Horowitz et al., 1996). These include CaM, troponin C, saponin, calbindin, 
calretinin, parvalbumin and the annexin family (Heizmann, 1992; Niki et al., 1996). 
The myoplasma also contains many inorganic compounds or other small organic 
molecules such as amino acids, nucleotides and organic acids which have the ability 
to bind to Ca2+ (Toescu, 1995). 
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1.4.2 Mechanisms controlling the Ca2+ sensitization of the contractile apparatus 
 
Ca2+ sensitivity can be regulated by either MLC20 phosphorylation-dependent 
or -independent mechanisms. The phosphorylation-dependent mechanism involves 
mediators controlling MLCP activity, such as Rho-kinase (Rho-activated 
kinase/ROKα/ROCKII), PKC, arachidonic acid and telokin, in addition to the 
CaMKII that regulates MLCK activity (Somlyo & Somlyo, 2000; Hirano, 2007). The 
phosphorylation-independent mechanism depends on cross-bridge regulation by thin 
filament-associated proteins, such as caldesmon and calponin (Morgan & 
Gangopadhyay, 2001). 
 
MLCP is composed of three subunits: a catalytic subunit of type 1 phosphatase 
(PP1Cδ; ~37 kDa); and two noncatalytic subunits, a large 110-130 kDa regulatory 
subunit termed myosin phosphatase target subunit (MYPT1) or myosin-binding 
subunit and a 20-kDa subunit of unknown function (Hartshorne, 1998; Ito et al., 
2004). RhoA, a small monomeric G-protein, activates Rho-kinase that 
phosphorylates the MYPT1 and inhibits its catalytic activity, increasing MLC20 
phosphorylation and, hence, contraction (Feng et al., 1999). In addition, Rho-kinase 
may phosphorylate and activate CPI-17, leading to the inhibition of PP1Cδ, and 
thereby inhibiting MLCP (Koyama et al., 2000).  
 
PKC is another important regulator of MLCP. PKC is a family of closely 
related serine/threonine kinases. The PKC family can be divided into four major 
groups (classical, novel, atypical and group D) depending on the requirement for 
Ca2+ , DAG, and/or phosphatidylserine for activation in addition to sensitivity to 
phorbol esters (Walsh et al., 1996). DAG and arachidonic acid can activate PKC 
leading to phosphorylation of CPI-17 with subsequent inhibition of MLCP (Li et al., 
1998). Arachidonic acid, released through the activation of PLA2 and/or PLD 
(Parmentier et al., 2001), was shown to directly activate Rho-kinase independent of 
RhoA (Feng et al., 1999) and PKC (Kitazawa et al., 2000).  
 
The 17 kDa protein telokin represents another regulator of MLCP. It mediates 
Ca2+ desensitization through activation of MLCP in VSMCs, which lead to a 
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decreased MLC20 phosphorylation with subsequent relaxation (Wu et al., 1998b; 
Choudhury et al., 2004).  
 
In addition to MLCP, MLCK can play a role in Ca2+ desensitization. The 
activity of MLCK is primarily regulated by the Ca2+-CaM complex. However, the 
phosphorylation of MLCK, by CaMKII, in the region of its CaM-binding domain 
decreases its affinity for the Ca2+-CaM complex and, hence, its phosphorylating 
activity (Stull et al., 1993).  
 
The thin-filament-associated proteins caldesmon and calponin possess actin- 
and CaM-binding activities, and the capability to inhibit the actomyosin ATPase 
activity and, hence, crossbridge cycling (Winder et al., 1998). When phosphorylated, 
their inhibitory action on actomyosin ATPase can be reversed, possibly leading to 
enhanced crossbridge cycling and thus to an enhanced contractile response without 
an increase in MLC20 phosphorylation (Winder et al., 1998). Thus, these thin-
filament-associated proteins may participate in the regulation of myofilament Ca2+ 
sensitivity through their phosphorylation by MAPKs and/or other kinases such as 
PKC, CaMKII, or p21-activated kinase (Morgan & Gangopadhyay, 2001).  
 
1.4.3 Other mechanisms regulating VSM contraction 
 
1.4.3.1 Cyclic nucleotides 
 
An increase in the cytosolic level of cGMP (by NO, carbon monoxide (CO), or 
natriuretic peptides) or cAMP (by β-adrenergic agonists, PGI2 or adenosine) in 
VSMCs is considered one of the major mechanisms that mediate vasodilation 
through reduction of both [Ca2+]i and Ca2+ sensitivity in VSMCs (Vaandrager & de 
Jonge, 1996; Polson & Strada, 1996; Levin et al., 1998). The increase in cGMP 
levels leads to the activation of PKG, which in turn reduces [Ca2+]i through 
activation of SERCA, PMCA and NCX, inhibition of IP3R/ IP3 synthesis, activation 
of K+ channels and inhibition of VOCCs (Vaandrager & de Jonge, 1996). The PKG-
induced reduction of myofilament Ca2+ sensitivity is possibly due to the upregulation 
of MLCP (Vaandrager & de Jonge, 1996; Somlyo & Somlyo, 2000). Similarly, the 
increase in cAMP levels exerts profound influences on cellular Ca2+ mobilization 
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through the activation of PKA, including inhibition of the activation of PLC and Ca2+  
channels, stimulation of PMCA, SERCA and the NCX and activation of K+ channels 
(Minami et al., 1993; Takuwa, 1996). In addition, the increase in cAMP reduces 
myofilament Ca2+ sensitivity, presumably by phosphorylating MLCK and thereby 
decreasing its affinity for the Ca2+-CaM complex (Takuwa, 1996).  
 
1.4.3.2 Potassium channels 
 
In VSMCs potassium (K+) channels play a fundamental role in maintaining the 
membrane potential, a major determinant of vascular tone, particularly in systemic 
resistance vessels. Specifically, the blockade of K+ channels results in membrane 
depolarization and increased Ca2+ influx through VOCCs, leading to 
vasoconstriction. Conversely, the activation of K+  channels results in plasmalemmal 
K+ efflux, membrane hyperpolarization, and reduced Ca2+ influx through VOCCs, 
leading to vasodilation (Nelson & Quayle, 1995; Takuwa, 1996). Therefore, K+ 
channels may serve to limit membrane depolarization in response to vasoconstrictor 
stimuli (as ET-1, AngII, vasopressin or TxA2) and their activation may be involved 
in response to vasodilator stimuli (as NO, EDHF, PGI2 or adenosine) (Waldron & 
Cole, 1999). 
 
Several K+ channels exist in VSMCs, such as voltage-gated K+ (KV), 
Ca2+-activated K+ (KCa), ATP-sensitive K+ (KATP) and inward rectifying K+ (Kir) 
channels. Depolarization activates KV and KCa, [Ca2+]i activates KCa, 
hyperpolarization activates Kir while ATP inhibits KATP channels (Brayden, 1996; 
Clapp & Tinker, 1998). Membrane hyperpolarization by K+ channel opening, mainly 
the large-conductance KCa (BK) and KATP channels, has been shown to account for 
the observed vascular hyporeactivity of septic shock (Chen et al., 2000; Farias et al., 
2002; Wu et al., 2004; O'Brien et al., 2005; Pickkers et al., 2006). BK is the most 
abundant K+ channel in VSMCs (Ledoux et al., 2006) that can be upregulated in 
hypertension (Rusch et al., 1996). 
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1.4.3.3 Chloride channels 
 
Chloride (Cl−) channels also play an important role in the regulation of [Ca2+]i 
in VSMCs as they are abundantly distributed in the VSM membrane. Two types of 
Cl− channels exist in VSMCs including volume-regulated Cl− (Clv) and Ca2+-
dependent Cl−  (ClCa) channels (Large & Wang, 1996; Yamazaki et al., 1998). 
Vascular distension caused by a rise in blood pressure would activate Clv channels 
leading to membrane depolarization and subsequent opening of VOCCs resulting in 
vasoconstriction. Thus, the Clv channel may play a protective role in maintaining 
tissue integrity against mechanical stretch (Yamazaki et al., 1998; Kitamura & 
Yamazaki, 2001). The ClCa channels have been reported to be activated by an 
increase in [Ca2+]i and contribute to the contractile response to norepinephrine in 
some vascular beds (Large & Wang, 1996; Kitamura & Yamazaki, 2001).  
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1.5 Aim of the work 
 
Inflammation has incompletely characterised effects on cardiopulmonary 
vascular reactivity.  Both hypo- and hyper-responsiveness to vasoactive agents have 
been reported, depending on the experimental system used.  The changes reported in 
vascular reactivity are likely to be a consequence of altered expression of vasoactive 
substances and alterations in signalling transduction events in vascular tissue.  The 
aim of this project is to characterise the relationships between changed vascular 
reactivity induced by LPS, as a powerful inflammatory stimulus, and the expression 
and activity of vasoactive mediators and associated signalling events. 
 
A better understanding of the relationship between inflammation and vascular 
smooth muscle function will provide the basis for novel therapeutic strategies in the 
treatment of cardiopulmonary pathologies associated with inflammatory disease. 
 
Objectives: 
 
1- to establish and optimize an in vitro model that can be easily controlled to 
determine the effects and mechanisms of LPS on vascular reactivity. 
 
2- to examine the effect of LPS on vascular reactivity to different 
vasoconstrictors and vasodilators in the developed in vitro model, using different 
arteries representing the systemic and pulmonary circulations. 
 
3- to determine the vasoactive mediators that could be involved in vascular 
reactivity changes induced by LPS. 
 
4- to investigate the possible alterations in signalling transduction events 
involved in VSM contraction that could be induced by LPS, including the role of 
specific receptor expression, [Ca2+]i and Ca2+ sensitization.  
 
These objectives will be used to test the hypothesis that LPS induces changes in 
VSM reactivity through affecting signalling events, such as specific receptor 
expression, Ca2+ influx, [Ca2+]i and/or Ca2+ sensitization, and these changes depend 
on the type of vascular tissue and the vasoactive mediator being tested.
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Chapter 2 
 
2.1 Tissue preparation 
 
Male Wistar rats of 8-9 weeks age (250-300 g) from the University of Bath 
Animal House (Bath, UK) were used. Animal housing and care was carried out in 
accordance with UK Home Office legislation and guidelines [Animals (Scientific 
procedures) Act 1986]. Standard animal facilities were used, including constant 
temperature (20±2°C), relative humidity (55±10%) and alternating 12 h light and 
dark cycles in addition to providing food and water ad libitum.  
 
Rats were humanely killed by cervical dislocation and the side branches of the 
pulmonary artery and the descending thoracic aorta were separated and placed in 
ice-cold HEPES-buffered physiological salt solution (PSS) (see Table 2.1 for 
composition). The vessels were dissected free of fat and connective tissue, and cut 
into rings (2-4 mm in length).  
 
2.2 Organ tissue culture 
 
Under sterile tissue culture conditions in a class 2 microflow safety biological 
cabinet (Astec Environmental Systems, North Somerset, UK), vascular rings were 
gently washed in Dulbecco’s modified Eagle’s medium (DMEM) before being 
placed into 48-well tissue culture plates, with each well containing 1 ring in 1 ml 
DMEM supplemented with penicillin (100 unit.ml-1), streptomycin (100 µg ml-1) and 
10% certified and heat-inactivated foetal bovine serum (FBS). After 1 h stabilization, 
vascular rings were transferred to a fresh medium of the same composition (control 
group) or supplemented with LPS (10 µg ml-1; LPS-treated group) and incubated for 
20 h at 37oC in humidified atmosphere of 5% CO2 in air using a Leec CO2 incubator 
(Leec Limited, Nottingham, UK). Different vasoactive reagents and inhibitors used 
in this study are listed in Table 2.2. 
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Table 2.1 Composition of physiological salt solutions (PSS) 
 
 
Krebs-Henseleit HEPES-buffered 
Ca2+-free 
HEPES-buffered 
NaCl 118 118 118 
KCl 4.7 4.7 4.7 
Glucose 11.1 11.1 11.1 
KH2PO4 1.2 ––– ––– 
NaHCO3 25 ––– ––– 
MgSO4 1.2 ––– ––– 
MgCl2 ––– 1.2 1.2 
HEPES ––– 10 10 
CaCl2 2.5 1.5 ––– 
 
All values are expressed in mM. The pH of HEPES-buffered PSS was adjusted to 7.4 
with NaOH, while that of Krebs-Henseleit solution was adjusted to the same value with 
continuous bubbling with carbogen mixture (5% CO2 + 95% O2). For [Ca2+]i 
measurements, HEPES-buffered PSS was used, but with CaCl2 2.5 mM instead of 1.5 
mM. 
 
2.3 In vitro vascular reactivity studies 
 
Following 20 h of incubation, arterial rings from the control and the 
LPS-treated groups were suspended in an organ bath between 2 stainless steel 
parallel hooks, one of which was fixed and the other attached to an isometric tension 
transducer. The organ bath was filled with 18 ml of Krebs-Henseleit solution at a 
temperature of 37oC and continuously bubbled with a mixture of 95% O2 and 5% 
CO2. Rings were allowed to equilibrate under 12 (aorta) and 7 (pulmonary artery) 
mN resting tension for 60 minutes, during which time the bath solution was replaced 
every 15 minutes and the resting tension was readjusted when necessary. Isometric 
tension generated by the VSM was measured using a force displacement transducer 
(K30, Hugo-sachs Elektronik, March, Germany) and recorded with a MacLab 4S 
unit linked to a PC running Chart v4.2 software (ADInstruments Ltd., Chalgrove, 
Oxfordshire, UK). The software was adjusted to record 20 samples per second at 
2mV sensitivity and a 20 Hz filter was applied to remove electronic noise. 
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At the beginning of each experiment, arterial ring responsiveness was assessed 
by measuring contraction to 80 mM KCl and this procedure was repeated until 
consistent responses were obtained, and then rings were washed until tension 
returned to the base line.  
 
To measure vasoconstriction, cumulative concentration-response curves were 
constructed to ET-1 (0.3-100 nM), phenylephrine (1 nM-10 µM) and U46619 (3 nM- 
1 µM). Contraction to ET-1 was also measured in absence of external Ca2+ (Ca2+ was 
omitted from PSS and 1 mM EGTA was added) or in presence of different inhibitors 
(Table 2.2).  
 
To measure vasorelaxation, rings were first preconstricted with 30 nM ET-1 
and after reaching a steady state contraction (plateau), relaxation responses to ACh (1 
nM- 30 µM), SNP (1 nM-30 µM), 8-pCPT-cGMP (0.1 µM-100 µM), BAY 41-2272 
(1 nM-10 µM), T-0156 (0.1 nM-100 nM), Ro-31-8425 (300 nM), nifedipine (10 nM-
30 µM), SKF-96365 (10 µM), and Y-27632 (0.1 µM-30 µM) were measured (Table 
2.2).  
 
In some preparations, endothelium was removed by gentle mechanical rubbing, 
and denudation was confirmed by absence of relaxation to 1 µM ACh. Appropriate 
vehicle control experiments were also conducted. 
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Table 2.2 Different vasoactive mediators and inhibitors used in this study 
Compound Function Solubility 
Final 
concentration 
ET-1 ET receptor agonist, VC H2O 0.3–100 nM 
Phenylephrine α1-adrenoceptor agonist, VC H2O 10 nM-30 µM 
U46619 TxA2 mimetic, VC DMSO 3 nM-1 µM 
KCl 
Depolarizing agent, 
receptor-independent VC 
H2O 80 mM 
ACh eNOS stimulant, VD H2O 1 nM-30 µM 
SNP NO releasing agent H2O 1 nM-30 µM 
1400W Specific iNOS inhibitor DMSO 1 µM 
8-pCPT-cGMP PDE-resistant cGMP analogue H2O 0.1 µM-100 µM 
BAY 41-2272 Direct sGC activator, VD DMSO 1 nM-10 µM 
ODQ sGC inhibitor DMSO 10 µM 
T-0156 PDE5 inhibitor DMSO 0.1 nM-100 nM 
Y-27632 ROCK inhibitor H2O 0.1 µM-30 µM 
Ro-31-8425 PKC inhibitor DMSO 300 nM 
Indomethacin COX inhibitor 
Na2CO3  
(5 mM) 
10 µM 
Trolox Antioxidant, ROS inhibitor Ethanol 200 µM 
Cycloheximide Protein synthesis inhibitor Ethanol 10 µM 
Glybenclamide K+ATP channel blocker DMSO 10 µM 
Iberiotoxin BK channel blocker H2O 100 nM 
EGTA Ca2+-chelating agent H2O 1 mM 
Nifedipine L-type VOCC blocker DMSO 10 nM-30 µM 
SKF-96365 ROCCs & SOCCs blocker H2O 10 µM 
 
VC, vasoconstrictor; VD, vasodilator. Stock solutions were normally prepared as 
1000x of the maximum concentration required. 
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2.4 Measurement of NO release 
 
In aqueous solutions, NO has a very short half-life and is oxidized to nitrite and 
nitrate, therefore, NO production was determined by measuring the accumulation of 
these breakdown products in the culture medium (Bishop-Bailey et al., 1997). Nitrate 
was first reduced to nitrite and the total nitrite was measured spectrophotometrically 
by the Greiss reaction.  
 
Pulmonary and aortic rings were divided into four groups: control, LPS, 
LPS+L-NAME (100 µM) or LPS+1400W (1 µM). Each ring was incubated in 1 ml 
medium as described above, but phenol red-free DMEM was used. After 20 h 
incubation, 60 µl supernatant was taken from each well and samples were incubated 
for 60 min at 37°C with 0.2 unit ml-1 nitrite reductase, 50 µM NADPH and 5 µM 
FAD to reduce nitrate to nitrite. Remaining NADPH, which absorbs at 550 nm, was 
oxidized by the addition of 10 unit ml-1 lactate dehydrogenase and 10 mM sodium 
pyruvate for a further 10 min at 37°C. A final sample volume of 100 µl was then 
mixed with an equal volume of modified Greiss reagent for 5 min in 96-well plates. 
Absorbance was measured at 550 nm by Versamax tunable microplate reader with 
Softmax Pro software (Molecular Devices, USA) and total nitrite concentration was 
calculated using the standard curves of sodium nitrate (0-128 nmole  ml-1) in culture 
medium run simultaneously in parallel. 
 
2.5 Assay of SNP-induced cGMP production  
 
To assess changes in cGMP production, a NO donor (100 µM SNP) was used 
to stimulate production of cGMP in the presence of a non-selective PDE inhibitor 
(100 µM IBMX) to prevent cGMP degradation (Toward et al., 2005; Fernandes et 
al., 2006). This assay is based on the competitive binding technique in which cGMP 
present in a sample competes with a fixed amount of horseradish peroxidase 
(HRP)-labeled cGMP for sites on a rabbit polyclonal antibody. During the 
incubation, the polyclonal antibody becomes bound to the goat anti-rabbit antibody 
coated onto the microplate. Following a wash, to remove excess conjugate and 
unbound sample, a substrate solution is added to the wells to determine the bound 
enzyme activity. The colour development is stopped and the absorbance is read at 
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450 nm. The intensity of the colour is inversely proportional to the concentration of 
cGMP in the sample. 
 
Rings from control and LPS groups were transferred to a HEPES-buffered PSS 
and incubated for 1 h at 37oC. Rings were then incubated with the non-selective PDE 
inhibitor 100 µM IBMX for 30 min followed by incubation with 100 µM SNP for an 
additional 10 min further incubation. Rings were then quickly frozen and 
homogenized in ice-cold 6% trichloroacetic acid to give a 10% (w/v) homogenate. 
Homogenates were centrifuged at 2000 g for 15 min at 4°C, the supernatant was 
recovered and the pellet discarded. The supernatant was washed 4 times with 5 
volumes of water saturated diethyl ether and the upper ether layer was discarded after 
each wash. The remaining aqueous extract was heated at 60oC for 10 min to remove 
any traces of ether, then lyophilised using Edwards modulyo freeze dryer (Edwards 
high vacuum international, Sussex, UK) attached to a vacuum pump (RV8, Edwards, 
UK) with samples placed in 1.5 microfuge tubes with open caps in a Savant 
SVC-100H Speed Vac Concentrator (Savant, Farmingdale, NY, USA). The dried 
extract was dissolved in a suitable volume of assay buffer and cGMP was measured 
in duplicate by ELISA using a commercially available enzyme immunoassay (R&D 
Systems Europe Ltd., Abingdon, UK) according to the manufacturer’s instructions. 
Results were expressed as picomoles of cGMP per milligram of tissue weight. 
 
2.6 Measurement of changes in [Ca2+]i in isolated aortic VSMCs 
 
2.6.1 Isolation of VSMCs 
 
Aortic rings (4-6 mm in length) were separated and incubated as before (control 
and LPS 10 µg ml-1) for 20 h. After incubation, the endothelium was removed 
mechanically by gentle rubbing and aortic rings were washed with Ca2+-free HEPES-
buffered PSS (Table 2.1) for 15 min at 37oC with continuous shaking. Vascular rings 
were digested by transferring into 2 ml enzymatic solution composed of Ca2+-free 
HEPES-buffered PSS plus the components shown in Table 2.3 and incubated at 37oC 
for 45 min with continuous shaking. The digested rings were carefully washed 3 
times in fresh Ca2+-free PSS (each 5 min), then tissues were placed in fresh Ca2+-free 
HEPES-buffered PSS and gently triturated by a fire-polished Pasteur pipette to 
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release VSMCs.  Undispersed pieces of tissue were removed by syringe filtration 
through a nylon mesh (95 µm) very slowly. The Ca2+ concentration was increased 
gradually in the final cell suspension to 0.5 mM. The viability of the cells were tested 
with trypan blue exclusion, with >85% of the cells viable considered as acceptable. 
Suspended VSMCs were then incubated at room temperature for 1 h over glass 
coverslips, coated with poly-L-lysine overnight, in a 6-well plate.  
 
Table 2.3 Enzymatic solution to separate aortic VSMCs 
Component Concentration (mg ml-1) 
Papain 1 
Collagenase-P 2 
Soyabean trypsin inhibitor 0.5 
Dithiothrietol 1 
Bovine serum albumin (BSA) 1 
 
2.6.2 Measurement of [Ca2+]i 
 
VSMCs were loaded for 1 h at room temperature with 5 µM 
membrane-permeant Fura-2 AM in HEPES-buffered PSS but with Ca2+ 2.5 mM 
(Table 2.1) containing 0.02% Pluronic F-127 at room temperature in the dark. The 
ratiometric nature of the Fura-2 dye allows for assessment of [Ca2+]i that are 
independent of diameter changes. The coverslips with attached fura-2 loaded cells 
were placed in a 0.25-ml chamber on the stage of a Zeiss Axiovert S 100 inverted 
microscope with a 40x/1.30 Fluar oil immersion objective. The cells were excited 
alternately at 340- and 380-nm wavelengths of ultraviolet light at a frequency of 0.75 
Hz by using a Spectramaster I variable excitation wavelength generator (EG&G 
Wallac LSR, Cambridge, UK). Emitting fluorescence was collected through a 
510-580nm band pass emission filter and cell images were acquired using an 
Ultrapix (PDCI) CCD camera (1024x1024 max pixels) and analysed using Ultraview 
software version 4 (Perkin-Elmer, USA). The background fluorescence signal was 
subtracted by measuring emitted fluorescence from an area on the coverslip with no 
cells.  
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The cells were perfused with either HEPES-buffered PSS (2.5 mM CaCl2) or 
Ca2+-free HEPES-buffered PSS (with 1 mM EGTA added) at 2 ml min-1 at 37oC  for 
10 min. [Ca2+]i baseline was recorded for 30 s before the perfusion of ET-1 (100 
nM). At the end of the experiment, 2 µM ionomycin with 10 mM Ca2+ followed by 2 
mM EGTA were added to obtain the fluorescence intensity maximum (Fmax) and the 
fluorescence intensity minimum (Fmin) respectively.  
 
The [Ca2+]i was determined from the Grynkiewicz equilibrium equation 
(Grynkiewicz et al., 1985):  
 
[Ca2+]i=KD×β×(R–Rmin)/(Rmax–R) 
 
R, the experimental value of fluorescence ratio, 
KD, the dissociation constant for fura-2 (224 nM at 37oC),  
β is the ratio of fluorescence of fura-2 when excited at 380 nM in the zero and 
saturating Ca2+.  
The [Ca2+]i  during sustained phase was expressed as % of the transient peak [Ca2+]i.  
 
2.7 Immunoblotting 
 
Immunoblotting or Western blotting is a technique that allows visualisation of 
the relative amounts of specific proteins in a given sample. Samples are lysed using 
different buffers containing detergents, solubilising agents and different protease 
inhibitors. To fully dissociate proteins into their polypeptide subunits, samples are 
heated with sodium dodecyl sulphate (SDS) and thiol reagent.  The negative charge 
associated with protein by the bound detergent enables proteins to migrate through a 
polyacrylamide gel strictly according to polypeptide size. Following electrophoresis, 
separated proteins are transferred into a membrane, and then probed with primary 
antibodies raised against specific proteins. Secondary antibodies, tagged with an 
enzyme such as HRP, are then added to bind specifically to the primary antibodies. 
The enzyme bound to the secondary antibodies catalyses a chemiluminescence 
reaction that enables the antibodies to be detected using photosensitive film. 
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2.7.1 Tissue lysis 
 
After 20 h of incubation with either control or LPS, pulmonary and aortic rings 
were rapidly frozen in liquid nitrogen, either directly or after reaching maximal 
contraction to ET-1, and collected at the plateau of maximal contraction in organ 
bath and then stored at -80 oC until used. Vascular tissue was mechanically 
homogenized using PowerGen 125 homogenizer (Fisher Scientific, UK) in 10 
volumes per weight (between 200-400 µl) of an ice-cold lysis buffer (see Table 2.4 
for composition). Homogenates were rotated at 4 oC for 30 min to allow inhibition of 
proteases and then centrifuged (18000 g for 15 min at 4 oC) and supernatant was used 
as described below. 
 
Table 2.4 Immunoblotting buffers 
Buffer Composition 
Lysis buffer I 
150 mM NaCl, 1 mM EDTA, 50 mM Tris HCl pH 7.5, 1% 
Nonidet-P40, 10% glycerol, 1 mM sodium orthovanadate, 10 mM 
sodium fluoride, 1 mM PMSF and 1% protease inhibitor cocktail 
Lysis buffer II 
1x RIPA buffer, 10 mM sodium fluoride, 1 mM sodium molybdate, 1 
mM PMSF and 1% protease inhibitor cocktail  
Sample buffer 
10% SDS, 200 mM Tris HCl pH 6.8, 50% glycerol, 0.01% 
bromophenol blue and 5% 2-mercaptoethanol (added just prior use) 
Running buffer 
192 mM glycine, 25 mM Trizma base, 0.1% (w/v) SDS, ultrapure 
water 
Semi-dry transfer 
buffer 
39 mM glycine, 48 mM Trizma base, 0.0375% SDS, 20% (v/v) 
methanol, ultrapure water 
Tris-buffered 
saline (TBS) 
20 mM Tris-HCl pH 7.5 and 150 mM NaCl  
TBSN TBS + 0.05% Nonidet-P40 
 
2.7.2 Determination of protein concentrations in lysates 
 
In order to provide similar amounts of proteins in the same volume of each 
sample, supernatant protein concentration was quantified by the BioRad protein 
assay (Bio-Rad, Hercules, USA) which is based on the Bradford protein 
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quantification assay (Bradford, 1976; Zor & Selinger, 1996). A 1 mg ml-1 solution of 
BSA was used to construct the standard curve at concentrations of 0-32 µg µl-1. 
Equal volumes (2 µl) of each lysate sample or the standard were added to 250 µl of 
Quickstart Bradford dye reagent 1x (BioRad) in triplicate in a 96-well microtitre 
plate. Protein concentration was measured at 595 nm using Versamax tunable 
microplate reader with Softmax Pro software (Molecular Devices, USA). The protein 
concentrations of the lysate samples were then calculated from the standard curve by 
linear regression with additional compensation for any dilutions.  
  
2.7.3 Immunoblotting sample preparation 
 
After determining protein concentrations, lysate samples containing higher 
concentrations of proteins were diluted with ice-cold lysis buffer to equalize the 
protein concentrations between all samples. Samples (100-200 µl each) were mixed 
with 5x SDS sample buffer (see Table 2.4 for composition) in 4 to 1 volumes 
respectively, heated at 100 oC for 5 min using Techne dri-block DB-2A (Techne 
Cambridge Limited, Cambridge, UK), placed on ice for 5 min and then stored at -20 
oC until used.  
 
2.7.4 Polyacrylamide gel electrophoresis 
 
One-dimensional polyacrylamide gels were prepared using BioRad Mini 
Protean II gel electrophoresis with attached PowerPac 300 unit (Bio-Rad Labs, 
Hemel Hempstead, UK) and assembled according to the manufactures guidelines, 
utilising pre-cleaned glass plates. The resolving gel was prepared at the desired 
percentage of acrylamide depending on the relative size of the proteins under 
investigation (Table 2.5), where 7.5% gel was used for all proteins studied except 
those less than 30 kDa (MLC20 and CPI-17) in which 15% gel was used. The 
resolving gel was poured between the glass plates and overlaid with water to achieve 
a uniform line and left to polymerise for 40 min. The water was then aspirated and 
the stacking gel poured on top, with a 10-well comb inserted between the plates to 
create the wells for the loading of protein samples, and left for 20 min to polymerize. 
The wells were thoroughly cleaned with water to remove any residual stacking gel 
before being filled with lx SDS-PAGE running buffer (Table 2.4). Protein samples 
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(40 µg per lane) were then loaded into the wells with one well loaded with 10 µl of 
pre-stained molecular weight markers to serve as a guide to ease protein band 
identification at a later stage. Pre-cast gels were then placed into a gel tank with lx 
SDS-PAGE running buffer in the top and bottom reservoirs and electrophoresis was 
run at 80 volts until the bromophenol blue present in the lysate samples entered the 
resolving gel. At that time, the voltage was increased to 180 volts. Gels were run 
until the bromophenol blue dye reached the bottom of the resolving gel or the desired 
separation of bands in reference to the molecular weight markers was achieved, then 
gels were removed and placed into semi-dry transfer buffer.  
 
Table 2.5 Recipes for electrophoresis gels 
Running gel  
 7.5% 15% 
Stacking gel 5% 
30% acrylamide/Bis-acrylamide 3.75 7.5 1.67 
MilliQ H2O 5.6 1.85 6.0 
1M Tris-HCl pH 8.8 5.6 5.6 –– 
1M Tris-HCl pH 6.8 –– –– 1.25 
10% SDS 0.25 0.25 0.15 
 
All values are expressed in ml. Total volume of the running gel is sufficient for three 1 
mm thick mini gels, while that of stacking gel is sufficient for four 1 mm thick mini gels. 
50 µl ammonium persulfate (10% w/v) and 20 µl TEMED are added to running and 
stacking gel mixtures just before pouring into the gel cassettes. 
 
2.7.5 Semi-dry transfer of proteins to nitrocellulose membrane 
 
Following gel electrophoresis, the separated proteins were transferred onto 
nitrocellulose membranes by semi-dry transfer using Bio-Rad Transblot SD cell 
(BioRad, USA). This approach was achieved by removing the gel from the 
pre-assembled gel apparatus and soaked in semi-dry transfer buffer (Table 2.4). In 
order to ensure efficient transfer of the proteins, the bottom (positive) graphite 
electrode was dampened with transfer buffer. A gel-membrane sandwich composed 
of four pieces of 3MM Whatman paper, a piece of nitrocellulose membrane, the gel 
and finally another four pieces of Whatman paper, all of the same size as the gel and 
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all pre-soaked in the semi-dry transfer buffer, were placed on the bottom electrode 
and rolled to gently expel any air bubbles then the upper negative electrode, which 
was dampened with transfer buffer, was gently lowered into place. The proteins were 
transferred at a rate of 0.8 mA cm-2 (40 mA per gel) for 1 hour.  
 
2.7.6 Antibody probing and immunoblot developing 
 
Once the transfer had finished, the transfer apparatus was disassembled and 
the nitrocellulose membrane was washed in TBSN (See Table 2.10) prior to the 
addition of water soluble Ponceau S to check for successful and even transfer of 
proteins and to mark the molecular weight standards. Excess stain was removed by 
washing the membrane in TBSN. The non-specific binding of antibody was blocked 
by incubation of the membranes for 1 h with TBSN containing 5% non-fat milk with 
gentle shaking on a Stuart rocking platform (Sterilin LTD, Staffordshire, UK) at 
room temperature. The membranes were then subjected to wash in TBSN before 
incubation overnight at 4 oC with one of the primary antibodies (see Table 2.6 for 
conditions used for different antibodies) with gentle shaking. The next day, blots 
were washed three times each for five min with TBSN before being incubated for 1 h 
with HRP-conjugated secondary antibodies (1: 10000-20000 dilution in TBSN with 
2% milk, Dako, Glostrup, Denmark). Immunoreactive protein bands were detected 
by ECL or ECL Advance kit (Amersham Biosciences) and visualized on an X-Ray 
film (Fujifilm Corporation, Tokyo, Japan). The intensity of the specific bands was 
quantified by densitometric analysis using Labimage software (Kapelan Bio-imaging 
Solutions, Halle, Germany).  
 
2.7.7 Membrane stripping and reprobing 
 
In order to probe for a different molecule in the lysate samples of a 
nitrocellulose membrane that had already been used, the used membranes were 
stripped free of antibody before reusing. Membranes were first washed with TBSN 
for 10 min at room temperature in a rocking platform, and then they were stripped 
using Re-Blot Plus solution (Chemicon, USA) according to manufacturer instruction. 
After washing several times with TBSN, membranes were blocked and reprobed 
with antibodies as described before. This procedure of stripping and reprobing was 
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specifically used for examining equal loading of phospho-proteins using antibodies 
specific for their non-phospho proteins. For other non-phosphorylated proteins, an 
antibody against abundant protein in the lysate samples, such as rabbit polyclonal 
anti-β-actin antibody, was used usually without stripping if there is an appropriate 
size difference between β-actin and the desired protein, otherwise stripping was 
applied.  
 
Table 2.6 Immunoblotting conditions for primary antibodies 
Molecule targeted by 
antibody 
Primary 
antibody 
species 
MW (kDa) 
Primary 
antibody 
conc. 
Secondary 
antibody 
conc 
CPI-17 rabbit 17 1  µg ml
-1
 1:10000 
MLC20 rabbit 20 1:1000 1:10000 
MYPT1 rabbit 130 1:200 1:10000 
Phospho-CPI-17 (Thr38) rabbit 17 2  µg ml-1 1:10000 
Phosphodiesterase 5 mouse 85/95 1:500 1:10000 
Phospho-MLC20 (Ser19) rabbit 20 1:1000 1:10000 
Phospho-MYPT1 (Thr850) rabbit 130 1  µg ml-1 1:10000 
Phospho-ROCK α (The396) rabbit 160 2 µg ml-1 1:10000 
PKC rabbit 80 1:200 1:10000 
sGCα1 rabbit 80 1:10000 1:10000 
sGCβ1 rabbit 69 1:4000 1:10000 
β-actin rabbit 45 1:1000 1:10000 
 
All antibodies used are polyclonal except anti-phosphodiesterase 5 which is monoclonal. 
Primary antibody concentration represents the antibody dilution in TBSN with 0.01% 
(w/v) sodium azide (10 ml per each membrane). Secondary antibody concentration 
represents the antibody dilution in TBSN with 2% (w/v) skimmed milk (10 ml per each 
membrane). 
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2.8 Quantitative RT-PCR 
 
To measure changes induced by LPS in the gene expression of NO and ET-1 
systems, RNA was extracted from aortic and pulmonary arterial rings after culturing, 
reverse-transcribed (RT) to cDNA and then quantified using gene specific primers 
for eNOS, iNOS, ET-1, ETA and ETB by real-time polymerase chain reaction (PCR). 
 
2.8.1 RNA isolation and purification 
 
After 20 h of incubation with either control or LPS, pulmonary and aortic rings 
were rapidly frozen in liquid nitrogen and then stored at -80 oC until used. Vascular 
tissue was mechanically homogenized using PowerGen 125 homogenizer (Fisher 
Scientific, UK) in 2 ml RNAase free microfuge tube with rounded bottom 
containing 1 ml TRIZOL reagent (Invitrogen, USA). The homogenized samples 
were then incubated for 5 minutes at 15-30°C before adding 0.2 ml chloroform in an 
Airone PCR-640 UV cabinet (Safelab Systems, Bristol, UK), vortexing, incubating 
at 15-30°C for 2-3 min and centrifugation at 15,400g for 15 min at 4°C using 
Beckman GS-15R centrifuge. Following centrifugation, the upper colourless aqueous 
phase containing RNA was transferred to 1.5 ml RNAase free microfuge tube and 
the RNA was precipitated by adding 0.5 ml of isopropyl alcohol. Samples were 
incubated at 15-30°C for 10 minutes and then centrifuged at 15,400g for 10 min at 
4°C. The precipitated gel-like RNA pellet was washed once by adding 1 ml of 75% 
ethanol, vortexed and then centrifuged at 15,400g for 5 min at 4°C. The RNA pellet 
was dried in air for 5-10 min prior to being resuspended in 50-100 µl of sterile water 
and heating the samples to 55°C for 10 minutes to break secondary structures within 
the RNA and enhancing its solubility. The produced RNA pellet was further purified 
using High Pure RNA Tissue Kit (Roche Applied Science, Mannheim, Germany) 
which contains DNase digest step to remove any genomic DNA according to 
manufacturer’s instructions.  
RNA concentration and purity for each sample was determined using a 1:100 
dilution of the RNA and the absorbance measured at 260nm and 280nm using the 
GeneQuant II spectrophotometer. 
The concentration of RNA was determined as following: 
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Concentration of RNA (µg ml-1) = dilution factor x 40* x A260 
 
* The standard consideration is that 40 µg m1-1 of RNA has an absorbance of 1 at 
260 nm 
Ratio values of 1.8-2.0 verified acceptable RNA purity. RNA samples were then 
stored at -80°C. 
 
2.8.2 cDNA synthesis 
 
RNA samples (1 µg each) were reverse-transcribed using Omniscript RT kit 
(Quiagen GmbH, Hilden, Germany) with anchored oligo dT primers (ABgene, 
Surrey, UK) in the presence of an RNase inhibitor (RNasin Plus, Promega, Madison, 
WI, USA) according to manufacturer’s instructions using a Perkin Elmer GeneAmp 
PCR System 2400 thermal cycler. The reaction mixture (Table 2.7) was setup at 
40°C for 60 minutes followed by 70°C for 10 minutes to inactivate the reverse-
transcriptase. RT-negative samples, in which no reverse-transcriptase was added, 
were also prepared to identify any possible genomic DNA contamination within 
RNA samples. cDNAs produced were stored at -20°C. 
 
Table 2.7 Reverse-transcriptase (RT) reaction mixture 
Component Volume (µl) 
10x RT buffer 2 
dNTP (5 mM) 2 
Anchored oligo dT primers (500 ng ml-1) 2 
RNasin plus  0.25 
Reverse transcriptase (RT) 1 
RNA template 1-12 
PCR grade H2O to 20 
 
2.8.3 Primers 
 
Primers were designed using Primer3 software (Whitehead Institute for 
Biomedical Research, Cambridge, MA, USA) and ProbeFinder Version 2.04 
software (Roche Applied Science, Mannheim, Germany), after retrieving gene 
Chapter 2 - Methods & Materials 
 
 48 
specific sequences and intron-exon information from Pubmed (Entrez Gene) and 
Ensembl v37 (Rattus norvegicus genome). Primers were analysed by NetPrimer 
software (PREMIER Biosoft International, Palo Alto, CA, USA) to detect any 
primer-dimer, haipins or other secondary structures. Each primer was then blasted on 
Pubmed/Ensembl to ensure its specificity to the gene required. All primers were 
intron-spanning to avoid amplification of any genomic DNA and their product sizes 
are less than 150 bp which is optimal size for real-time PCR. The primers used in this 
study are presented in Table 2.8. 
 
Table 2.8 Primers used in this study 
Primer Sequence 
Annealing 
temp. (°C) 
Amplicon 
size (bp) 
Forward CTACTTCTGCCACCTGGACAT 
ET-1  
Reverse CCTAGTCCATACGGGACGAC 
55 66 
Forward ATCTCTGCGCTCTCAGTGTG 
ETA  
Reverse GATCCCGATTCCTTGAACC 
55 71 
Forward CTGTTGGCTTCCCCTTCAC 
ETB 
Reverse TGTAGTCCAAAACCAGCAAAAA 
57 107 
Forward TGACCCTCACCGATACAACA 
eNOS  
Reverse CGGGTGTCTAGATCCATGC 
55 60 
Forward TGGTGGTGACAAGCACATTT 
iNOS  
Reverse GGTATGCCCGAGTTCTTTCA 
55 95 
Forward CCCGCGAGTACAACCTTCT 
β-actin  
Reverse CGTCATCCATGGCGAACT 
55 72 
 
Annealing temperature was determined by software (NetPrimer and Primer3) 
and tested using PCR 
  
2.8.4 PCR 
 
PCR is an in vitro method for the enzymatic synthesis of specific DNA 
sequences, using two oligonucleotide primers that bind to opposite strands and flank 
the region of interest in the target DNA. Numerous cycles involving template 
denaturation to open the double stranded DNA, primer annealing, and the extension 
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of the annealed primer by a DNA polymerase are performed using a thermal cycler. 
The products synthesized at the end of each cycle then serve as the template in the 
next round, hence the number of target DNA copies doubled at every cycle 
(exponential accumulation).  
 
All PCR reactions were set-up in 25 µl reaction volumes (Table 2.9), in thin 
walled PCR tubes. The PCR reaction was amplified using a Perkin Elmer GeneAmp 
PCR System 2400 thermocycler, and the amplification cycles are illustrated in Table 
2.10. At the beginning of each run, the samples were incubated at 95°C to enable 
activation of the thermostable recombinant Taq DNA polymerase (Hot Start DNA 
polymerase, Promega) by the removal of specific blocking groups. Thus, the enzyme 
is completely activated at a temperature where primers can not bind non-specifically. 
PCR products were then analysed by agarose gel electrophoresis. 
 
Table 2.9 PCR reaction mixture 
Component Volume (µl) 
PCR Master Mix (Promega) 12.5 
Sense primer (0.5 µM final) 0.5 
Antisense primer (0.5 µM final) 0.5 
cDNA template  1-2.5 
PCR grade H2O to 25 
 
Table 2.10 PCR amplification cycles 
Cycle Temp. °C Time (min) No. of cycles 
Initial denaturation (hot start) 94 5 1 
Denaturation 94 0.5 
Annealing 55 0.5 Amplification 
Elongation 72 0.5 
40 
Final elongation 72 10 1 
Hold 4 ∞ 1 
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2.8.5 Agarose gel electrophoresis 
 
Electrophoresis-grade agarose was dissolved in 1x Tris-Borate EDTA (TBE) at 
a concentration of 1.8 %. For small 8-samples gel, 0.9 g of agarose was added to 50 
ml TBE buffer in a flask covered with aluminium foil to prevent spillover, heated in 
microwave for 1.5-2 min at medium power, cooled to around 50°C and the volume 
was readjusted to 50 ml with warm ultrapure water, and then poured into horizontal 
gel cast apparatus with a comb inserted to form wells and allowed to set at 4°C. The 
comb was removed and the buffer solution was poured into the gel box up to 2-3 mm 
above the gel. The wells were loaded with the samples (6x TrackIt loading buffer 3.3 
µl, DNA sample 2.7-6.7 µl, H2O to 20 µl) alongside low-molecular weight DNA 
ladder markers. The gel was run in Kodac Biomax QS 710 gel electrophoresis 
chamber attached to BioRad PowerPac 300 unit at 80 V for ~ 1.5 h until bands were 
clearly separated, as visualised by the migration of orangeG at 50 bp and 
bromophenol blue at 300 bp. The gel was then placed into the staining tray with 
ethidium bromide (50 µl in 100 ml TBE buffer to obtain final concentration of 
0.5µg/ml) for 10-20 min and then rinsed once with TBE buffer. DNA was visualised 
on a UV transilluminator (at 254 nm) and photographed with GeneGenius Gel 
Documentation System (Syngene Inc., Cambridge, UK). 
 
2.8.6 Real-time PCR 
 
Real-time or quantitative PCR is a system for monitoring the PCR kinetics as 
PCR products accumulate, based on the property that the intercalator SYBR Green l 
which binds to the minor groove of the double stranded DNA produced during each 
amplification reaction and fluoresces once bound. The fluorescence is recorded at the 
end of the elongation phase at 530mn using a special PCR thermocycler coupled with 
fluorescence acquisition system. Amplification enhances the amount of 
double-stranded DNA generated which SYBR Green I binds, thus resulting in an 
increase in fluorescence. This elevated fluorescence is monitored throughout the 40 
cycles, thus by plotting the increase in fluorescence versus cycle number; the system 
provides a complete picture of the PCR process in comparison to assaying product 
accumulation. To prove that only the desired PCR product has been amplified, melt 
curve analysis was performed. Melt curve analysis was carried out by heating the 
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PCR product slowly at a rate of 0.1°C sec-1 from 65°C to 95°C which causes melting 
of double-stranded DNA and a corresponding decrease in SYBR Green I 
fluorescence. The real-time PCR machine continuously monitors the fluorescence 
signal and displays it as melting peaks. Each specific peak represents the 
characteristic melting temperature of a particular DNA product. The resultant PCR 
product can also be analysed on an agarose gel and stained with ethidium bromide 
then visualised under a UV transilluminator to provide further confirmation of 
product identity. 
 
Real-time PCR amplification and on-line monitoring was performed using 
LightCycler® FastStart DNA Master SYBRgreen I in LightCycler® 1.5 thermal 
cycler (Roche Applied Science, Mannheim, Germany) according to manufacturer’s 
instructions. A master mix composed of 0.4 µM primers, 3.5 mM MgCl2, 2 µl SYBR 
Green Master Mix and PCR-grade water (to 18 µl) was added to pre-chilled 
capillaries, prior to the addition of 2 µl of 10-1 diluted cDNA. The capillaries were 
centrifuged at 3000 g for 30 seconds at 4°C before loading into the LightCycler. 
Each template was analyzed in duplicate within the same run. Following 40 
amplification cycles, melt-curve analyses were performed to verify specific 
amplification. PCR efficiency of both the target and reference genes was calculated 
from the derived slopes of standard curves by LightCycler software (v4.0). These 
PCR efficiency values were used to calculate the relative quantification values for 
calibrator-normalized target gene expression as following: 
 
Efficiency (E) = [10(-1/slope)-1] 
  
Cp target unknown / Cp reference unknown  
Normalized Ratio =  
Cp target calibrator / Cp reference calibrator 
 
 
- Cp or Ct = Crossing point or threshold cycle at which florescence starts linear part  
- Control= Calibrator = Exogenous standard 
- Unknown= Sample 
- Normalizer= Endogenous standard = Reference = Housekeeping Gene  
 
Chapter 2 - Methods & Materials 
 
 52 
 
 
 
  
 
  
In all cases transcript levels were normalized to β-actin. The real-time PCR 
amplification cycles and melt curve analysis program are shown in Table 2.11.  
 
Table 2.11 Lightcycler PCR program 
 
According to LightCycler® FastStart DNA Master SYBRgreen I manual 
instructions. 
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2.9 Data analysis 
 
Data are expressed as mean ± standard error of mean (SEM), where (n) equals the 
number of animals, except in qRT-PCR (n= number of independent experiments, 
each using duplicate PCR reactions from the same sample prepared from pooled 
tissue lysates of 2 animals) and in [Ca2+]i experiments (n= number of VSM cells 
from at least 3 animals). The [Ca2+]i  during the sustained phase is expressed as a % 
of the transient [Ca2+]i phase. Vascular relaxation is calculated as % of maximal 
steady state contraction induced by 30 nM ET-1. The highest response obtained is 
considered as the maximum response (Emax). pEC50 (= negative log the concentration 
producing 50% of maximal response) was determined from non-linear regression 
analysis (4-parameter curve fit) carried out using Graphpad Prism software (V 4.03, 
Graphpad Software Inc., San Diego, USA). Significant differences between groups 
were determined with paired Student’s t-test or one-way ANOVA with Dunnett’s, 
Tukey-Kramer’s or Student-Newman-Keuls Multiple Comparisons post-hoc tests as 
appropriate. 
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2.10 Materials 
 
Material Catalogue No. Company 
1400W 1415 Tocris Bioscience  
2-Mercaptoethanol M3148 Sigma-Aldrich  
2-Propanol P/7507/17 Fisher Scientific 
30 ml container sterile 128C Sterilin 
30% Acrylamide/Bis-acrylamide solution 161-0158 BioRad 
60 ml container sterile TP35-004 Fisher Scientific 
7 ml Bijou 129B Fisher Scientific 
8-pCPT-cGMP C5438 Sigma-Aldrich 
Absolute ethanol E/0650DF/17 Fisher Scientific 
Acetylcholine chloride 15917-0050 Fisher Scientific 
Agarose 1000 10975-035 Invitrogen 
Albumin from bovine serum A4919 Sigma-Aldrich 
Ammonium persulphate A9164 Sigma-Aldrich  
Anchored oligo dT AB-1247 ABgene 
Anti-CPI-17 antibody 07-344 Upstate 
Anti-MLC20 antibody 3672 Cell Signaling Technology 
Anti-MYPT1 (H-130) antibody Sc-25618 Santa Cruz Biotechnology 
anti-phospho-CPI-17 (Thr38) antibody 36-006 Upstate 
Anti-phosphodiesterase 5 antibody 611498 BD Biosciences 
Anti-phospho-MLC20 (Ser19) antibody 3671 Cell Signaling Technology 
Anti-phospho-MYPT1 (Thr850) antibody 36-003 Upstate 
Anti-phospho-ROCK α (The396) antibody Ab24843 Abcam 
Anti-PKC (H-300) antibody Sc-10800 Santa Cruz Biotechnology 
Anti-soluble guanylyl cyclase α1 antibody Ab50358 Abcam 
Anti-soluble guanylyl cyclase β1 antibody Ab50333 Abcam 
Anti-β-actin antibody 4967 Cell Signaling Technology 
BAY 41-2272 196876 Calbiochem 
Bromophenol blue B8026 Sigma-Aldrich 
Calcium Chloride 1M solution 190464K BDH 
Cell culture 24-multiwell plates 662160 Greiner bio-one 
Cell culture 6-multiwell plates 657160 Greiner bio-one 
Cell culture 96-multiwell plates 137101 NUNC 
Cell culture dishes, 30 mm 153066 Nunc 
Chloroform C/4960/17 Fisher Scientific 
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Chromotography paper 3MM 46*57 cm 3030917 Whatman 
Collagenase-P 1213857 Roche Applied Science 
Coverslips, borosilicate glass,  ––––– BDH 
Cryotube vials 1.8 ml 368632 Nunc 
Custom primers (25 nmole) ––––– Invitrogen 
Cycloheximide 239764 Calbiochem 
Deltiazem D2521 Sigma-Aldrich 
Diethylether D/2450/17 Fisher Scientific 
Dimethyl sulphoxide (DMSO) D8418 Sigma-Aldrich 
Disposable serological pipets 10 ml 607180 Greiner bio-one 
Disposable serological pipets 25 ml 760180 Greiner bio-one 
Dithiothreitol D0632 Sigma-Aldrich 
DMEM 21969-035 Gibco 
DMEM without phenol red 31053 Gibco 
ECL advance Western Blotting detection kit RPN2135 GE Healthcare 
ECL Western Blotting detection kit RPN2209 GE Healthcare 
EDTA E5134 Sigma-Aldrich 
EGTA E4378 Sigma-Aldrich 
Endothelin-1 (ET-1) 88-1-10A American peptide company 
Ethidium Bromide solution H5041 Promega 
FAD F6625 Sigma-Aldrich 
Filter tips P2/P10 racked 771288 Greiner bio-one 
Filter tips P20 racked 774288 Greiner bio-one 
Filter tips P200 racked 772288 Greiner bio-one 
Foetal bovine serum (FBS) certified (heat-
inactivated) 10082-139 Gibco 
Fuji Medical X-Ray Film 2731261 Fisher Scientific 
Fura-2 AM F1221 Molecular Probes 
Glucose anhydrous 284508W BDH 
Glybenclamide G0639 Sigma-Aldrich 
Glycerol G5516 Sigma-Aldrich 
Glycine 50046 Sigma-Aldrich 
Griess reagent (modified) G4410 Sigma-Aldrich 
HEPES H3375 Sigma-Aldrich 
High Pure RNA tissue kit 2033674 Roche Applied Science 
Horseradish peroxidase-conjugated goat anti-
mouse secondary antibody P0447 Dako 
Horseradish peroxidase-conjugated goat anti-
rabbit secondary antibody P0448 Dako 
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Horseradish peroxidase-conjugated rabbit 
anti-goat secondary antibody P0449 Dako 
Hydrochloric acid 37% H/1150/PB17 Fisher Scientific 
Iberiotoxin L8211 Latoxan 
IBMX 410957 Calbiochem 
Indomethacin I-7378 Sigma-Aldrich 
Ionomycin calcium I0634 Sigma-Aldrich 
K2HPO4, anhydrous P/5240/53 Fisher Scientific 
KH2PO4 P/4760/53 Fisher Scientific 
Lactate dehydrogenase from rabbit muscle L1254 Sigma-Aldrich 
Lightcycler capillaries 20 ul 1909339 Roche Applied Science 
LightCycler FastStart DNA Master SYBR 
Green I kit 2239264 Roche Applied Science 
Lipopolysaccharide (LPS) from E.coli 055:B5 L2880 Sigma-Aldrich 
Lipopolysaccharide (LPS) from Salmonella 
typhimurium L6511 Sigma-Aldrich 
L-NAME hydrochloride N-5751 Sigma-Aldrich 
Low Molecular Weight DNA Ladder N3233S New England Biolabs 
Magnesium chloride 1M solution 220933M BDH 
Magnesium sulphate M/1000/60 Fisher Scientific 
Methanol M/4056/17 Fisher Scientific 
Microcentrifuge tubes 0.5 ml amber TUL-150-130T Fisher Scientific 
Microcentrifuge tubes 0.5 ml Clear TUL-150-010G Fisher Scientific 
Microcentrifuge tubes 1.5 ml amber TUL-150-270D Fisher Scientific 
Microcentrifuge tubes 1.5 ml Clear TUL-150-150N Fisher Scientific 
Microcentrifuge tubes 2 ml Clear FB74111 Fisher Scientific 
NADPH 481973 Calbiochem 
Natural gel saver II tips (1-200 ul) FB56205 Fisher Scientific 
Nifedipine N7634 Sigma-Aldrich 
Nitrate reductase (Aspergillus) N7265 Sigma-Aldrich 
Nitrile Gloves 52003M Kimberly Clark 
Nonidet P-40 56009 Sigma-Aldrich 
Non-sterile 96-well plate 260836 NUNC 
ODQ 0880 Tocris Bioscience 
Omniscript RT Kit 205111 Quiagen 
Papain P4762 Sigma-Aldrich 
Parameter cGMP assay Kit KGE003 R&D Systems 
Pasteur pipettes, disposable 3 ml FB55354 Fisher Scientific 
PCR Master Mix M7502 Promega 
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Penicillin/streptomycin 15140-122 Invitrogen 
Petri Dish, 90 mm, sterile 101VR20 Sterilin 
Phenylephrine P6126 Sigma-Aldrich 
Phenylmethanesulfonylfluoride (PMSF) P7626 Sigma-Aldrich 
Phosphate buffered saline (PBS, 10X) 3082920A Invitrogen 
Pipet tips 0.1-10 µl FB34521 Fisher Scientific 
Pipette tips blue 200-1000 µl 740295 Greiner bio-one 
Pipette tips Clear 1-5 ml 745290 Greiner bio-one 
Pipette tips yellow 10-200 µl 739295 Greiner bio-one 
Pluronic acid F-127 20% in DMSO P3000MP Invitrogen 
Poly-L-Lysine solution 70000-150000 KDa 3438-100-01 R&D Systems 
Ponceau S solution P7170 Sigma-Aldrich 
Potassium chloride P/4240/53 Fisher Scientific 
Protease inhibitor cocktail for 
mammalian/tissue extracts P8340 Sigma-Aldrich 
Protein Standards (Precision Plus, ALL Blue) 161-0373 BioRad 
Quickstart Bradford dye reagent 1X 500-0205 BioRad 
Reblot Plus Strong antibody stripping solution 
10X 2504 Millipore 
RIPA buffer 10X 9806 Cell Signaling Technology 
RNasin Plus RNase inhibitor N2611 Promega 
Ro-31-8425 557514 Calbiochem 
SKF-96365 1147 Tocris Bioscience 
Skimmed Milk LP0031 Oxoid  
Sodium azide S2360 Sigma-Aldrich 
Sodium bicarbonate S/4200/63 Fisher Scientific 
Sodium carbonate S/2920/53 Fisher Scientific 
Sodium Chloride S/3105/63 Fisher Scientific 
Sodium dodecyl sulphate L4390 Sigma-Aldrich 
Sodium fluoride S7920 Sigma-Aldrich 
Sodium hydroxide 22146-5 Sigma-Aldrich 
Sodium molybdate S6646 Sigma-Aldrich 
Sodium nitrate 71752 Sigma-Aldrich 
Sodium nitroprusside 71778 Sigma-Aldrich 
Sodium orthovanadate 567540 Calbiochem 
Sodium pyruvate 100 mM sterile liquid S8636 Sigma-Aldrich 
Syringe driven filter unit (0.22 µm) SLGP033RS Millipore 
Syringes, plastipack, different volumes –––– BD Biosciences 
T-0156 1676 Tocris Bioscience 
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TEMED T9281 Sigma-Aldrich 
Thapsigargin 586005 Calbiochem 
TrackIT Cyan/Orange loading buffer 10482-028 Invitrogen 
Trans-Blot nitrocellulose membrane 0.45 µm 162-0115 BioRad 
Trichloroacetic acid T9159 Sigma-Aldrich 
Trizma base T87602 Sigma-Aldrich 
Trolox 648471 Calbiochem 
Tryban blue T6146 Sigma-Aldrich 
Trypsin inhibitor from soybean T9003 Sigma-Aldrich 
Tubes 15 ml polypropylene, sterile 188261 Greiner bio-one 
Tubes 50 ml polypropylene, sterile 227270 Greiner bio-one 
U46619 16450.1 Cayman 
Ultrapure H2O (MilliQ) –––– Millipore 
Ultrapure TBE buffer 10X 15558-042 Invitrogen 
Y-27632 1254 Tocris Bioscience 
 
Company addresses: 
Abcam (Cambridge, UK), ABgene (Surrey, UK), American peptide company 
(Sunnyvale, CA, USA), BD Biosciences (Oxford, UK), BDH (VWR International, 
Lutterworth, UK), BioRad (Hercules, CA, USA), Calbiochem (Nottingham, UK), 
Cayman/Axxora (Nottingham, UK), Cell Signaling Technology (Danvers, MA, USA), 
Dako (Glostrup, Denmark), Fisher Scientific (Loughborough, UK), GE Healthcare 
(Little Chalfont, UK), Gibco/Molecular Probes/Invitrogen (Carlsbad, USA), Greiner bio-
one (Frickenhausen, Germany), Kimberly Clark (Zaventem, Belgium), Latoxan 
(Valence, France), Upstate/Millipore (Billerica, MA, USA), New England Biolabs 
(Ipswich, MA, USA), NUNC (Roskilde, Denmark), Oxoid (Basingstoke, UK), Promega 
(Madison, WI, USA), R&D Systems (Abingdon, UK), Roche Applied Science 
(Mannheim, Germany), Santa Cruz Biotechnology (Santa Cruz, CA, USA), Sigma-
Aldrich (Poole, UK), Sterilin/Barloworld (Stone, UK), Tocris Bioscience (Avonmouth, 
UK), Whatman (Maidstone, UK). 
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Chapter 3 
3.1 Introduction 
 
LPS is a powerful stimulator of inflammatory pathways and a key molecule 
involved in the initiation of sepsis and associated syndromes (Heine et al., 2001; 
Buras et al., 2005). The administration of LPS, both in humans (Suffredini et al., 
1989) and in animals (Ruetten et al., 1996; Peters & Lewis, 1996; Gardiner et al., 
1996b), has been used as a model to study sepsis and septic shock, which is a 
complex pathophysiological state characterized by systemic vasodilation and 
hyporesponsiveness to different vasoconstrictor agents (Wakabayashi et al., 1987; 
Guc et al., 1990; Umans et al., 1993; Sirmagul et al., 2006; Matsuda & Hattori, 
2007).  
 
Different models have been developed to study LPS-induced changes in 
vascular reactivity. These include in vitro models (McKenna, 1990; Hall et al., 1996; 
O'Brien et al., 2001; Piepot et al., 2002; Miyamoto et al., 2004; Boer et al., 2005) 
and in vivo models (Gardiner et al., 1995; Griffiths et al., 1995; Ruetten et al., 1996; 
Weitzberg et al., 1996; Ruetten & Thiemermann, 1996; Curzen et al., 1997; Griffiths 
et al., 1997; Rees et al., 1998; Mitaka et al., 1999; Hirata & Ishimaru, 2002) as well 
as ex vivo models using vessels harvested from endotoxic animals (Schneider et al., 
1992; Gunnett et al., 1998; Wu et al., 2004). 
 
The results of the previous studies are highly variable. For example, LPS 
induces hyporeactivity to phenylephrine in rat in vivo (Guc et al., 1990), in rat 
superior mesenteric artery in vitro (O'Brien et al., 2001) and in rat and rabbit aortas 
ex vivo (Umans et al., 1993), but not in rat pulmonary arteries ex vivo (McIntyre, Jr. 
et al., 1997; Pulido et al., 2000) and not in rat perfused mesenteric vascular bed ex 
vivo (Mitchell et al., 1993). ET-1 induced vasoconstriction is increased by LPS 
treatment in rat mesenteric artery ex vivo (Buyukafsar et al., 2004) and guinea pig 
coronary and mesenteric arteries ex vivo (Jones et al., 1999), but is decreased in rat 
pulmonary arteries ex vivo (Curzen et al., 1995) and not affected in rat in vivo (Guc 
et al., 1990).  
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 Even in the same model, there is variability in LPS-induced changes in 
vascular reactivity between different blood vessels towards different vasoconstrictors 
(Piepot et al., 2002; Farmer et al., 2003). This suggests that the type of blood vessel, 
mechanism of action of the vasoactive agent and the experimental conditions all 
affect the vascular reactivity observed in endotoxemic models.    
 
The in vivo studies represent real pathological features, but it is difficult to 
controlling experimental conditions due to multiple factor interactions including 
neurological, blood components and metabolic factors. On the other hand, in the in 
vitro studies using cultures of dispersed VSMCs, it is easy to control the 
experimental conditions, although these do not represent cell to cell interaction in 
real tissue architecture and real pathological conditions. An organ culture system has 
the distinct advantages of better preservation of tissue architecture, cell-to-cell 
interactions, extracellular matrix and cell morphology and function (Ozaki & Karaki, 
2002). In addition, organ culture has been shown to preserve tissue structure and 
contractility (Adner et al., 1998; Guibert et al., 2005). Thus, the organ culture study 
has several advantages over the classical, in vivo and in vitro methodologies. 
 
This study focused mainly on LPS-induced changes in contractile responses to 
ET-1 since plasma levels of this powerful vasoconstrictor are elevated in animal 
models of sepsis (Curzen et al., 1997; Fujii et al., 2000) and in septic patients (Pittet 
et al., 1991) and its level correlates with the severity of illness (Pittet et al., 1991; 
Piechota et al., 2007). An organ culture method was used to study the effect of LPS 
on vascular reactivity of the pulmonary artery and the aorta, studied under similar 
experimental conditions. The main objectives were: 
 
 establish an organ culture model to examine if LPS is capable of changing 
vascular reactivity and study the different factors that could affect vascular 
reactivity in this model, such as LPS type, concentration and incubation time. 
 examine a pulmonary and a systemic blood vessel under the same 
experimental conditions, since they respond differently in sepsis which could 
help in finding contributing mechanisms involved in sepsis-induced vascular 
complications. 
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3.2 Methods 
 
Pulmonary and aortic arterial rings were incubated with LPS (10 µg ml-1, 20 h) 
before measuring the contractile responses to ET-1 (0.3 nM-100 nM), 80 mM KCl, 
phenylephrine (1 nM-10 µM) or U46619 (3 nM-1 µM). In addition, the effect of 
organ culture on vascular contractile responses to ET-1 was measured by comparing 
fresh control to cultured control vascular rings. The effect of LPS type was 
investigated by measuring changes in responses to ET-1 and 80 mM KCl induced by 
either E.coli 055:B5 or Salmonella typhimurium LPS. Responses to different LPS 
concentrations were also investigated. The effect of incubation time was investigated 
by measuring iNOS expression at different time points (4, 8 and 20 h) using 
qRT-PCR. 
 
3.3 Effect of organ culture on vascular reactivity 
 
In control experiments, there were no significant differences between freshly 
isolated and 20h-incubated pulmonary or aortic vascular rings in the contractile 
responses to ET-1 (Figure 3.1), indicating that tissue responsiveness was not 
adversely influenced by prolonged incubation. 
 
3.4 Effect of LPS type on vascular reactivity changes 
 
The vascular changes induced by LPS in both the pulmonary artery and the 
aorta were similar when incubating with either E.coli 055:B5 or Salmonella 
typhimurium LPS. Neither type of LPS affected the contractile response of the 
pulmonary artery to either ET-1 (Figure 3.2a and 3.2b) or 80 mM KCl (Figure 3.2e 
and 3.2f). On the other hand, the contractile responses of the aortic rings to either 
ET-1 (Figure 3.2c and 3.2d) or 80 mM KCl (Figure 3.2e and 3.2f) were decreased by 
incubation with either type of LPS. These results suggest that LPS-induced changes 
in vascular reactivity are not dependent on the type of LPS, but on a common 
pathway induced by different LPS types.  
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Figure 3.1 Effect of organ culture on contractile responses to ET-1 in 
pulmonary and aortic rings. Contraction to ET-1 (0.3 nM-100 nM) was 
measured in pulmonary (a) and aortic (b) rings before and after incubation with 
control culture medium for 20 h. Data are expressed as mean ± s.e.m., where (n) 
equals the number of animals. 
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Figure 3.2 Effect of LPS type on vascular reactivity of the pulmonary 
artery and the aorta. Contraction to ET-1 (0.3 nM-100 nM) and 80 mM KCl in the 
pulmonary artery and the aorta was measured after incubation with LPS (10 µg 
ml-1, 20 h) either from E.coli 055:B5 (a, c, e) or Salmonella typhimurium (b, d, f). 
Data are expressed as mean ± s.e.m., where (n) equals the number of animals.  
** p<0.01, ***p<0.001 for Emax and pEC50 values compared with control group 
using paired Student’s t-test. 
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3.5 Effect of LPS concentration on vascular reactivity changes 
 
Increasing the concentration of LPS significantly enhanced aortic 
hyporeactivity to ET-1 (Figure 3.3). The decrease in Emax was 16±3 %, 25±4% and 
31±5% for LPS concentrations of 1, 10 and 100 µg ml-1, respectively (n=4). All three 
LPS concentrations caused hyporeactivity to ET-1, but the hyporeactivity induced by 
LPS 10 µg ml-1 was not significantly different from that induced by LPS 100 µg ml-1. 
This result suggests that an LPS concentration of 10 µg ml-1 caused near maximal 
response, therefore, this concentration was chosen for subsequent experiments in this 
study.  
 
3.6 Effect of incubation time on the mRNA expression iNOS 
 
Continuous incubation with LPS resulted in enhanced gene expression of iNOS 
both in the pulmonary artery (Figure 3.4a) and the aorta (Figure 3.4b). This increase 
in iNOS gene expression was 666±103 % in the pulmonary artery and 1287±447% in 
the aorta when compared to their respective controls at 20 h. The presence of 
matching time controls ensures that the increase in iNOS was only due to LPS and 
not due to incubation itself. Moreover, all the time point controls and LPS-treated 
groups for each sample were pooled exactly from the same animals to prevent any 
changes due to different genetic backgrounds of different animals. These results 
suggest that increasing incubation time had a cumulative effect on vascular 
expression of iNOS, with the 20 h timepoint showing the highest increase in iNOS 
gene expression by LPS in the present model. 
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Figure 3.3 Effect of LPS concentration on aortic hyporeactivity to ET-1. 
Contraction to ET-1 (0.3 nM-100 nM) was measured after incubation with LPS (1, 
10 or 100 µg ml-1, 20 h) in the aortic rings. Data are expressed as mean ± s.e.m., 
where (n) equals the number of animals. For Emax and pEC50 values: * p<0.05,  
** p<0.01 compared with control group; $p<0.05 compared with LPS 100 µg group 
using one-way ANOVA followed by Tukey Kramer’s post-hoc test. 
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Figure 3.4 Effect of LPS incubation on mRNA expression of iNOS in the 
pulmonary artery and aorta. RNA was extracted from control and LPS (10 µg 
ml-1, 20 h)-treated vascular rings at 4, 8 and 20 h and reverse-transcribed into 
cDNA before carrying out quantitative RT-PCR to detect changes in the gene 
expression of iNOS in the pulmonary artery (a) and aorta (b). Data are expressed 
as mean ± s.e.m., where (n) equals the number of independent experiments, each 
using duplicate PCR reactions from the same sample prepared from pooled tissue 
lysates of 2 animals. * p<0.05 compared with matching time-control using paired 
Student’s t-test. 
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3.7 Effect of LPS on vascular reactivity to different vasoconstrictors 
 
Incubation of arterial rings with LPS had a differential effect on the responses 
to different vasoconstrictors. In the pulmonary artery, no significant changes in 
contraction induced by ET-1 were found between control and LPS-treated groups 
(Figure 3.5a). In the aorta, however, a significant decrease in tissue contractility to 
ET-1 was observed in the LPS-treated group compared with the control group 
(p<0.01, n=9) (Figure 3.5b). This hyporeactivity to ET-1 was manifested by a 26±4 
% decrease in Emax from 8.41±0.40 mN to 6.26±0.32 mN and an increase in EC50 
from 9.6±0.5 nM to 15.7±0.8 nM in the control and LPS-treated groups, respectively.  
 
Similar aortic hyporeactivity to other vasoconstrictors was also observed. For 
KCl, a receptor-independent vasoconstrictor, maximal contraction induced by 80 
mM KCl was significantly decreased by 20±2 % in LPS-treated aortic rings 
compared to control (P<0.001, n=18), whereas pulmonary artery responses were 
unchanged (Figure 3.6). 
 
The maximal contractile response to the α-adrenergic agonist phenylephrine 
was unchanged in the pulmonary artery (Figure 3.7a), but it was reduced by 78±2 % 
in LPS-treated aortic rings compared to control (P<0.001, n= 5) (Figure 3.7b). In 
contrast, the contraction induced by the TxA2 mimetic U46619 was not affected by 
incubation with LPS either in the pulmonary artery (Figure 3.8a) or in the aorta 
(Figure 3.8b), suggesting that the mechanisms of contraction induced by U46619 
were not affected by LPS. 
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Figure 3.5 Effect of LPS on contractile responses to ET-1 in the 
pulmonary artery and the aorta. Contraction to ET-1 (0.3 nM-100 nM) was 
measured after incubation with LPS (10 µg ml-1, 20 h) in the pulmonary (a) and 
aortic (b) arterial rings. Data are expressed as mean ± s.e.m., where (n) equals the 
number of animals. ** p<0.01 for Emax and pEC50 values compared with control 
group using paired Student’s t-test. 
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Figure 3.6 Effect of LPS on contractile responses to 80 mM KCl in the 
pulmonary artery and the aorta. Contraction to 80 mM KCl was measured after 
incubation with LPS (10 µg ml-1, 20 h) in the pulmonary (a) and aortic (b) arterial 
rings. Data are expressed as mean ± s.e.m., where (n) equals the number of animals. 
*** p<0.001 for Emax values compared with control group using paired Student’s 
t-test. 
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Figure 3.7 Effect of LPS on contractile responses to phenylephrine in the 
pulmonary artery and the aorta. Contraction to phenylephrine (1 nM-10 µM) was 
measured after incubation with LPS (10 µg ml-1, 20 h) in the pulmonary (a) and 
aortic (b) arterial rings. Data are expressed as mean ± s.e.m., where (n) equals the 
number of animals. *** p<0.001 for Emax and pEC50 values compared with control 
group using paired Student’s t-test. 
 
Chapter 3-LPS & Vascular Reactivity 
 72 
 
 
Figure 3.8 Effect of LPS on contractile responses to U46619 in the 
pulmonary artery and the aorta. Contraction to U46619 (3 nM-1 µM) was 
measured after incubation with LPS (10 µg ml-1, 20 h) in the pulmonary (a) and 
aortic (b) arterial rings. Data are expressed as mean ± s.e.m., where (n) equals the 
number of animals. 
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3.8 Discussion 
 
The results presented in this chapter show that pulmonary and aortic contractile 
responses to ET-1 were not affected by organ culture. LPS-induced changes in 
vascular contractility to ET-1 and KCl were not affected by changing the LPS type, 
but aortic hypocontractility to ET-1 was increased by increasing LPS concentration. 
Continuous incubation with LPS in vitro resulted in an enhanced gene expression of 
iNOS in both vessels, indicating a cumulative effect of LPS. Moreover, LPS 
selectively induces vascular hypocontractility to ET-1, KCl and phenylephrine in 
isolated rat aorta but not in the pulmonary artery, while the contractile responses to 
the TxA2 mimetic U46619 were not affected in either vessel.  
 
The organ culture method used in this study had no effect on vascular 
reactivity to ET-1 when compared to fresh control, indicating that tissue 
responsiveness was not adversely influenced by prolonged incubation. Previous 
studies showed that the contractile responses to ET-1 of human omental arteries 
(Adner et al., 1995), rat vessels including the aorta and mesenteric artery (Adner et 
al., 1998) and rat extra- and intrapulmonary vessels (Guibert et al., 2005) were not 
altered by organ culture. In addition, ACh-induced relaxation was not changed by 20 
h organ culture of rat mesenteric artery, although there was a loss in NO and 
PG-mediated dilatation which is compensated for by EDHF (Alm et al., 2002). In 
contrast, organ culture has been shown to upregulate ETB receptors on VSM of 
different rat blood vessels except the aorta although the contractile responses to ET-1 
were not affected (Adner et al., 1998). These studies support the usefulness of organ 
culture model to study contractile responses, especially at short time points such as 
20 h as used in this study. 
 
In addition to the effect of organ culture, LPS type, concentration and 
incubation time were also studied. The profile of LPS-induced changes in vascular 
reactivity was similar between different types of LPS, indicating that these vascular 
changes are independent of LPS type. With regard to LPS concentration, LPS 
concentration of 10 µg ml-1 was optimum in the present model. This LPS 
concentration was previously reported to give a maximal iNOS induction (Kleschyov 
et al., 1998; O'Brien et al., 2001). Also, O'Brien et al. (2001) found that 
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hyporeactivity was unaffected by the concentration of LPS over 1 to 100 µg ml-1, 
although responses were dependent upon incubation time and were prolonged in 
presence of serum. 
 
The effect of incubation time was examined by measuring vascular expression 
of iNOS gene, which is known to be upregulated by LPS (Lorente et al., 1993; Szabo 
et al., 1995; Bishop-Bailey et al., 1997; Liu et al., 1997). Increasing incubation time 
was found to enhance the expression of iNOS, which was extensively expressed at 
20 h.  
 
The findings of this in vitro organ culture model are similar to observations in 
clinical sepsis where systemic vasodilation and pulmonary hypertension occur 
(Manthous et al., 1993; Lorente et al., 1993) and to an ex vivo rat endotoxemic model 
using phenylephrine (McIntyre, Jr. et al., 1997). In addition, in vivo differences in 
vascular responses to LPS are characterized by systemic vasodilation and 
hyporesponsiveness to vasoconstrictor agents, but the pulmonary, renal and 
mesenteric circulations often exhibit various degrees of vasoconstriction (Curzen et 
al., 1997; Farmer et al., 2003). These results confirm the usefulness of organ culture 
models to study LPS-induced changes in vascular reactivity. 
 
LPS in this study induced hypocontractility to ET-1, in addition to KCl and 
phenylephrine, in rat aorta but not in the pulmonary artery. In contrast to ET-1, KCl 
and phenylephrine, the contractile responses to U46619 were not altered by LPS in 
either the pulmonary artery or the aorta, indicating that LPS does not affect the 
contractile pathways induced by U46619. Similar results were obtained previously in 
rat aorta ex vivo (Farmer et al., 2003) and rat mesenteric artery ex vivo (Farmer et al., 
2003) and in vitro (O'Brien et al., 2001). In contrast, contractile responses to U46619 
were attenuated in vitro in rat coronary arteries (Piepot et al., 2002) and pulmonary 
artery (Boer et al., 2005). The last two studies utilized higher concentrations of LPS 
(50 µg ml-1), that is 5 times as the concentration used in this study, which may 
explain the difference in results. 
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3.9 Summary and conclusions 
 
By using an organ culture method, the effect of in vitro incubation with LPS as 
a powerful inflammatory stimulus, was examined on the pulmonary artery and the 
aorta under similar experimental conditions. The main findings are: 
 
1- The pulmonary and aortic contractile responses to ET-1 were not affected by 
20 h organ culture. 
 
2- The LPS-induced changes in vascular reactivity to ET-1 and KCL were 
independent of LPS type. 
 
3- Increasing LPS concentration enhanced aortic hyporeactivity to ET-1, with 
the concentration of 10 µg ml-1 being optimum in this model. 
 
4- Continuous incubation with LPS induced cumulative iNOS expression in 
both vessels. 
 
5- LPS caused a selective decrease in contractile responses to ET-1, 80 mM 
KCl and phenylephrine, but not to the TxA2 mimetic U46619, in the aorta 
while the pulmonary artery responses were not affected. 
 
In conclusion, the present organ culture model showed that LPS selectively 
induced vascular hyporeactivity to different vasoconstrictors in rat aorta but not the 
pulmonary artery, similar to clinical symptoms in vivo in endotoxemia and sepsis. 
This aortic hyporeactivity was not due to organ culturing per se and was not affected 
by changing the LPS type. Increasing LPS concentration or the incubation time 
enhances this aortic hyporeactivity. Therefore, this organ culture model is suitable to 
study LPS-induced changes in vascular reactivity and can be easily controlled to 
study the molecular mechanisms involved.  
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Chapter 4 
4.1 Introduction 
 
Several mediators have been suggested to play a major role in sepsis-induced 
vascular complications, including NO, derivatives of COX and reactive oxygen 
species (ROS). Excessive NO production, derived mainly from iNOS, has been 
shown to contribute to the development of acute lung injury, delayed hypotension 
and vasoplegia in patients with septic shock (Feihl et al., 2001; Lopez et al., 2004) as 
well as in animals injected with LPS (Szabo et al., 1995; Bishop-Bailey et al., 1997).  
 
In septic shock, inhibition of the activity of eNOS precedes the induction of 
iNOS (Lu et al., 1996). Moreover, down-regulation of eNOS occurs at time points 
similar to those where iNOS induction is seen. iNOS has been shown to impair 
eNOS by limiting availability of a major NOS cofactor, tetrahydrobiopterin (Gunnett 
et al., 2005) and by producing peroxynitrite which causes nitration of protein 
tyrosine residues leading to inhibition of different enzymes involved in 
endothelium-dependent relaxation, such as eNOS (Pasquet et al., 1996). The 
impaired endothelium-dependent relaxations, either mediated by iNOS or other 
factors, have been shown in blood vessels from endotoxemic animals (Umans et al., 
1993; Myers et al., 1995; Piepot et al., 2000; Wiel et al., 2000; Piepot et al., 2003).   
 
Different experimental strategies have been used to control excessive NO 
production in sepsis, such as inhibiting NO production preferentially with selective 
iNOS inhibitors or by inhibiting NO-dependent pathways such as sGC, however 
results are conflicting. For example, the potent and highly selective iNOS inhibitor 
1400W (Garvey et al., 1997) has been shown to prevent LPS-induced hypotension 
(Bachetti et al., 2003) and delay hypotension and circulatory failure in rats in vivo 
(Cuzzocrea et al., 2006), but only partially reverses LPS-induced hyporeactivity to 
phenylephrine in rat superior mesenteric artery in vitro (O'Brien et al., 2001) and is 
not effective in rabbits (Bachetti et al., 2003). ODQ, an irreversible and highly 
selective heme-site inhibitor of sGC (Garthwaite et al., 1995), prevents aortic 
hypocontractility to norepinephrine ex vivo in rat (Chen et al., 2005) and both in vitro 
and in vivo in rat and mouse (Zingarelli et al., 1999). Conversely, ODQ is partially 
effective in restoring vascular reactivity to phenylephrine in the rat superior 
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mesenteric artery in vitro (O'Brien et al., 2001) and ex vivo in rat aorta (Wu et al., 
1998a). 
 
Previous studies have shown that LPS decreases sGC activity in rat lung and 
aorta (Fernandes et al., 2006), and in cultured rat aortic (Papapetropoulos et al., 
1996) and pulmonary (Scott & Nakayama, 1998) VSMCs. PDE5 activity is increased 
in rat lung after LPS injection (Holzmann et al., 1996) and 1 h after LPS inhalation 
in guinea pig lungs (Toward et al., 2005) but is decreased after 48 h in the same 
model. These studies have examined whole lung tissue or cultured pulmonary 
VSMCs, but there are no direct measurements published using isolated pulmonary 
arteries. Furthermore, these changes in NO signalling pathways have not been related 
to vascular reactivity in the same experimental model.  
 
COX has also been suggested to play a role in LPS-induced changes in vascular 
reactivity, since enhanced COX-2 expression has been shown in mesenteric vessels 
from endotoxemic rats (Virdis et al., 2005), in rat pulmonary VSMCs (Ermert et al., 
2000), in rat lung and heart in vivo (Liu et al., 1996) and in rat aorta in vitro (Bishop-
Bailey et al., 1997). However, inhibition of inducible and/or constitutive COX 
pathways rarely reverses hypotension (Bernard et al., 1997; Leach et al., 1998; 
O'Brien et al., 2001) 
 
Similarly, ROS have been shown to be induced by LPS since treatment of rats 
with LPS enhances vascular expression of xanthine and NADPH oxidases and 
increases formation of O2.– and peroxynitrite (Brandes et al., 1999). In addition, 
reduced plasma levels of different antioxidants and increased levels of markers of 
oxidative stress have been found in patients with septic shock (Goode et al., 1995; 
Galley et al., 1997) and in rats (Carbonell et al., 2000). Inhibition of ROS yielded 
controversial results. For example, LPS-induced vasoconstrictor hyporeactivity can 
be corrected in human by high doses of vitamin C (Pleiner et al., 2003) and in a rat 
endotoxic shock model in vivo by a peroxynitrite decomposition catalyst (Cuzzocrea 
et al., 2006). In contrast, inhibition of O2.– does not restore but further deteriorates 
relaxation of LPS-treated rat aortic rings (Brandes et al., 1999). 
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In this chapter the role of different mediators (including the 
endothelium-derived mediators NO/cGMP, COX and ROS) involved in LPS-induced 
changes in vascular reactivity to ET-1 was investigated in isolated rat pulmonary 
artery and aorta.  
 
4.2 Methods 
 
Pulmonary and aortic arterial rings were incubated with LPS (10 µg ml-1, 20 h) 
in the presence or absence of endothelium, COX inhibitor indomethacin (10 µM), the 
antioxidant trolox (200 µM), the iNOS inhibitor 1400W (1 µM) and sGC inhibitor 
ODQ (10 µM) before measuring the contractile responses to ET-1 (0.3 nM-100 nM). 
Relaxation responses to ACh, SNP, 8-pCPT-cGMP, BAY 41-2272 and T-0156 were 
also measured. NO production was measured by Griess method and SNP-induced 
cGMP production was measured by ELISA. The expression of sGCα1, sGCβ1 and 
PDE5 proteins were measured by immunoblotting. Appropriate control experiments 
were done to exclude vehicle effects on vascular tissue responsiveness. 
 
4.3 Effect of endothelium removal on LPS-induced changes in vascular 
reactivity to ET-1 
 
As previously shown in chapter 3, LPS selectively causes hyporeactivity to 
ET-1 in the aorta but not in the pulmonary artery (Figure 3.5). The role of 
endothelium was studied in endothelium-denuded control and LPS-treated aortic 
rings. In the pulmonary artery, removal of endothelium did not cause a significant 
difference between control and LPS-treated vascular rings (Figure 4.1a). In the aorta, 
removal of endothelium did not abolish the decreased contractility to ET-1 in 
LPS-treated group (Figure 4.1b). This result indicates that endothelium does not play 
a major role in LPS-induced changes in vascular reactivity to ET-1. 
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Figure 4.1 Effect of removal of endothelium on LPS-induced changes in 
vascular reactivity to ET-1 in the pulmonary artery and the aorta. 
Contraction to ET-1 (0.3 nM-100 nM) was measured in endothelium-denuded 
pulmonary artery (a) and aorta (b) after incubation with LPS (10 µg ml-1, 20 h). 
Data are expressed as mean ± s.e.m., where (n) equals the number of animals.  
** p<0.01 for Emax and pEC50 values compared with control group using paired 
Student’s t-test. 
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4.4 Effect of COX-inhibition on LPS-induced changes in vascular reactivity to 
ET-1 
 
Inhibition of COX by 10 µM indomethacin added 1 h before and during LPS 
incubation did not affect LPS-induced changes in vascular reactivity to ET-1. In the 
pulmonary artery, inhibition of COX did not cause a significant difference between 
control and LPS-treated rings (Figure 4.2a). In the aorta, inhibition of COX did not 
abolish the difference between control and LPS-treated aortic rings in response to 
ET-1 (Figure 4.2b), since the Emax was still reduced by 19±2% in LPS-treated group. 
Since removal of endothelium and inhibition of COX did not abolish LPS-induced 
aortic hyporeactivity to ET-1, mediators produced by COX, such as prostaglandins 
and TxA2, are not a major pathway involved in vascular hyporeactivity to ET-1 
induced by LPS.  
 
4.5 Effect of ROS-inhibition on LPS-induced changes in vascular reactivity to 
ET-1 
 
Inhibition of ROS by 200 µM trolox (a cell-permeable, water-soluble derivative 
of vitamin E with potent antioxidant properties) added 1 h before and during LPS 
incubation did not affect LPS-induced changes in vascular reactivity to ET-1. In the 
pulmonary artery, inhibition of ROS did not cause a significant difference between 
control and LPS-treated rings (Figure 4.3a). Similarly, inhibition of ROS did not 
abolish the difference between control and LPS-treated aortic rings in response to 
ET-1 (Figure 4.3b), where the Emax was still reduced by 20±3%. These results 
suggest that ROS does not play a major role in LPS-induced changes in vascular 
reactivity to ET-1. 
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Figure 4.2 Effect of indomethacin on LPS-induced changes in vascular 
reactivity to ET-1 in the pulmonary artery and the aorta. Contraction to ET-1 
(0.3 nM-100 nM) was measured in the pulmonary artery (a) and the aorta (b) after 
incubation with LPS (10 µg ml-1, 20 h) in the presence of 10 µM indomethacin. 
Data are expressed as mean ± s.e.m., where (n) equals the number of animals.  
** p<0.01 for Emax and pEC50 values compared with control group using paired 
Student’s t-test. 
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Figure 4.3 Effect of trolox on LPS-induced changes in vascular reactivity 
to ET-1 in the pulmonary artery and the aorta. Contraction to ET-1 (0.3 nM-
100 nM) was measured in the pulmonary artery (a) and the aorta (b) after 
incubation with LPS (10 µg ml-1, 20 h) in the presence of 200 µM trolox. Data are 
expressed as mean ± s.e.m., where (n) equals the number of animals. ** p<0.01 
for Emax and pEC50 values compared with control group using paired Student’s 
t-test. 
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4.6 Role of NO in LPS-induced changes in vascular reactivity to ET-1 
 
4.6.1 Effect of LPS on eNOS and iNOS gene expression 
 
The PCR primers designed for eNOS, iNOS and the housekeeping gene β-actin 
were tested first by using standard RT-PCR to detect the presence of the expected 
products at 60, 95 and 72 bp respectively (Figure 4.4). Melt-curve analyses, verifying 
specific amplification and the absence of secondary primers products and PCR 
standard curves of both the target (eNOS and iNOS) and reference (β-actin) genes 
are shown in Figure 4.5.  
 
Although eNOS mRNA expression was changed by incubation in both the 
pulmonary artery and the aorta, but changes in eNOS mRNA expression at 4, 8 and 
20 h were not significantly different between control and LPS-treated pulmonary 
(Figure 4.6a) or aortic rings (Figure 4.6b). This result, together with the absence of 
an effect of endothelium removal, confirms that eNOS is not involved in 
LPS-induced changes in vascular reactivity to ET-1. Conversely, continuous 
incubation with LPS resulted in enhanced gene expression of iNOS to a similar 
extent both in the pulmonary artery (Figure 4.6c) and the aorta (Figure 4.6d). This 
increase in iNOS gene expression was 666±103 % in the pulmonary artery and 
1287±447% in the aorta when compared to their respective controls at 20 h. The 
presence of matching time controls ensures that the increase in iNOS is only due to 
LPS and not due to incubation itself. Moreover, all the time point controls and 
LPS-treated groups for each sample were pooled exactly from the same animals to 
prevent any changes due to genetic variation between different animals. These results 
suggest that LPS-induced expression of iNOS may contribute to changes in vascular 
reactivity to ET-1 through excessive NO production. 
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Figure 4.4 Representative PCR gel for eNOS, iNOS, ET-1, ETA, ETB and 
β-actin genes. RNA was extracted from LPS (10 µg ml-1)-treated rings after 20 h 
and reverse-transcribed into cDNA before carrying out standard PCR and 
detecting the products on agarose gel with ethidium bromide and UV-imaging. 
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Figure 4.5 Representative qRT-PCR standard curves and melting peaks 
for eNOS, iNOS and β-actin genes. RNA was extracted from control and LPS 
(10 µg ml-1)-treated vascular rings at 0, 4, 8 and 20 h and reverse-transcriped into 
cDNA before carrying out quantitative RT-PCR using the Lightcycler. 
 
 
 
 
Chapter 4-LPS & Vasoactive Mediators 
 87 
 
 
 
 
Figure 4.6 LPS-induced changes in gene expression of eNOS and iNOS 
in the pulmonary artery and the aorta. RNA was extracted from control and 
LPS (10 µg ml-1)-treated vascular rings at 0, 4, 8 and 20 h and reverse-transcribed 
into cDNA before carrying out qRT-PCR to detect changes in the gene expression 
of eNOS (a and b) and iNOS (c and d) in the pulmonary artery and aorta. Data are 
expressed as mean ± s.e.m., where (n) equals the number of independent 
experiments, each using duplicate PCR reactions from the same sample prepared 
from pooled tissue lysates of 2 animals. * p<0.05 compared with matching 
time-control using paired Student’s t-test. Data for iNOS (c and d) was presented 
before in Figure 3.4. 
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4.6.2 Effect of LPS on NO release 
 
To detect if the LPS-induced iNOS expression is associated with NO 
overproduction the accumulation of nitrite and nitrate (NOx), as the breakdown 
products of NO, was measured in the culture medium. Incubation of the pulmonary 
artery and the aorta with LPS caused a significant 5- to 10- fold increase in NO 
release (p<0.01, n=5) (Figure 4.7). The increases in NO production were not 
significantly different between the two preparations. Co-incubation of pulmonary 
and aortic rings with LPS together with either the non-specific NOS-inhibitor 
L-NAME (100 µM) or the iNOS-specific inhibitor 1400W (1 µM) prevented the 
LPS-induced overproduction of NO in both vessels (Figure 4.7). This result confirms 
that LPS enhances NO release through increasing iNOS expression. 
 
4.6.3 Effect of LPS on endothelium-dependent relaxation 
 
Incubation of the pulmonary artery and the aorta with LPS caused a significant 
impairment of the endothelium-dependent relaxation. Vascular relaxation to ACh 
was significantly decreased by LPS in the pulmonary artery, as manifested by a 
decrease in Emax from 68±10 % to 41±5 % in the control and LPS-treated groups 
respectively (p<0.01, n=5) (Figure 4.8a). Similarly, vascular relaxation to ACh was 
significantly decreased by LPS in the aorta, as manifested by a decrease in Emax from 
71±5 % to 56±3 % in the control and LPS-treated groups respectively (p<0.01, n=5) 
(Figure 4.8b). This result suggests that either eNOS activity or the downstream 
signalling of NO in the VSMCs is impaired.  
 
4.6.4 Effect of LPS on endothelium-independent relaxation 
 
Endothelium-independent vascular relaxation induced by SNP was 
significantly decreased (p<0.01, n=6) by LPS in the pulmonary artery, as manifested 
by a decrease in Emax from 64±7 % to 40±3 % in the control and LPS-treated groups 
respectively (Figure 4.9a). Conversely, there were no significant differences in 
SNP-induced vasorelaxation between control and LPS-treated groups in the aorta 
(Figure 4.9b). This result suggests that the downstream signalling of NO is 
selectively impaired by LPS in the pulmonary artery but not in the aorta. 
Chapter 4-LPS & Vasoactive Mediators 
 89 
 
 
 
 
 
 
Figure 4.7 Effect of LPS treatment on NO release from isolated rat 
pulmonary artery and aorta. NO release (total amount of nitrite plus nitrate, 
NOx) was determined in the supernatant spectrophotometrically using Greiss 
reagent after reduction of nitrate to nitrite. LPS-induced NO overproduction was 
inhibited by co-incubation with either L-NAME (100 µM) or 1400W (1 µM). 
Data are expressed as mean ± s.e.m., where (n) equals the number animals. 
**p<0.01 compared with control group, ## p<0.01 compared with LPS group 
using one-way ANOVA followed by Dunnett’s post-hoc test. 
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Figure 4.8 Effect of LPS on ACh-induced relaxation in the pulmonary 
artery and the aorta. LPS (10 µg ml-1, 20 h)-treated pulmonary (a) and aortic (b) 
arterial rings were preconstricted with 30 nM ET-1 before measuring relaxation 
responses to ACh (1 nM-30 µM). Data are expressed as mean ± s.e.m., where (n) 
equals the number animals. **p<0.01 for Emax and pEC50 values compared with 
control group using paired Student’s t-test. 
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Figure 4.9 Effect of LPS on SNP-induced relaxation in the pulmonary 
artery and the aorta. LPS (10 µg ml-1, 20 h)-treated pulmonary (a) and aortic (b) 
arterial rings were preconstricted with 30 nM ET-1 before measuring relaxation 
responses to SNP (1 nM-30 µM). Data are expressed as mean ± s.e.m., where (n) 
equals the number animals. ##p<0.01 for Emax values compared with control 
group using paired Student’s t-test. 
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4.6.5 Effect of LPS on NO-independent direct sGC activation 
 
Incubation of the pulmonary artery and the aorta with LPS caused a differential 
effect on the relaxation induced by the direct NO-independent sGC activator BAY 
41-2272. Vascular relaxation to BAY 41-2272 was significantly decreased (p<0.01, 
n=4) by LPS in the pulmonary artery (Figure 4.10a), as manifested by a 32±8 % 
decrease in Emax. Conversely, BAY 41-2272-induced relaxation was significantly 
increased in the aorta (p<0.01, n=4) (Figure 4.10b) as manifested by a 15±7 % 
increase in Emax. These results suggest that sGC activation, the main downstream 
signalling pathway for NO, is impaired by LPS in the pulmonary artery, while it is 
enhanced in the aorta. 
 
4.6.6 Effect of LPS on relaxation induced by PDE-resistant cGMP analogue 
 
To assess whether LPS-mediated pulmonary hyporeactivity to SNP was due to 
decreased cGMP or impaired downstream cGMP-effector signalling molecules (such 
as PKG), the relaxation response to the PDE-resistant cGMP analogue 
8-pCPT-cGMP was studied. LPS treatment had no significant effect on relaxation 
responses to 8-pCPT-cGMP either in the pulmonary artery (Figure 4.11a) or in the 
aorta (Figure 4.11b). These results suggest that pulmonary hyporeactivity to SNP is 
likely to be due to either decreased cGMP synthesis by sGC or increased cGMP 
degradation (mainly by PDE5), or both.  
 
4.6.7 Effect of LPS on SNP-induced cGMP production 
 
Incubation with LPS significantly decreased (p<0.05, n=4) the SNP-stimulated 
cGMP production in the pulmonary artery by 24±4 % from 4.15±0.23 to 3.13±0.18 
pmole mg-1 tissue, whereas cGMP levels in the aorta were not significantly affected 
(Figure 4.12). These results confirm that cGMP synthesis is impaired by LPS in the 
pulmonary artery but not in the aorta. 
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Figure 4.10 Effect of LPS on BAY 41-2272-induced relaxation in the 
pulmonary artery and the aorta. LPS (10 µg ml-1, 20 h)-treated pulmonary (a) 
and aortic (b) arterial rings were preconstricted with 30 nM ET-1 before 
measuring relaxation to BAY 41-2272 (1 nM-10 µM). Data are expressed as mean 
± s.e.m., where (n) equals the number animals. ##p<0.01 for Emax, **p<0.01 for 
Emax and pEC50 values compared with control group using paired Student’s t-test. 
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Figure 4.11 Effect of LPS on 8-pCPT-cGMP-induced relaxation in the 
pulmonary artery and the aorta. LPS (10 µg ml-1, 20 h)-treated pulmonary (a) 
and aortic (b) arterial rings were preconstricted with 30 nM ET-1 before 
measuring relaxation to the non-hydrolysable cGMP analogue 8-pCPT-cGMP 
(0.1 µM-100 µM). Data are expressed as mean ± s.e.m., where (n) equals the 
number animals. 
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Figure 4.12 Effect of LPS on SNP-induced cGMP production in the 
pulmonary artery and the aorta. Pulmonary and aortic rings from LPS (10 µg 
ml-1, 20 h)-treated and control groups were stimulated by SNP (100 µM for 10 
min) in the presence of the non-selective PDE-inhibitor IBMX (100 µM), 
freeze-dried and cGMP levels were determined by ELISA. Data are expressed as 
mean ± s.e.m., where (n) equals the number animals. *p<0.05 compared with 
control group using paired Student’s t-test. 
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4.6.8 Effect of iNOS inhibition on LPS-induced changes in vascular reactivity to 
ET-1 
 
In the pulmonary artery, inhibition of iNOS did not cause a significant 
difference between control and LPS-treated rings (Figure 4.13a). In the aorta, 
inhibition of iNOS did not abolish the difference between control and LPS-treated 
aortic rings in response to ET-1 (compare Figure 3.5 with Figure 4.13b), where the 
Emax was still reduced by 16±1% as a result of LPS treatment. These results suggest 
the presence of mediator(s) other than iNOS-derived NO that play a major role in 
LPS-induced changes in vascular reactivity to ET-1. 
 
4.6.9 Effect of sGC inhibition on LPS-induced changes in vascular reactivity to 
ET-1 
 
In contrast with iNOS inhibition, inhibition of sGC by incubation with 10 µM 
ODQ abolished the LPS-induced changes in vascular reactivity to ET-1. In the 
pulmonary artery, inhibition of sGC did not cause a significant difference between 
control and LPS-treated rings (Figure 4.14a). In contrast, inhibition of sGC prevented 
the LPS-induced decrease in contraction to ET-1 in the aorta (Figure 4.14b). These 
results suggest that LPS induces sGC activation through mediator(s) other than NO, 
leading to aortic hyporeactivity to ET-1. 
 
4.6.10 Effect of LPS on protein expression level of sGC subunits 
 
In the pulmonary artery, LPS pre-treatment caused a significant decrease 
(p<0.01, n=4) in protein expression levels of sGCβ1 subunit by 36±7 % (protein 
density ratio to β-actin), while the expression of the sGCα1 subunit was not 
significantly affected (Figure 4.15). In contrast, LPS did not significantly change the 
protein expression levels of either sGC subunits in the aorta (Figure 4.15). Since both 
subunits are required for sGC function, the decrease in the protein expression level of 
one subunit (sGCβ1 in the pulmonary artery) would impair sGC activity. 
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Figure 4.13 Effect of 1400W on LPS-induced changes in vascular reactivity 
to ET-1 in the pulmonary artery and the aorta.  Contraction to ET-1 (0.3 nM-
100 nM) was measured in the pulmonary artery (a) and the aorta (b) after 
incubation with LPS (10 µg ml-1, 20 h) in the presence of 10 µM 1400W. Data are 
expressed as mean ± s.e.m., where (n) equals the number animals. ** p<0.01 for 
Emax and pEC50 values compared with control group using paired Student’s t-test. 
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Figure 4.14 Effect of ODQ on LPS-induced changes in vascular reactivity 
to ET-1 in the pulmonary artery and the aorta.  Contraction to ET-1 (0.3 nM-
100 nM) was measured in the pulmonary artery (a) and the aorta (b) after 
incubation with LPS (10 µg ml-1, 20 h) in the presence of 10 µM ODQ. Data are 
expressed as mean ± s.e.m., where (n) equals the number animals. 
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Figure 4.15 Effect of LPS on protein expression levels of sGCα1 and sGCβ1, 
in the pulmonary artery and the aorta. (a): representative immunoblots for 
sGCα1 and sGCβ1 in the pulmonary artery (left) and the aorta (right). (b):  
densitometric ratio of sGC protein subunits normalized to β-actin in the 
pulmonary artery (left) and the aorta (right). Data are expressed as mean ± s.e.m., 
where (n) equals the number animals. **p<0.01 compared with control group 
using paired Student’s t-test.  
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4.6.11 Effect of LPS on relaxation responses induced by PDE5 inhibition 
 
The role of PDE5 activity in LPS-induced impairment of vasorelaxation in the 
pulmonary artery was investigated using the potent and highly selective PDE5 
inhibitor T-0156. Relaxation responses to T-0156 were significantly increased by 
LPS in the pulmonary artery, as manifested by an increase in Emax from 75±5 % to 
94±2 % in the control and LPS-treated groups respectively (p<0.01, n=6) (Figure 
4.16a). Conversely, LPS treatment did not have a significant effect on 
T-0156-induced relaxation in the aorta (Figure 4.16b). These results suggest that 
PDE5 expression or activity could be increased by LPS treatment in the pulmonary 
artery but not in the aorta. 
 
4.6.12 Effect of LPS on protein expression level of PDE5 
 
For the protein expression levels of PDE5, two bands were obtained at 95 and 
85 kDa since PDE5 is dimeric (Lin et al., 2006). LPS treatment of the pulmonary 
artery and the aorta did not significantly alter PDE5 protein expression levels in 
either vessel (Figure 4.17a and b). These results therefore suggest that the LPS-
induced increase in the effects of T-0156 in the pulmonary artery is likely due to 
changes in PDE5 activity. 
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Figure 4.16 Effect of LPS treatment on T-0156-induced relaxation in the 
pulmonary artery and the aorta. LPS (10 µg ml-1, 20 h)-treated pulmonary (a) 
and aortic (b) arterial rings were preconstricted with 30 nM ET-1 before 
measuring relaxation to T-0156 (0.1 nM-100 nM). Data are expressed as mean ± 
s.e.m., where (n) equals the number animals. **p<0.01 for Emax and pEC50 values 
compared with control group using paired Student’s t-test. 
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Figure 4.17 Effect of LPS on the protein expression levels of PDE5. (a) 
representative immunoblots for PDE5 in the pulmonary artery (left) and the aorta 
(right). (b) densitometric ratio of PDE5 protein subunits normalized to β-actin in 
the pulmonary artery and the aorta. Data are expressed as mean ± s.e.m., where 
(n) equals the number animals. 
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4.7 Discussion 
 
The results presented in this chapter show that LPS activates sGC through a 
NO-independent pathway in the aorta. The effect of this activation is impaired in the 
pulmonary artery by decreasing protein expression of sGCβ1 and by increasing PDE5 
activity. As a consequence, LPS causes selective hypocontractility to ET-1 only in 
the aorta, while the pulmonary artery is not affected. 
 
In both vessels, LPS significantly increased NO production via iNOS, as it was 
blocked by the selective iNOS inhibitor 1400W (1 µM).  Such LPS-induced NO 
overproduction through iNOS was reported previously in the aorta (Griffiths et al., 
1995) and in the pulmonary artery (Bishop-Bailey et al., 1997). We found, however, 
that ET-1 mediated contraction was significantly impaired only in the aorta but not in 
the pulmonary artery, a finding similar to observations in clinical sepsis where 
systemic vasodilation and pulmonary hypertension occurs (Manthous et al., 1993; 
Lorente et al., 1993) and to an ex vivo rat endotoxemic model using phenylephrine 
(McIntyre, Jr. et al., 1997).   
 
Endothelial removal did not affect vascular changes induced by LPS which is 
consistent with previous reports (McKenna, 1990; Hall et al., 1996; O'Brien et al., 
2001), suggesting that endothelium does not play a major role in LPS-induced aortic 
hypocontractility to ET-1. Moreover, the expression of eNOS was not different 
between control and LPS-treated pulmonary and aortic vascular rings, while 
relaxation to ACh, an endothelium-dependent vasorelaxant, was impaired in both 
vessels. The impaired endothelium-dependent relaxations observed in endotoxemic 
blood vessels may result from several mechanisms including alteration in eNOS 
expression, activation, and signal transduction in addition to the mechanisms 
involved in NO release and degradation (Matsuda & Hattori, 2007).  The eNOS 
expression has been shown to be diminished in blood vessels from rabbits (Matsuda 
et al., 2003) and in lung tissues from mice (Matsuda et al., 2004) following induction 
of sepsis with LPS.  Furthermore, it has been demonstrated that sepsis causes a 
progressive and profound reduction in phosphorylation of eNOS in rabbit mesenteric 
arteries, possibly as a result of impaired phosphatidylinositol-3-kinase pathway 
(Matsuda et al., 2006), suggesting less production of NO by eNOS in sepsis. Since 
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eNOS expression was not changed in this study, but ACh relaxation was decreased, it 
appears that either eNOS activity or the downstream signalling of NO is impaired. It 
is also worth noting that the impaired relaxation to ACh observed in both vessels is 
probably not involved in hypocontractility to ET-1 which was found only in the 
aorta.  
 
LPS is also known to induce the expression of COX-2 (Bishop-Bailey et al., 
1997), suggesting that additional mechanisms are likely to contribute to LPS-induced 
changes in vascular reactivity. Inhibition of COX with indomethacin did not abolish 
the difference in contractile responses to ET-1 in LPS-treated aortic rings, indicating 
that COX may not play a major role in the present model. Similar results have been 
previously shown, where inhibition of COX-1 and/or COX-2 pathways does not 
reverse hypotension or vascular hyporeactivity induced by LPS (Bernard et al., 1997; 
Leach et al., 1998; O'Brien et al., 2001). Similarly, inhibition of ROS, which could 
impair vascular reactivity, did not have a profound effect on LPS-induced changes in 
vascular reactivity to ET-1, suggesting a little role for ROS in the present system. 
 
The selective inhibition of iNOS by 1400W was unable to prevent the aortic 
hypocontractility to ET-1, although the same concentration of 1400W did suppress 
the NO overproduction in both vessels. On the other hand, incubation with the sGC 
inhibitor ODQ prevented aortic LPS-induced hypocontractility to ET-1, leading to 
the conclusion that the hypocontractility is mediated through NO-independent 
regulator(s) of sGC activity. In addition, the aortic relaxation responses to the novel 
non-NO-based heme-dependent sGC activator BAY 41-2272 (Stasch et al., 2001; 
Boerrigter & Burnett, Jr., 2007) were enhanced in the aorta, confirming that LPS 
treatment enhances NO-independent sGC activation in the aorta. These experiments 
show that inhibition of sGC could be more effective than NOS inhibition in 
preventing vascular hyporeactivity induced by LPS in systemic arteries. 
 
LPS treatment in the present study decreased pulmonary artery relaxation 
responses to both the NO donor SNP and the sGC activator BAY 41-2272, 
suggesting that LPS treatment impairs sGC/cGMP pathway activation (both 
NO-dependent and independent) in the pulmonary artery. This impairment in 
sGC/cGMP pathway could be either due to an altered cGMP synthesis and/or 
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metabolism, or due to downstream changes in cGMP-effector signalling molecules 
such as PKG. Because the relaxation to the non-hydrolysable cGMP analogue 
8-pCPT-cGMP was not affected in the LPS-treated vessels, cGMP-effector 
signalling molecules are not involved; leaving the likelihood that LPS modifies 
cGMP synthesis and/or degradation.  
 
The involvement of the reduced synthesis of cGMP in the pulmonary artery is 
indicated by decreased sGC activity and was confirmed by a significant decrease in 
the expression of the sGCβ1 subunit. Since both sGC subunits are required for the 
enzyme activity, reduced levels of either subunit lead to reduced sGC activity. 
Importantly, sGCβ1 contains the major heme binding domain and seems to be more 
rapidly and robustly regulated after inflammatory stimuli (Takata et al., 2001; Friebe 
& Koesling, 2003). Although previous studies demonstrate the involvement of sGC 
modulation in LPS-induced effects, these studies detected sGC in whole lung tissue 
or in isolated VSMCs, but not in isolated pulmonary arteries. For example, LPS 
decreases sGC activity and sGCβ1 protein expression in rat lung (Fernandes et al., 
2006) and the expression of sGCβ1 mRNA and both sGC protein subunits in mice 
lung (Glynos et al., 2007). It is noteworthy that LPS decreases sGCα1 but not sGCβ1 
expression in cultured rat aortic (Papapetropoulos et al., 1996) or pulmonary (Scott 
& Nakayama, 1998) smooth muscle cells, raising the possibility that expression of 
sGC subunits may be influenced by cell isolation or culture.  
 
Besides reduced cGMP synthesis by sGC, an increased degradation of cGMP 
by PDE5 could also contribute to NO hyporeactivity in the pulmonary artery. This 
was directly confirmed using T-0156, a potent and highly selective PDE5 inhibitor 
(Mochida et al., 2002). Since the enhanced pulmonary artery relaxation to T-0156 in 
LPS-treated tissue was not associated with changes in protein expression of PDE5, 
the most likely explanation is that the activity of PDE5 was increased. An increased 
PDE5 activity was demonstrated in perfused rat lungs isolated from rats 18 h after 
LPS injection (Holzmann et al., 1996) and 1 h after LPS inhalation in guinea pig 
lungs (Toward et al., 2005) but was decreased after 48 h in the same model. The 
mechanism for increased PDE5 activity could include PKG-mediated 
phosphorylation and allosteric cGMP binding (either of which will upregulate PDE5 
activity) and a decreased PP1 phosphatase activity and/or expression (Lin et al., 
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2006). The latter will lead to a decreased dephosphorylation of PDE5, leading to 
maintained or enhanced PDE5 activity (Lin et al., 2006). Since the results with the 
non-hydrolysable cGMP analogue suggest that downstream cGMP-effector 
signalling molecules are not affected by pre-treatment of vessels with LPS, 
downregulation of PP1 phosphatase activity and/or expression seems likely.   
 
In sepsis, excessive vasodilation is counterbalanced by increased release of 
vasoconstrictors such as ET-1 and angiotensin II (Knotek et al., 2000), therefore 
reduced sensitivity to sGC activation and increased PDE5 activity in pulmonary 
arteries could contribute to the development of pulmonary hypertension during 
sepsis. These mechanisms could also explain, at least in part, why a significant 
fraction (up to 30%) of pulmonary hypertensive patients fail to respond to 
therapeutic doses of inhaled NO (Holzmann et al., 1996).  
 
4.8 Summary and conclusions 
 
By using an organ culture method and different inhibitors to the vasoactive 
mediators that could be involved in LPS-induced changes in vascular reactivity to 
ET-1 in the pulmonary artery and the aorta, the main findings are: 
 
1- LPS-induced changes in vascular reactivity to ET-1 were not affected by 
endothelium removal, COX inhibition, ROS inhibition, or iNOS inhibition, but 
were abolished by sGC inhibition. 
 
2- eNOS expression was not significantly affected by LPS, but iNOS 
expression was progressively increased leading to NO overproduction in both 
the pulmonary artery and the aorta. 
 
3- Endothelium-dependent relaxation was impaired by LPS in both vessels, but 
endothelium-independent relaxation and cGMP production was impaired only 
in the pulmonary artery. 
 
4- Relaxation responses to PDE-resistant cGMP analogue was not affected in 
either vessel, while relaxation to a direct sGC activator was decreased in the 
pulmonary artery and increased in the aorta.  
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5- The sGCβ1 protein expression was decreased only in the pulmonary artery, 
while sGCα1 expression was not affected in either vessel. 
 
6- LPS increased relaxation responses to the PDE5 inhibitor T-0156 only in the 
pulmonary artery, but without changes in PDE5 protein expression. 
 
In conclusion, LPS treatment in vitro causes a selective hypocontractility of rat 
aorta to ET-1, which is largely mediated by NO-independent activation of sGC. The 
pulmonary artery is not affected because LPS induces a desensitization of the 
sGC/cGMP dependent pathway by decreasing protein expression levels of sGCβ1, 
and hence sGC activity, and increasing PDE5 activity. Neither endothelium, COX 
nor ROS are involved in these LPS effects. Therefore, sGC and/or PDE5-selective 
inhibitors could be important in controlling systemic and pulmonary vasomotor 
complications in sepsis.  
  
 
 
 
 
 
Chapter 5 
Result III: Molecular Mechanisms Involved in 
LPS-induced Changes in Vascular Reactivity 
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Chapter 5 
5.1 Introduction 
 
Numerous experimental studies of sepsis have clearly documented the presence 
of both in vivo and in vitro vascular hyporesponsiveness to α-adrenergic agonists 
(Guc et al., 1990; O'Brien et al., 2001; Farmer et al., 2003), AngII (Umans et al., 
1993), KCl (Wakabayashi et al., 1987; Umans et al., 1993), ET-1 (Curzen et al., 
1997; Ishimaru et al., 2001), serotonin (Wakabayashi et al., 1987; Umans et al., 
1993), vasopressin (Guc et al., 1990) and TxA2 (Piepot et al., 2002; Boer et al., 
2005). Vascular hyporesponsiveness could be mediated either by an increase in 
vasodilating or a decrease in vasoconstricting mechanisms. Excessive production of 
vasodilator molecules, such as NO, has been shown to contribute to the hypotension 
and vasoplegia in septic shock (Lorente et al., 1993; Szabo et al., 1995; Liu et al., 
1997), however inhibition of NO production yields conflicting results. 
 
Membrane hyperpolarization by K+ channel opening, mainly the BK and KATP 
channels, has been shown to account for the observed vascular hyporeactivity of 
septic shock (Chen et al., 2000; Farias et al., 2002; Wu et al., 2004; O'Brien et al., 
2005; Pickkers et al., 2006). Using different blockers for KATP and BK resulted in 
conflicting results. For example, the KATP channel inhibitor glibenclamide restored 
blood pressure in canine, porcine and rat in vivo models of LPS-induced shock (Wu 
et al., 1995; Vanelli et al., 1995; Gardiner et al., 1999; Sorrentino et al., 1999), but 
had no effect on vascular hyporeactivity in all ex vivo organ bath studies to date (Wu 
et al., 1995; Taguchi et al., 1996). Similarly, the BK channel inhibitor iberiotoxin 
restored aortic hyporeactivity to phenylephrine in endotoxemic rat ex vivo (Taguchi 
et al., 1996), but did not protect against LPS-induced mortality in mice (Cauwels & 
Brouckaert, 2008). 
 
Receptor-mediated vasoconstriction, which may also be affected in sepsis, 
could involve changes in receptor expression, Ca2+-entry pathways, [Ca2+]i and Ca2+ 
sensitization. Only a limited number of studies have examined the role of Ca2+ entry 
pathways in sepsis-induced vascular hyporeactivity without investigating Ca2+ 
sensitization or changes in receptor expression in the same model. For example, 
mesenteric hyporeactivity to the α-adrenergic agonist methoxamine in rat (Farmer et 
Chapter 5-LPS & Vascular Molecular Mechanisms 
110 
al., 2003) or hyperreactivity to ET-1 in pig (Jones et al., 1999) were not associated 
with changes in [Ca2+]i, while aortic vascular hyporeactivity to KCl was associated 
with enhanced Ca2+ uptake (Wakabayashi et al., 1987) or with no change in [Ca2+]i 
release (Biguad et al., 1990). 
 
The mechanisms involved in LPS-induced changes in vascular reactivity to 
ET-1 in the pulmonary artery and the aorta were evaluated by measuring changes in 
the expression levels of mRNA of ET-1, ETA and ETB and the expression levels of 
PKC and phosphorylation of MLC20, ROKα, CPI-17 and MYPT1. The role of 
external Ca2+ and changes in [Ca2+]i have also been studied.  
 
5.2 Methods 
 
Pulmonary and aortic arterial rings were incubated with LPS (10 µg ml-1, 20 h) 
before measuring the following: 
 mRNAs expression levels of ET-1 and its receptors (ETA or ETB) by 
qRT-PCR.  
 contractile responses to ET-1 (0.3 nM-100 nM) in the presence or absence 
of external Ca2+, KATP inhibitor glibenclamide (10 µM) or BK inhibitor 
iberiotoxin (100 nM). 
 relaxation responses to the L-type VOCCs blocker nifedipine (1 nM- 30 
µM), PKC inhibitor Ro-31-8425 (300 nM), ROKα inhibitor Y-27632 (100 
nM- 30 µM) and the ROCCs and SOCCs blocker SKF-96365 (10 µM). 
 the expression levels of PKC and phosphorylation of MLC20, ROKα, 
CPI-17 and MYPT1 by Immunoblotting 
 changes in aortic VSMCs [Ca2+]i induced by ET-1 in the presence or 
absence of external Ca2+, 20 µM diltiazem or 10 µM SKF-96365.  
 contractile responses to ET-1 (0.3 nM-100 nM) in the presence of the 
protein synthesis inhibitor cycloheximide (10 µM) 
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5.3 Effect of LPS-pretreatment on gene expression of ET-1, ETA and ETB in 
pulmonary and aortic vascular rings 
 
The PCR primers designed for ET-1, ETA and ETB together with the 
housekeeping gene β-actin were tested first by using normal PCR to detect presence 
of the expected products at 66, 71, 107 and 72 bp respectively (Figure 4.4). 
Melt-curve analyses, verifying specific amplification and absence of secondary 
primers products, and PCR standard curves of both the target (ET-1, ETA and ETB) 
and reference (β-actin) genes are shown in Figure 5.1.  
 
Incubation of the pulmonary and aortic rings with LPS for 4, 8 or 20 h did not 
result in significant differences in the mRNAs expression levels of ET-1, ETA or ETB 
(Figure 5.2) when compared with the their matchged time-controls. This evidence 
argues against the involvement of changes in gene expression of ET-1 and its 
receptors in the observed LPS-induced aortic hyporeactivity to ET-1. However, it is 
acknowledged that the strength of this conclusion is limited by the small number of 
observations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5-LPS & Vascular Molecular Mechanisms 
112 
 
 
Figure 5.1 Representative qRT-PCR standard curves and melting peaks 
for ET-1, ETA and ETB. RNA was extracted from control and LPS (10 µg ml-1)-
treated vascular rings at 0, 4, 8 and 20 h and reverse-transcribed into cDNA 
before carrying out quantitative RT-PCR using the Lightcycler. 
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Figure 5.2 Effect of LPS on gene expression of ET-1, ETA and ETB in 
the pulmonary artery and the aorta. RNA was extracted from control and LPS 
(10 µg ml-1)-treated vascular rings at 0, 4, 8 and 20 h and reverse-transcribed into 
cDNA before carrying out qRT-PCR to detect changes in the gene expression of 
ET-1 (a and b), ETA (b and c) and ETB (e and f) in the pulmonary artery and aorta 
respectively. Data are expressed as mean ± s.e.m., where (n) equals the number of 
independent experiments, each using duplicate PCR reactions from the same 
sample prepared from pooled tissue lysates of 2 animals. 
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5.4 Effect of external Ca2+ removal on LPS-induced changes in vascular 
reactivity to ET-1 
 
As previously mentioned in chapter 3, LPS selectively causes hyporeactivity to 
ET-1 in the aorta but not in the pulmonary artery (Figure 3.5). Removal of external 
Ca2+ had a significant effect on this selective LPS-induced vascular reactivity to 
ET-1. In the pulmonary artery, removal of external Ca2+ decreased maximal 
contractility to ET-1 as manifested by the decreased Emax for both the control (from 
4.3±0.2 mN to 1.1±0.1 mN) and LPS-treated (from 4.4±0.2 mM to 1.0±0.1 mN) 
without revealing a difference between both of them (Figure 5.3a). Similarly, 
removal of external Ca2+ decreased Emax for both the control (from 8.0±0.4 mN to 
4.0±0.4 mN) and LPS-treated (from 6.0±0.4 mN to 4.0±0.3 mN) aortic rings. 
However, this decrease in Emax in the aorta by removal of external Ca2+ abolished the 
difference in ET-1-induced contractions in the control and LPS-treated aortic rings 
(Figure 5.3b). This result suggests that external Ca2+ plays a major role in 
LPS-induced changes in vascular reactivity to ET-1. 
 
5.5 Effect of external Ca2+ addition on LPS-induced changes in vascular 
reactivity to ET-1 
 
In experiments performed to determine the role of Ca2+ influx, the addition of 
Ca2+ (0.1-10 mM) to pulmonary and aortic rings preconstricted with 100 nM ET-1 
resulted in a stepwise increase in vessel contraction (Figure 5.4). The Emax values of 
this stepwise contractile response to Ca2+ addition was not affected by 
LPS-pretreatment in the pulmonary artery (Figure 5.5a), but it was significantly  
reduced by 56±8 % after LPS-pretreatment in aortic rings (p<0.01, n=5) (Figure 
5.5b). The presence of the L-type VOCCs blocker nifedipine (10 µM) had no 
significant effect on contractile responses to external Ca2+. This result suggests that 
external Ca2+ influx through non-VOCCs plays a major role in LPS-induced changes 
in vascular reactivity to ET-1. 
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Figure 5.3 Effect of removal of external Ca2+ on LPS-induced changes in 
vascular reactivity to ET-1 in the pulmonary artery and the aorta. 
Contraction to ET-1 (0.3 nM-100 nM) was measured in the absence of external 
Ca2+ in the pulmonary artery (a) and aorta (b) after incubation with LPS (10 µg 
ml-1, 20 h). Data are expressed as mean ± s.e.m., where (n) equals the number 
animals. 
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Figure 5.4 Representative control trace of contractile response to Ca2+ 
addition. This trace is showing the effect of subsequent increases in extracellular 
Ca2+ on the aorta preconstricted with 100 nM ET-1 in the presence of 10µM 
nifedipine. The starting point of Ca2+ addition at the plateau of ET-1 contraction 
was taken as the baseline for the Ca2+ response curve.  
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Figure 5.5 Effect of LPS on contractile responses to Ca2+ addition in the 
pulmonary artery and the aorta preconstricted with ET-1. Contraction 
responses to the addition of Ca2+ (0.1-10 mM) was measured in control and LPS 
(10 µg ml-1, 20 h)- treated pulmonary (a) and aortic (b) rings preconstricted with 
100 nM ET-1 in presence of 10µM nifedipine. The starting point of Ca2+ addition 
at the plateau of ET-1 contraction was taken as the baseline for the Ca2+ response 
curve. Data are expressed as mean ± s.e.m., where (n) equals the number animals. 
** p<0.01 for Emax and pEC50 values compared with control group using paired 
Student’s t-test. 
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5.6 Effect of VOCCs blocking on LPS-induced changes in vascular reactivity to 
ET-1 
 
Blocking of L-type VOCCs by nifedipine caused approximately a 50% 
relaxation of both the pulmonary (Figure 5.6a) and aortic (Figure 5.6b) rings 
preconstricted with 30 nM ET-1, suggesting the presence of other types of Ca2+ 
channels that is involved in ET-1-induced contractions. In both the pulmonary artery 
and the aorta, no significant changes were found between the control and LPS-treated 
vascular rings preconstricted with 30 nM ET-1 in the relaxation responses to 
nifedipine (0.1-30 µM), suggesting that changes in VOCCs are not responsible for 
LPS-induced aortic hyporeactivity to ET-1. 
 
5.7 Effect of blocking of ROCCs and SOCCs on LPS-induced changes in 
vascular reactivity to ET-1 
 
By using 10 µM SKF-96365, which is a blocker of ROCCs and SOCCs, a 
similar 50% relaxation was obtained in both the pulmonary and aortic rings  
preconstricted with 30 nM ET-1 (Figure 5.7) suggesting the involvement of ROCCs 
and/or SOCCs in ET-1-induced contractions. In the pulmonary artery, there was no 
significant difference in the relaxation induced by 10 µM SKF-96365 between 
control and LPS-treated rings. However, LPS-pretreatment decreased 
SKF-6365-induced relaxation in the aorta (p<0.05, n=4), suggesting that ROCCs 
and/or SOCCs could be downregulated or deactivated by LPS. 
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Figure 5.6 Effect of LPS on relaxation responses to nifedipine in the 
pulmonary artery and the aorta. Pulmonary (a) and aortic (b) arterial rings 
from control and LPS (10 µg ml-1, 20 h)-treated groups were preconstricted with 
30 nM ET-1 before measuring relaxation responses to nifedipine (1 nM- 30 µM). 
Data are expressed as mean ± s.e.m., where (n) equals the number animals. 
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Figure 5.7 Effect of LPS on relaxation responses to 10 µM SKF-96365 in 
the pulmonary artery and the aorta. Pulmonary and aortic arterial rings from 
control and LPS (10 µg ml-1, 20 h)-treated groups were preconstricted with 30 nM 
ET-1 before measuring relaxation to 10 µM SKF-96365. Data are expressed as 
mean ± s.e.m., where (n) equals the number animals. * p<0.05 compared with 
control group using paired Student’s t-test. 
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5.8 Effect of KATP channels blocking on LPS-induced changes in vascular 
reactivity to ET-1 
 
KATP channels represent a possible pathway that could be involved in 
LPS-induced vascular effects. Blocking of KATP channels by glibenclamide (10 µM, 
30 min) caused no significance difference in ET-1-induced contraction between 
control and LPS-treated pulmonary artery (Figure 5.8a). In the aorta, glibenclamide 
did not abolished the LPS-induced hyporeactivity to ET-1 (Figure 5.8b), since there 
was still a 27±4 % decrease in Emax in the LPS group compared to control, suggesting 
that KATP channels are not affected by LPS treatment in this model. 
 
5.9 Effect of BK channels blocking on LPS-induced changes in vascular 
reactivity to ET-1 
 
BK channels are another important pathway that could play an important role 
in LPS-induced vascular hyporeactivity. Blocking of BK channels by incubation with 
100 nM iberiotoxin for 30 min before measuring the contraction to ET-1 caused no 
significance difference in ET-1-induced contraction between control and LPS-treated 
pulmonary artery (Figure 5.9a). In the aorta, iberiotoxin did not abolish the 
LPS-induced hyporeactivity to ET-1 (Figure 5.9b), since there still a 25±4 % 
decrease in Emax in the LPS group compared to control, suggesting that BK channels 
are not involved in LPS-induced changes in contraction responses to ET-1. 
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Figure 5.8 Effect of glibenclamide on LPS-induced changes in contractile 
responses to ET-1 in the pulmonary artery and aorta. Control and LPS (10 µg 
ml-1, 20 h)-treated pulmonary (a) and aortic (b) rings were incubated with the 
KATP channel blocker glibenclamide (10 µM, 30 min) before measuring the 
contraction to ET-1 (0.3 nM-100 nM). Data are expressed as mean ± s.e.m., 
where (n) equals the number animals. ** p<0.01 for Emax and pEC50 values 
compared with control group using paired Student’s t-test. 
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Figure 5.9 Effect of iberiotoxin on LPS-induced changes in contractile 
responses to ET-1 in the pulmonary artery and aorta. Control and LPS (10 µg 
ml-1, 20 h)-treated pulmonary (a) and aortic (b) rings were incubated with the BK 
channel blocker iberiotoxin (100 nM, 30 min) before measuring the contraction to 
ET-1 (0.3 nM-100 nM). Data are expressed as mean ± s.e.m., where (n) equals the 
number animals. ** p<0.01 for Emax and pEC50 values compared with control 
group using paired Student’s t-test. 
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5.10 Effect of ROKα inhibitor on LPS-induced changes in vascular reactivity to 
ET-1 
 
Y-27632 is a selective inhibitor of ROKα that affects Ca2+ sensitization by 
removing the inhibitory effect of ROKα on MLCP leading to relaxation. ROKα is 
involved in several pathological conditions and could represent a possible pathway 
through which LPS can cause vascular hyporeactivity. Application of Y-27632 (100 
nM- 30 µM) on pulmonary and aortic rings preconstricted with 30 nM ET-1 resulted 
in a full relaxation. In both vessels, there was no significance difference in the 
relaxation responses induced by Y-27632 between control and LPS-treated 
pulmonary artery (Figure 5.10a) and aorta (Figure 5.10b), suggesting that Ca2+ 
sensitization through the ROKα pathway is not affected by LPS treatment in this 
model. 
 
5.11 Effect of PKC inhibitor on LPS-induced changes in vascular reactivity to 
ET-1 
 
Ro-31-8425 is a non-selective PKC inhibitor that can cause relaxation similar 
to ROKα inhibitor by by removing the inhibitory effect of PKC on MLCP. PKC is an 
important pathway involved in the mechanism of contraction of several vasoactive 
agents, including ET-1. PKC inhibition or downregulation could be a possible 
pathway involved in LPS-induced vascular hyporeactivity. Inhibition of PKC by 
adding 300 nM Ro-31-8425 on pulmonary and aortic rings preconstricted with 30 
nM ET-1 resulted in around 50 % relaxation of the vessels (Figure 5.11). The 
relaxation responses induced by Ro-31-8425 in control group were not significantly 
different from that of LPS-treated groups in both the pulmonary artery and the aorta, 
suggesting that changes in PKC are not involved in LPS-induced changes in 
contraction responses to ET-1. 
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Figure 5.10 Effect of Y-27632 on LPS-induced changes in contractile 
responses to ET-1 in the pulmonary artery and aorta. Pulmonary (a) and 
aortic (b) arterial rings from control and LPS (10 µg ml-1, 20 h)-treated groups 
were preconstricted with 30 nM ET-1 before measuring relaxation responses to 
Y-27632 (100 nM- 30 µM). Data are expressed as mean ± s.e.m., where (n) 
equals the number animals. 
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Figure 5.11 Effect of Ro-31-8425 on LPS-induced changes in contractile 
responses to ET-1 in the pulmonary artery and aorta. Pulmonary (a) and 
aortic (b) arterial rings from control and LPS (10 µg ml-1, 20 h)-treated groups 
were preconstricted with 30 nM ET-1 before measuring relaxation responses to 
Ro-31-8425 (300 nM). Data are expressed as mean ± s.e.m., where (n) equals the 
number animals. 
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5.12 Effect of LPS-pretreatment on the expression of different proteins involved 
in Ca2+-sensitization induced by ET-1 
 
Phosphorylation of MLC20 is the major step leading to contraction of VSMCs, 
and this phosphorylation can be controlled by the level of [Ca2+]i or through the 
Ca2+-sensitization that depends mainly on the activity of MLCP. In both the 
pulmonary artery and the aorta, contraction with ET-1 caused a significant increase 
in the phosphorylation of MLC20 (p<0.05, n=4) (Figure 5.12). ET-1-stimulated 
phosphorylation of MLC20 was not affected by LPS-pretreatment in the pulmonary 
artery (Figure 5.12 a and b), but was significantly decreased in the aorta (p<0.05, 
n=4) (Figure 5.12 c and d), a result in line with the observed aortic hypocontractility 
to ET-1 (Figure 3.5).  
 
To measure changes in the proteins involved in Ca2+-sensitization, PKC, 
ROKα, CPI-17 and MYPT1 were investigated in both the pulmonary artery and the 
aorta. There were no significant changes in the ET-1-induced changes in the protein 
expression levels of PKC or the phosphorylation levels of ROKα, CPI-17 or MYPT1 
between control and LPS-pretreated vascular rings (Figure 5.13). These results 
suggest that ET-1-induced sensitization to Ca2+ are not altered in LPS-pretreated 
pulmonary artery and aorta. 
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Figure 5.12 Effect of LPS on ET-1-induced phosphorylation of MLC20 in 
the pulmonary artery and aorta. (a, c) Representative immunoblots for pMLC20 
and MLC20 in the pulmonary artery and the aorta from control (C), (LPS), control 
+ 100 nM ET-1 (C+ET) and LPS + 100 nM ET-1 (LPS+ET) groups. (b, d) 
densitometric ratio of pMLC20 normalized to MLC20 in the pulmonary artery and 
the aorta. Data are expressed as mean ± s.e.m., where (n) equals the number 
animals. * p<0.05 compared with control or LPS groups, # p<0.05 compared with 
C+ET group using one-way ANOVA with Student-Newman-Keuls Multiple 
Comparisons post-hoc test. 
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Figure 5.13 Effect of LPS on the protein expression levels of PKC and the 
phosphorylation levels of ROKα, CPI-17 and MYPT1 in the pulmonary 
artery and aorta. Representative immunoblots of PKC (a), pROKα (b), pCPI-17 
(c) and pMYPT1 (d) in the pulmonary artery (left) and the aorta (right) from 
control (C), (LPS), control + 100 nM ET-1 (C+ET) and LPS + 100 nM ET-1 
(LPS+ET) groups. 
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5.13 Effect of LPS-pretreatment on [Ca2+]i changes induced by ET-1 in isolated 
aortic VSMCs 
 
The resting level of [Ca2+]i was significantly higher in LPS-treated VSMCs (106±5 
nM) compared to control (94±5 nM) (p<0.05, n=12), but this difference was 
abolished when external Ca2+ was removed, where the baselines were 111±4 nM and 
108±3 nM for LPS and control groups, respectively. Infusion of 100 nM ET-1 caused 
an initial increase in [Ca2+]i (transient phase) followed by a continuous plateau 
elevation in [Ca2+]i (sustained phase) (Figure 5.14b). There were no significant 
differences in the transient [Ca2+]i increase induced by 100 nM ET-1 between control 
(111±10 nM) and LPS-treated (109±13 nM) aortic VSMCs. However, the sustained 
phase [Ca2+]i level of control (26±3 % of transient phase in each cell) was 
significantly reduced to 15±2 % in the LPS-treated group (p<0.001, n=12) (Figure 
5.14c). Removal of external Ca2+ had no significant effect on the transient phase 
[Ca2+]i elevations in either the control (103±10 nM) or the LPS-treated (104±11 nM) 
group, but the sustained phase [Ca2+]i was decreased in both control (11±1 %) and 
LPS-treated (11±2 %) groups which abolished the difference between control and 
LPS-treated groups (Figure 5.14c). Conversely, addition of 2.5 mM Ca2+ during the 
sustained phase, produced a continuous elevation in [Ca2+]i, which was significantly 
higher in control (210±17 %) compared to LPS-treated (155±12 %) groups (p<0.05, 
n=12) (Figure 5.15a and b). This continuous elevation in [Ca2+]i was not significantly 
affected by incubation with 20 µM diltiazem for 5 minutes before the addition of the 
2.5 mM Ca2+ (Figure 5.15b). However, incubation with 10 µM SKF-96365 
significantly decreased the continuous elevation in [Ca2+]i in both groups and 
abolished the difference between the control and LPS-treated groups (Figure 5.15b). 
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Figure 5.14 Effect of LPS on ET-1-induced changes of [Ca2+]i in aortic 
VSMCs. (a) representative photos of the different shapes of isolated aortic 
VSMCs. (b) representative trace showing biphasic [Ca2+]i changes induced by 100 
nM ET-1 in control aortic VSMC. (c) The effect of external Ca2+ removal on 
sustained phase [Ca2+]i induced by 100 nM ET-1. Data are expressed as % change 
from transient phase, n=12 cells prepared using tissue from 3 rats. ***p<0.01 
compared with control group using paired Student’s t-test. 
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Figure 5.15 Effect of Ca2+ addition, diltiazem, and SKF-96365 on 
ET-1-induced changes of [Ca2+]i in control and LPS-treated aortic VSMCs. 
(a) representative trace showing the effect of 2.5 mM Ca2+ addition on
 
ET-1-induced biphasic [Ca2+]i changes in control aortic VSMCs. (b) The effect of 
20 µM diltiazem or 10 µM SKF-96365 on sustained phase [Ca2+]i induced by 
addition of 2.5 mM Ca2+ to aortic VSMCs preconstricted with 100 nM ET-1. Data 
are expressed as % change from transient phase, n=12 cells prepared using tissue 
from 3 rats. *p<0.05 using one-way ANOVA with Student-Newman-Keuls 
Multiple Comparisons post-hoc test. 
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5.14 Effect of protein synthesis inhibition on LPS-induced changes in vascular 
reactivity to ET-1 
 
To determine if LPS-induced changes are dependent on protein synthesis or 
not, pulmonary and aortic rings were incubated with the protein synthesis inhibitor 
cycloheximide (10 µM) 1 h before and during the incubation with LPS. In the 
pulmonary artery, there was no significance difference in the contraction responses 
to ET-1 between control and LPS-treated vascular rings (Figure 5.16a). In the aorta, 
cycloheximide abolished the difference in contractile responses to ET-1 induced by 
LPS (Figure 5.16b), suggesting that LPS-induced aortic hyporeactivity to 
ET-depends on protein synthesis. 
 
Figure 5.16 Effect of cycloheximide on LPS-induced changes in 
contractile responses to ET-1 in the pulmonary artery and aorta. Contraction 
to ET-1 (0.3 nM-100 nM) was measured in the pulmonary artery (a) and the aorta 
(b) after incubation with LPS (10 µg ml-1, 20 h) in presence of 10 µM 
cycloheximide. Data are expressed as mean ± s.e.m., where (n) equals the number 
animals. 
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5.15 Discussion 
 
The results presented in this chapter show that LPS-induced vascular 
hypocontractility to ET-1 in rat aorta is primarily dependent on Ca2+ influx through 
non-VOCCs, but not on changes in ET-1 receptor expression or Ca2+ sensitization. 
 
In the present study, LPS treatment impaired contractile responses of rat aorta 
to both receptor-dependent and -independent vasoconstrictors. Although changed 
expression of ET-1 specific receptors ETA and ETB has been suggested as a 
mechanism of hypocontractility, no systematic study has evaluated this possibility in 
intact arteries. Previous studies have shown that LPS treatment decreases ETA 
mRNA in rat heart (Ishimaru et al., 2001; Hirata & Ishimaru, 2002), aortic VSM cell 
line A7r5 (Bucher & Taeger, 2002) and rat pulmonary VSM (Dschietzig et al., 
2008), but increases expression in septic pig heart (Forni et al., 2005). Conversely, 
increased ETB mRNA was observed in these previous studies but ETB mRNA was 
decreased in rat pulmonary ECs (Dschietzig et al., 2008). Few studies have examined 
ET-1 gene expression in intact arteries, where ET-1 mRNA is increased in mouse 
aorta (Shindo et al., 1998) and in rat aorta and pulmonary artery (Curzen et al., 
1997), but was not affected in porcine aorta (Magder et al., 2001) by LPS treatment. 
Since LPS had no effect on the ET-1, ETA or ETB receptors mRNA levels, changes 
in the gene expression of ET-1 system is unlikely to be involved in LPS-induced 
hyporeactivity in the present model. Using different animals for control and 
LPS-treated groups can influence the outcome due to the difference in genetic 
background, but in the present model all the time points representing LPS treatment 
have their respective controls which, for each sample, are pooled exactly from the 
same animals to eliminate any genetic background influence.  
 
By using blockers for KATP (glibenclamide) and BK (iberiotoxin), LPS-induced 
changes in vascular reactivity to ET-1 were not affected in either the pulmonary 
artery or the aorta. These results are similar to previous ex vivo organ bath studies, 
where glibenclamide had no effect on vascular hyporeactivity (Wu et al., 1995; 
Taguchi et al., 1996) or even further reduced contractions (Sorrentino et al., 1999) 
and to an in vivo model where both glibenclamide and iberiotoxin did not protect 
against LPS-induced mortality in mice (Cauwels & Brouckaert, 2008). In addition, 
Chapter 5-LPS & Vascular Molecular Mechanisms 
135 
since K+ channels activation causes hyperpolarization and closing of VOCCs, the 
absence of effects with either K+ channels blockers or VOCCs blockers confirms that 
both K+ channels and VOCCs are not involved in LPS-induced hyporeactivity to 
ET-1 in the aorta.  
 
No previous studies are available where the role of different proteins involved 
in Ca2+-sensitization was assessed in vascular hyporeactivity changes in animal 
models of sepsis. Therefore, the present results demonstrating the absence of 
significant changes between control and LPS-treated aortic rings in the protein 
expression levels of PKC or the phosphorylation levels of ROKα, CPI-17 or MYPT1, 
are an important evidence suggesting that Ca2+-sensitization is not the primarily 
mechanism responsible for LPS-induced hyporeactivity to ET-1. These observations 
suggest that changes in Ca2+ mobilization or Ca2+ entry are more important.  
 
Previous studies have mainly examined LPS-induced changes in depolarizing 
KCl (40-100 mM)-stimulated Ca2+-entry via VOCCs. Increasing extracellular Ca2+ 
up to 30 mM reverses the diminished vascular reactivity to KCl in the aorta from 
septic rats (Wakabayashi et al., 1987; Biguad et al., 1990), an effect attributed to the 
impairment of either Ca2+ sensitization (Wakabayashi et al., 1987) or Ca2+ influx 
(Biguad et al., 1990), although specific mechanisms were not identified. The present 
results using the VOCCs blockers nifedipine or diltiazem suggest that 
VOCCs-dependent Ca2+-entry is not responsible for LPS-induced hyporeactivity to 
ET-1. Furthermore, the difference in the sensitivity to external Ca2+ in the aorta 
preconstricted with ET-1 in the presence of nifedipine suggests that LPS impairs 
non-VOCCs Ca2+-entry. Similarly, rat aorta from endotoxic rats display reduced 
sensitivity to Ca2+ in high K+ depolarizing medium (Gray et al., 1990; Ho et al., 
1996) and nitrendipine is not able to inhibit vascular hyporeactivity to phenylephrine 
in septic rat aorta (Biguad et al., 1990). Conversely, pre-administration of verapamil 
and nifedipine (Sirmagul et al., 2006) or nifedipine (Wu et al., 1999) is able to 
prevent hypotension in vivo in endotoxin-shocked rats. Interestingly, amlodipine 
prevents LPS-induced hypotension in vivo but not in vitro (Salomone et al., 1998), 
suggesting that results obtained with VOCCs modulators in vivo may be affected by 
other factors inside the body, such as metabolism, interaction with other 
mediators/cells and the presence of neuronal factors.  
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To study LPS-induced changes in Ca2+ influx further, changes in [Ca2+]i levels 
in isolated aortic VSMCs were examined. The basal [Ca2+]i levels were slightly 
higher in LPS-treated aortic VSMCs compared to control, a result consistent with 
previous studies using rat aorta (Song et al., 1993) and rat mesenteric arteries 
(Martinez et al., 1996). Since removal of external Ca2+ abolishes this difference in 
basal [Ca2+]i levels, it is unlikely to result from an impairment of [Ca2+]i storage 
(Hotchkiss & Karl, 1996; Farmer et al., 2003), but probably from enhanced Ca2+ 
influx through VOCCs (Wilkinson et al., 1996), or other Ca2+ channels.  
 
The ET-1-induced biphasic increase in Ca2+ levels, comprising transient and 
sustained components, has been previously shown (Jones et al., 1999; Zhang et al., 
1999). The transient phase of [Ca2+]i increase was not affected by external Ca2+ 
removal, suggesting that it is mainly due to intracellular release of Ca2+ as previously 
demonstrated (Zhang et al., 1999; Ko et al., 2005). Since LPS treatment had no 
effect on the transient phase increase in [Ca2+]i, it is unlikely that Ca2+-mobilization 
from intracellular stores was affected under the present experimental conditions. 
However, the ET-1-induced sustained phase [Ca2+]i increase was significantly 
reduced in LPS-treated aortas. This difference was abolished by removal of external 
Ca2+, suggesting that it is mediated by voltage-independent Ca2+ influx. Similar 
differences were observed in response to the addition of external Ca2+ in the presence 
of ET-1 and the lack of response to diltiazem confirms this conclusion. The complete 
inhibition of the difference in the sustained level of [Ca2+]i, by SKF-96365, an 
inhibitor of both ROCCs and SOCCs (Merritt et al., 1990; Zhang et al., 1999), 
indicates that LPS impairs Ca2+ influx through voltage-independent Ca2+ channels. 
Since Ca2+ mobilization was not affected by LPS, it is likely that ROCCs more than 
SOCCs are involved.  
It should be noted that U46619 did not show hyporeactivity after 
LPS-treatment in contrast to ET-1, phenylephrine and KCl. U46619-mediated 
contraction of rat aortic rings through TP receptors was not affected by external Ca2+ 
removal (Dorn & Becker, 1993). In addition, U46619 induces RhoA activation 
higher than ET-1 and norepinephrine in rabbit aortic smooth muscle (Sakurada et al., 
2001). Therefore, U46619 resistance to LPS effects may be due its different 
mechanism of contraction, which depends on internal Ca2+ mobilization and Ca2+ 
sensitization more than on external Ca2+. 
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5.16 Summary and conclusions 
 
In this chapter, LPS-induced changes in ET-1 receptor expression, Ca2+-entry 
pathways, [Ca2+]i and Ca2+-sensitization were examined in the pulmonary artery and 
aorta. The main findings are: 
 
1- mRNA expression levels of ET-1, ETA and ETB are not affected by LPS in 
either vessel. 
 
2- LPS-induced aortic hyporeactivity to ET-1 is dependent on external Ca2+ 
influx through voltage-independent Ca2+ channels. 
 
3- Neither KATP nor BK have a major role in LPS-induced vascular effects. 
 
4- The major proteins involved in Ca2+ sensitization, including ROKα, PKC, 
MYPT1 and CPI-17, are not affected by LPS treatment in either vessel. 
 
5- LPS impairs ET-1-induced changes in [Ca2+]i in aortic VSMCs by impairing 
Ca2+ influx mainly through ROCCs, although SOCCs could also be involved. 
 
6- Inhibition of protein synthesis abolished LPS-induced aortic 
hypocontractility to ET-1 
 
In conclusion, the mechanism of LPS-induced aortic hyporeactivity to ET-1 
depends on external Ca2+ influx through non-VOCCs, but not on ET-1 receptor 
expression or Ca2+ sensitization. The effect of LPS on the non-VOCCs Ca2+ influx 
depends on protein synthesis. Therefore, Ca2+ homeostasis could be important in 
controlling systemic vasomotor complications in sepsis. 
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Chapter 6 
 
Inflammation has incompletely characterized effects on cardiopulmonary 
vascular reactivity.  One of the major diseases involving inflammation is sepsis, a 
complex dysregulation of inflammation arising when the host is unable to contain an 
infection successfully. Sepsis is associated with two main vasomotor complications, 
septic shock and pulmonary hypertension (Parsons et al., 1989; Manthous et al., 
1993; Lorente et al., 1993), suggesting that systemic and pulmonary vasculature 
respond differentially to inflammation.  
 
The main aim of this study was to examine the molecular mechanisms involved 
in cardiopulmonary vascular reactivity changes induced during inflammation. By 
using LPS as a powerful inflammatory stimulus, the present study established a 
well-controlled in vitro model to study changes in vascular reactivity that allowed 
identification of the possible vasoactive mediators and the molecular mechanisms 
impaired by LPS in vascular tissues. 
 
6.1 The model 
 
The vascular effects of sepsis can be simulated by the administration of the 
bacterial endotoxin LPS, both in humans (Suffredini et al., 1989) and in animals 
(Ruetten et al., 1996; Peters & Lewis, 1996; Gardiner et al., 1996b). The effect of 
endotoxemia on the vasculature has been studied by many different groups, using 
different models of in vivo, in vitro and ex vivo endotoxemia. However, the results 
are highly variable. Even in the same model, there is variability in LPS-induced 
changes in vascular reactivity between different blood vessels and towards different 
vasoconstrictors (Piepot et al., 2002; Farmer et al., 2003). This suggests that the type 
of blood vessel, mechanism of action of the vasoactive agent and the experimental 
conditions all affect the vascular reactivity observed in endotoxemic models.    
 
The in vivo and ex vivo models, in contrast to in vitro models, represent real 
pathological conditions, but are difficult to control due to multiple interactions. The 
in vitro organ culture has been shown to preserve tissue structure and contractility 
(Adner et al., 1998; Ozaki & Karaki, 2002; Guibert et al., 2005), in contrast with in 
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vitro cultures of VSMCs, and its experimental conditions can be easily controlled. 
Therefore, the present study used an organ culture method as an endotoxemic model 
to investigate the effect of inflammation on vascular reactivity.  
 
In the present model, the effect of in vitro incubation with LPS was examined 
in the pulmonary artery and the aorta, to represent pulmonary and systemic 
circulations respectively, under similar experimental conditions. The present study 
showed that LPS selectively induced vascular hyporeactivity to different 
vasoconstrictors in rat aorta but not in the pulmonary artery, similar to real in vivo 
observations in endotoxemia and sepsis. This aortic hyporeactivity was not due to 
organ culturing per se and was not affected by changing the LPS type. Therefore, this 
organ culture model is suitable to study LPS-induced changes in vascular reactivity 
and can be easily controlled to study the molecular mechanisms involved.  
 
It should be noted that most in vivo and ex vivo studies used large bolus 
injection of LPS, with a few studies using continuous infusion of LPS (Guc et al., 
1990; Farmer et al., 2003). This high single LPS bolus models are different from 
human infection where the bacterial toxins are continuously present in blood. In 
addition, high single LPS dose can cause a burst of inflammatory mediators such as 
cytokines, which may lead to altered results. The in vitro models, such as the present 
one, use LPS concentrations much higher than levels measured in clinical sepsis, 
which may be considered as a drawback. In addition, the role of circulating cells and 
other in vivo factors were not studied here. 
 
6.2 The vasoactive mediators 
 
Several mediators have been suggested to play a major role in sepsis-induced 
vascular complications, including NO, derivatives of COX, ROS and 
vasoconstrictors such as catecholamines, ET-1 and AngII. The present study focused 
on ET-1 and NO as major mediators that could be involved in vascular responses to 
LPS. Overproduction of NO, the major vasodilator, is suggested to be the responsible 
cause of vascular hyporeactivity in a large number of studies (Szabo et al., 1995; 
Feihl et al., 2001; Lopez et al., 2004). Plasma levels of ET-1, the most powerful 
vasoconstrictor at present, are elevated in sepsis and its level correlates with the 
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severity of illness (Pittet et al., 1991; Piechota et al., 2007). Results with different 
blockers of NO pathway are conflicting and sometimes detrimental, while ET-1 
antagonism attenuates pulmonary hypertension in endotoxic shock (Wanecek et al., 
1999; Kuklin et al., 2004). 
 
Interestingly, NO was increased in both the pulmonary artery and the aorta in 
the present study, but vascular responses to ET-1 were impaired only in the aorta, 
raising a doubt about the role of NO in this model. Moreover, inhibition of iNOS was 
unable to reverse aortic hyporeactivity, but inhibition of sGC prevented this 
hyporeactivity. These results suggest that LPS-induced aortic hypocontractility to 
ET-1 is largely mediated by NO-independent activation of sGC. The pulmonary 
artery did not show hyporeactivity to ET-1 because LPS induced a desensitization of 
the sGC/cGMP-dependent pathway by decreasing protein expression levels of sGCβ1, 
and hence sGC activity, and increasing PDE5 activity. Importantly, previous studies 
examining sGC/cGMP pathway in sepsis examined whole lung tissue or cultured 
pulmonary VSMCs, but not isolated pulmonary artery, which may be more relevant 
and specific.  
 
Although endothelium removal and COX or ROS inhibition were unable to 
prevent LPS-induced aortic hyporeactivity to ET-1, this does not exclude their role in 
vivo. In addition, the complexity of LPS action could involve other mediators not 
studied in the present work. 
 
6.3 The mechanisms 
 
Since LPS can induce vascular hyporeactivity in vitro to different 
vasoconstrictors, which is independent of LPS type, and also in vessels removed 
from LPS-treated animals, the defect in the vascular contractility is intrinsic to the 
vasculature. The mechanisms involved in VSM contraction is therefore affected by 
LPS, either directly or through mediators released by LPS. 
 
Several mechanisms could be involved in LPS-induced vascular hyporeactivity, 
including changes in receptor expression, Ca2+-entry pathways, [Ca2+]i and 
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Ca2+-sensitization, in addition to membrane hyperpolarization by K+ channel 
opening, mainly the BK and KATP channels.  
 
Only a limited number of studies have examined the effect of LPS on these 
mechanisms. Using different blockers for KATP and BK produced conflicting results 
in previous studies, similar to the case with NO inhibitors. The present results with 
BK and KATP channels blockers show that K+ channels may not play a major role in 
this model. Similar to the endothelium, COX and ROS, this does not exclude the role 
of K+ channels in vivo.  
 
LPS treatment in the present study had no significant effect on ETA or ETB 
receptor mRNA levels, contrary to most studies showing that ETA is decreased while 
ETB is increased. It should be mentioned that no systematic study has evaluated ET-1 
receptor expression in intact arteries in endotoxemia, which make the present results 
more specific than examining the whole organ like the heart or the lung. In addition, 
using different animals for control and LPS-treated groups can influence the outcome 
results due to the difference in genetic background. In contrast, all the time points in 
the present model representing LPS treatment have their respective controls which, 
for each sample, are pooled exactly from the same animals to eliminate any genetic 
background influence.  
 
The exact role of Ca2+ homeostasis in LPS-induced vascular hyporeactivity is 
unknown. No previous studies examined the role of Ca2+-entry pathways, [Ca2+]i and 
Ca2+-sensitization in LPS-induced vascular hyporeactivity in detail. The present 
results show that LPS impairs ET-1-induced Ca2+ influx without affecting different 
proteins involved in Ca2+-sensitization (PKC, ROKα, CPI-17 or MYPT1) in the 
aorta. Previous studies have mainly examined LPS-induced changes in Ca2+-entry via 
VOCCs stimulated by depolarizing KCl. The present study shows that LPS impairs 
ET-1-induced Ca2+ influx through voltage-independent Ca2+ channels, which may 
include SOCCs and ROCCs. Since Ca2+ mobilization was not affected by LPS, it is 
likely that ROCCs more than SOCCs are involved. These effects of LPS are 
dependent on protein synthesis. These results show the importance of Ca2+ 
homeostasis in LPS-induced vascular hyporeactivity. Figure 6.1 represents a simple 
scheme to highglight the findings of this study. 
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LPS 
 
Protein expression 
 
 
 
Decreases sGCβ1      Mediator(s) ? 
Increases PDE5 activity   ?     
            
Hyporeactivity to NO     Stimulates sGC 
and other sGC activators        
          
 
        Decreases ROCCs  
and/or SOCCs 
Decreases vasodilator responses     
 
Decreases [Ca2+]i 
 
 
        Decreases pMLC20  
   
Normal or hyperreactive  
pulmonary vessel        Aortic hyporeactivity 
 
Figure 6.1 Simple scheme highlighting the findings of this study. [Ca2+]i, 
intracellular Ca2+; NO, LPS, lipopolysaccharide;nitric oxide; PDE5, 
phosphodiesterase 5; pMLC20, 20 kD phospho-myosin light chain; ROCCs, 
receptor-operated Ca2+ channels; SOCCs, store-operated Ca2+ channels; sGCβ1, 
soluble guanylyl cyclase β1. 
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6.4 Final conclusions 
 
Inflammation can cause either vasoconstriction or vasodilation depending on 
the type of vascular tissue, vasoconstrictor and experimental conditions. The 
powerful inflammatory stimulus LPS causes selective aortic hypocontractility to 
different vasoconstrictors without affecting the pulmonary artery responses. In the 
aorta, LPS-induced hypocontractility to ET-1 may be due to NO-independent 
activation of sGC. In addition, LPS in the aorta may impair external Ca2+ influx 
through non-VOCCs, but not ET-1 receptors expression or Ca2+ sensitization, and 
these effects depend on protein synthesis. In the pulmonary artery, LPS does not 
affect pulmonary artery responses to different vasoconstrictors, since it causes 
desensitization of the sGC/cGMP pathway by decreasing protein expression levels of 
sGCβ1, and hence sGC activity, and increasing PDE5 activity. In addition, LPS has 
no effect on ET-1 receptors expression or external Ca2+ influx induced by ET-1 in the 
pulmonary artery. 
 
Therefore, it is likely that both Ca2+ homeostasis and the sGC/cGMP pathway 
play important roles in vasomotor complications in sepsis. sGC and/or 
PDE5-selective inhibitors, together with manipulating VSMC [Ca2+]i, could be 
important in controlling systemic and pulmonary vasomotor complications in sepsis. 
 
6.5 Future work 
 
Next steps may include determination of the nature of the NO-independent sGC 
activator stimulated by LPS, the mechanism by which LPS impairs PDE5 activity in 
pulmonary vessels and the type of Ca2+ channels involved in LPS actions. The 
mechanisms investigated in this study are related mainly to ET-1, other 
vasoconstricors can be investigated as well. The reproducibility of these results can 
be tested using ex vivo and then in vivo models. This could detect the applicability of 
the suggested pathways, such as sGC and/or PDE5 inhibitors, as therapeutic targets 
in sepsis.  
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